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Abstract
The guaipyridines are a class of naturally occurring alkaloids isolated from plants
native to the Pacific Islands and Southeast Asia. One member of this family, cananodine, has
displayed potent in vitro cytotoxic effects against two different types of hepatocellular
carcinoma cell lines. More recently discovered guaipyridne compounds, rupestines A-M,
share structural similarities to cananodine and might possess similar anti-cancer properties.
The potential medical benefits and the rare and interesting structure of the guaipyridines
make them desirable and challenging synthetic targets. Two distinct synthetic routes were
developed to access the guaipyridine core, and in doing so the total synthesis of cananodine
and its diastereomers was accomplished.
The initial route (epoxide-opening route) had previously been explored by the
Vyvyan group (see Meyer, Ligon thesis; Yarbrough unpublished results) although room for
improved efficiency and the final stereoselective hydrogenation reaction left significant work
to be completed on this project. The critical Suzuki-Miyaura cross-coupling step involving a
dienyl boronate ester and pyridyl triflate produced lower than desired yields, thus numerous
combinations of coupling partners and reaction conditions were explored to improve the
performance of this reaction. Once optimized conditions were developed, the sequence was
continued and both enantiomers of the key 7-exo cyclization precursor was successfully
isolated after base-promoted epoxide-opening. Exhaustive hydrogenation and reduction
efforts of the remaining 1,1-disubstituted alkene provided a ~1:1 diastereomeric mixture of
cananodine and its C5 epimer.
The second route (intramolecular Heck cross-coupling route) to the guaipyridine
skeleton is new to the Vyvyan lab and hinges on two key reaction steps. After preparation of
iv

picolyl bromide and tert-butyl hexenoate precursors, an alkylation reaction provided the
carbon-backbone compound in satisfactory yields. Subsequent phenol deprotection and
functionalization allowed for intramolecular Heck coupling between the 1,1-disubstituted
side-chain alkene and a newly formed pyridyl triflate group provided the cyclized
guaipyridine core compound in good yields.
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1. Introduction
1.1. Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a malignant cancer of the liver and the third
leading cause of cancer related deaths worldwide.1 The death tolls are estimated to be
upwards of 700,000 people annually and the number of new cases per year is on the rise, now
approximately 1.2 million.2 While this particular type of cancer has historically been most
prevalent among developing countries in Africa and Southeast Asia, the number of HCC
diagnoses has been steadily increasing in the United States and Europe for over two decades,
with a noticeable shift in distribution to younger age groups.3
HCC can arise through a number of different external and genetic factors. The most
common cause of liver dysfunction, and thus HCC development, is extensive scarring of the
liver tissue, a condition called cirrhosis. This scarring of the liver is most commonly brought
about by alcohol abuse in addition to hepatitis B (HBV) and hepatitis C (HCV) viral
infections. These conditions promote inflammation, necrosis and regeneration processes in
liver cells, leading to genetic alterations and ultimately cancer. The potential for an even
larger number of annual HCC cases is present, as the combined number of people suffering
from chronic HBV and HCV exceeds 500 million.4 Other HCC promoting factors include
prolonged aflatoxin B exposure, steatosis (non-alcoholic fatty liver disease),
hemochromatosis (over exposure of the liver to iron) and virtually all cirrhosis inducing
afflictions.
The outlook for patients with HCC is especially grim relative to other forms of cancer
____________________________________________________
1

El-Serag, H.B.; Rudolph, K.L.; Gastroenterology, 2007, 132, 2557-2576.
Thomas, M.B.; Zhi, A.X.; J. Clin. Oncol. 2005, 23, 2892-2899.
3
El-Serag, H.B.; Mason, A.C.; N. Engl. J. Med. 1999, 340, 745-750.
4
Wilhelm, S.; Carter C.; Lynch, M. et al; Nature Reviews: Cancer. 2006, 6, 674-687.
2

and the prognosis for treatment depends largely on what stage the cancer is in when it is
identified. Common forms of cancer treatment such as chemotherapy (both single and
combination therapies) have proven generally ineffective, making HCC a notoriously
difficult cancer to treat.5 If treated at an early stage when liver function remains mostly
intact and the cancer has not yet metastasized, a 5-year survival rate as high as 70% is
observed when the patient is treated with radiofrequency ablation of the tumor or ethanol
injection.6,7 Despite the availability of effective HCC screening procedures and treatment
modalities, just 40% of HCC patients within the United States are identified early enough for
these treatments.8 Liver transplantation and resection have also found wide spread use in
treating liver cancer, but again are limited to early HCC identification. These treatments
methods, however, are often less effective as only 25-50% of patients who receive a liver
transplant live at least five years afterward, while a 75%-100% recurrence rate is observed in
patients who undergo resection of the affected part of the liver.5 Despite the lack of
consensus on treatment options, the advancement in our understanding of the cancer at a
molecular level has led to the development of structure-based drug design and small
molecule treatments of HCC.

1.2. Sorafenib and small molecule treatment of HCC
In the 1980’s, continued preserverence and advancements in the fields relating to
chemical and molecular biology led researchers to unequivocally established that proteins
known as kinases are intimately involved in cancer cell growth, proliferation and
____________________________________________________
5

Ikeda, M.; Okusaka, T.; Ueno, H. et al; Cancer 2005, 103, 756-763.
Clavien P.A.; Petrowsky H.; DeOliveira M.L. et al; N Engl. J. Med. 2007, 356, 1545–1559.
7
Cho Y.K.; Kim J.K.; Kim M.Y. et al; Hepatology. 2009, 49, 453–459.
8
Singal, A.; Volk, M.L.; Waljee, A. et al; Pharmacol. Ther., 2009, 21, 37-47.
6

2

regeneration pathways. Kinases make up the largest family of proteins in the human body
and are responsible for catalyzing the transfer of phosphate molecules from phosphate
donors, such as ATP, to other proteins or substrates. The importance of these proteins to the
survival of cancer cells has made them primary targets for small molecule inhibitor
development. Most kinase inhibitors are discovered by a process known as high through-put
screening (HTS) where thousands of candidate compounds are screened simultaneously for
inhibition hits, and then synthetically modified to improve their efficacy and selectivity.
Kinase inhibitors are further divided into two classes: type I and type II. Type I kinase
inhibitors bind to the active form of the kinase, occupying the purine pocket that would
otherwise be occupied by an ATP molecule. Type II inhibitors bind to the inactive form and
do not allow the kinase to become active.9
Through HTS, some of the first commercially available small molecule protein kinase
inhibitors were developed.10 A type II kinase inhibitor, imatinib [Novartis, Gleevec® (1.1)],
which received FDA approval in 2001, is among these pioneering small molecule cancer
treatments. Imatinib has found extensive use in inhibiting the BCR-ABL tyrosine kinase of
chronic myeloid leukemia (CML) with a concentration required to inhibit 50% of kinase
phosphorylation (IC50) of 0.25 μM.11

____________________________________________________
9

Zhang, J.; Gray, N.S.; Nature Reviews, 2009, 9, 28-39.
Wilhelm, S.; Carter C.; Lynch, M. et al; Nature Reviews: Drug Discovery 2006, 5, 835-844.
11
Druker B.; Tamura S.; Buchdunger E. et al; Nature Medicine, 1996, 2, 561-566.
10
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Other type II inhibitors include dasatinib [Bristol-Myers Squibb, Sprycel® (1.2)] and
sunitinib [Pfizer, Sutent® (1.3)], which are more recent additions to the cancer treatment
repertoire and aim to treat certain forms of cancer in imatinib-resistant patients. Dasatinib
was found to be a 300 times more effective inhibitor of the BCR-ABL kinase in CML, and
no dose-limited side effects were observed at dosages which were clinically effective.12
Sunitinib was the first drug to be simultaneously approved for treating multiple targets [renal
cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST)] and inhibits a variety of
protein kinases within these cancer cells.13 Interestingly, all of the approved protein kinase
inhibitors to date possess at least one nitrogen-containing heterocycle in their structure
including pyridines, piperazines, pyrimidines, thiazole and oxindoles which indicates that
this structural theme is vital to the inhibition mechanisms of these drugs.

Despite the advancements in small molecule treatment of many forms of cancer in the
1990’s and early 2000’s, none of the first developed compounds were observed to
significantly inhibit any of the prominent kinases in the mitogen activated protein kinase
(MAPK) pathway of HCC, largely responsible for tumor angiogenesis and proliferation.
With FDA approval in 2007, a new drug called sorafenib [Bayer, Nexavar® (1.4)]
____________________________________________________
12
13

Shah, P.; Drugs of Today, 2007, 43, 5-12.
Schoeffski, P.; Wolter, P.; Himpe, U. et al; J. Clin. Oncol., 2006, 24 (Suppl. 18), 143.

4

became the first commercial drug used to treat patients suffering from inoperable HCC.
A type II kinase inhibitor, sorafenib has been found to inhibit the HepG2 HCC cell
line with an IC50 value of 4.5 μM and specifically inhibits vascular endothelial growth factors
(VEGF) 1-3 and the platelet derived growth factor β (PDGFβ) receptor proteins, as well as
B-Raf and C-Raf protein kinases within the MAPK phosphorylation cascade.14 As expected,
the structural features of sorafenib allow for specific interactions with the kinases that it
inhibits. Its amide-substituted nitrogen heterocycle and di-aryl urea functionality play
important roles in the inhibition mechanism of the B-Raf kinase (Figure 1), a commonly
mutated protein. The backbone cysteine 531 residue of B-Raf, which normally binds ATP,
has been shown to form strong hydrogen bond interactions with the amide and pyridine
nitrogen atoms of sorafenib (3.2 Å and 3.0 Å respectively). The urea nitrogens also form
hydrogen bond interactions with backbone aspartate and glutamate residues of B-Raf while
the trifluoromethyl benzene ring also fits into a hydrophobic ‘allosteric site’ within the
protein (not shown).15
While these drugs have certainly provided an alternative to treating many cancers,
and in some cases the only option for treating HCC, they are by no means perfect. Besides
the prohibitive cost of many small molecules treatments, they are not without their adverse
side effects and often only extend the life of their patient by several months. Sorafenib for
____________________________________________________
14
15

Keating, G.M.; Santoro, A.; Drugs, 2009, 69, 223-40.
Barford, D.; Marais, R.; Cell, 2004, 116, 855-67.
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Figure 1. Hydrogen bond interactions between sorafenib and B-Raf

instance is the most effective available drug for treating HCC, yet only extends the life of
advanced liver cancer patients by an average of 3-6 months.14 Research towards the
development of more effective small molecule kinase inhibitors are endeavors that could
significantly benefit cancer patients.

1.3. Natural products as cancer fighting agents
For thousands of years, mankind has utilized its surrounding environment to treat and
cure many illnesses and ailments. Natural sources, and the recipes derived from them, have
been passed down with ever evolving refinement. As our understanding of medicine has
continued to expand, we have been able to slowly eliminate the number of diseases and
sicknesses that were once thought to be incurable. Due to the complex nature and
uncontrollable growth of cancer, it remains one of the few conditions that cannot be reliably
and consistently cured by any one treatment method. In spite of the many forms of treatment
options available (surgery, chemotherapy, radiation therapy etc.), none of them are
guaranteed to work for everyone or all types of cancers, nor do they guarantee that the cancer
will not return. Still, the vast diversity of natural products inspires hope that advancements
6

will continue to be made in treating all forms of cancer. We have already found use for
many naturally derived compounds possessing anti-carcinogenic, anti-proliferative, and antiangiogenic qualities in pharmaceutical drugs or in current clinical trials.
One of the most well recognized, naturally derived, chemotherapeutic agents is
paclitaxel [Bristol-Myers Squibb, Taxol® (1.5)]. Isolated from the bark of Taxus brevifolia
(Pacific Yew) in 1967 by Wani et al, paclitaxel has been established as the most effective
drug for treating breast, ovarian, certain types of lung cancer, as well as head and neck
cancers.16,17 Various parts of the tree itself have been used in traditional Native American
medicines for treating non-cancerous illnesses and conditions.

Unlike type I/II protein kinase inhibitors, paclitaxel exists in a class of
chemotherapeutic compounds known as mitotic inhibitors, which prevent cell division by
disrupting tubulin polymers known as microtubules, responsible for pulling the cell apart.
Paclitaxel stabilizes microtubules and prevents depolymerization, leading to microtubule
bundling, mitotic arrest and ultimately cell death.18
The unsustainable environmental impact of harvesting paclitaxel from the relatively
scarce Pacific Yew has necessitated alternate means of obtaining this precious compound.
____________________________________________________
16

Wani, M.C. et al; J. Am. Chem. Soc., 1971, 93, 2325-2327.
Cragg, G.M.; Newman, J.M.; J. Ethnopharmacology, 2005, 100, 72-79.
18
Manfredi, J.J.; Horwitz S.B.; Pharmacol. Ther, 1984. 25, 83–125.
17
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The more abundant Taxus baccata (European Yew) provides 10-deacetylbaccatin III which
is used in a semi-synthetic method for obtaining paclitaxel, and is currently meeting
consumer demand.19 Another taxane compound, docetaxel (1.6), is a semi-synthetic analog to
paclitaxel which is also used to treat a variety of cancers and works through a similar antimitotic mechanism.
Curcuma longa (turmeric) is another plant that produces biologically useful
compounds, notably the polyphenol diferuloylmethane [curcumin (1.7)]. Data from over 60
years of research indicates that curcumin suppresses an astonishing amount of cancers and
other conditions, and acts as both an anti-proliferative and anti-carcincogenic.20 Among
them, curcumin is thought to suppress and prevent colon, breast and prostate cancers. These
conditions, which are comparatively common in the United States and Europe, are far less
prevalent in India and surrounding countries where curcumin is frequently consumed in the
spice that it originates from.21 Despite the medical potential of curcumin, extensive
therapeutic research has been slow. The wide spread natural occurrence and dietary usage
prevents patenting of the molecule and thus has dissuaded pharmaceutical companies from
performing extensive research on curcumin as a curative or preventative agent. Recent
syntheses of curcumin analogs aim to uncover cancer inhibitors even more potent than the
curcumin parent compound.22

____________________________________________________
19

Rowinsky, E.K.; Annu. Rev. Med, 1997, 48, 353–374.
Aggarwal, B.B.; Kumar, A.; Bharti, A.C.; Anticancer Research, 2003, 23, 363-398.
21
Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington DC: World Cancer
Research Fund/American Institute for Cancer Research, 1997.
20
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Medicinally useful naturally occurring compounds are not limited to plant material,
but can also be found in a wide variety of sources throughout the animal kingdom. One
example is the mitotic inhibitor, discodermolide (1.8). Isolated from the marine sponge
Discodermia dissolute by Gunasekara et al in 1990, the limited quantities of the compound
obtained from its natural source (7 mg/434 g) initially hindered complete biological
evaluation.23 However, a number of recent total syntheses has allowed for larger scale
production and has established (+)-discodermolide as a potential chemotherapeutic drug,
which entered clinical trials in 2002.24

Preliminary biological activity assays in hollow fiber murine and human xenograph
models indicated substantial inhibition against multiple cancers including lung, breast and
colon, some of which are paclitaxel-resistant.25 Discodermolide was originally shown to be a
powerful immunosuppressant, leading to questions about its viability as a means for treating
cancer. Later research proved that this immunosuppressive activity was prominently due to
anti-proliferative effects on lymphoid cells.26
Another example of a lead anti-cancer compound obtained from marine animal
____________________________________________________
22

(a) Chellakili, B.; Elavarasan, T.; Gopalakrishnan, M. et al; Spectrochimca Acta, 2012, 97, 717-721.
(b) Fuchs, J.R.; Pandit, B.; Bhasin, D. et al; Bioorg. Med. Chem. Lett., 2009, 19, 2065-2068.
23
Gunasekera, S.P.; Gunasekera, M. et al; J. Org. Chem., 1990, 55, 4912.
24
(a) Schreiber, S.L.; Chen, J.; Hung, D.T.; Chem. Biol., 1996, 287.
(b) Rawat, D.S. et al; Anti-cancer Agents in Med. Chem., 2008, 8, 603-617.
25
Honore, S. et al; Mol. Cancer Therapeut., 2003, 2, 1303.
26
(a) Longley, R.E.; Gunasekera, M.; Gunasekera, S.P. et al; Transplantation, 1991, 52, 650.
(b) Longley, R.E.; Gunasekera, S.P. et al; Ann. N.Y. Acad. Sci., 1993, 696, 94.
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species is the aminosterol, squalamine (1.9), isolated from the liver of Squalus acanthias
(dogfish shark). Occasionally confused with controversial shark cartilage dietary
supplements, which are often marketed to claim anti-cancer properties with no scientific
evidence from clinical trials, squalamine was in phase II clinical trials in 2008 for significant
activity that it displayed against ovarian and non-small cell lung cancer.27 The limited natural
availability (approximately 10-20 µg/g of liver and gall bladder tissue) and non-viable
synthetic routes have, and continue to limit complete structure activity studies.28

Even with the vast amounts of therapeutically useful natural products at our disposal,
there are still relatively few that can be used to treat HCC, and an even smaller number that
significantly inhibit HCC proliferation. This fact further demonstrates the need to search and
examine our natural surroundings for biologically active compounds. The growing
importance of plant and animal derived natural products in medicinal and chemical fields
will likely facilitate our advancements towards a larger and more diverse treatment library.

____________________________________________________
27

(a) Moriarty, R.M.; Tuladhar, S.M.; Guo, L.; Wehrli, S. Tetrahedron Lett., 1994, 35, 8103.
(b) Pechulis, A.D.; Bellevue, F.H.; Cio, C.L.; Trapp, S.G. et al; J. Org. Chem., 1995, 60, 5121.
28
Brunel, J.M. et al; Curr. Cancer. Drug Targets, 2005, 5, 267-272.
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1.4. Discovery of (-)-cananodine and the rupestine natural products
One family within the plant kingdom that has garnered significant attention for the
exceptionally wide variety of natural products that it produces is the Annonaceae family.
Colloquially known as the ‘custard apple’ family, Annonaceae are generally found in tropical
and sub-tropical regions of the world and are further divided into over 130 genera and 2300
species.29,30 A number of species within the family have been used in folk medicines to treat
a wide range of symptoms and conditions.31
A particularly interesting species within the Annonaceae family is the tropical
evergreen tree labeled Cananga odorata, also known as the ylang-ylang tree. The tree,
which grows up to 12 m in height, is native to the rainforests of Indonesia and the Philippines
but has been purposely spread to many islands in the Pacific for its fragrant and attractive
yellow flowers. Its common name is derived from the ylang-ylang essential oil (comprised
of 49 different compounds) that can be obtained through steam distillation of the leaves and
flowers, which in turn finds many uses in floral perfumes and aromatherapy.32 Besides the
desirable scent that it produces, C. odorata is an example of an Annonaceae family member
that has long been used in folk medicine, specifically in Taiwanese tonics for alleviating
malaria, fever, and tinea infections.33
From 1999-2001, Wu et al examined the extracts from the fruit of C. odorata in
hopes of discovering interesting bioactive compounds that are often found in the alkaloid
____________________________________________________
29

Alali, F.G.; McLaughlin, J.L.; Liu, X.X.; J. Nat. Prod., 1999, 62, 504-540.
Cortes, D.; Figadère, B. et al; Nat. Prod. Rep., 2005, 22, 269-303.
31
(a) Hartwell, J.L.; Plants Used Against Cancer; Quarterman: Lawrence, MA, 1982, 406.
(b) Farnsworth, N.R. et al; J. Ethnopharm., 2000, 73, 347-377.
32
Olivero, J. et al; J. Pharm. Sci., 1997, 86, 625-630.
33
Kan, W.S.; Manual of Medicinal Plants in Taiwan, National Research Institute of Chinese Medicine. Taipei,
1971; 168.
30

11

and terpenoid rich Cananga genus.34 In their research, they isolated and characterized eight
alkaloids and sesquiterpenes (Figure 2.) The isolated compounds included the guaipyridine
(-)-cananodine (1.10) , the eudesmanes cryptomeridiol 11-α-L-rhamnoside (1.11), γeudesmol (1.12) and γ-eudesmol 11-α-rhamnoside (1.13), along with alkaloids
cleistopholine, (1.14), N-trans-feruloyltyramine (1.15), (+)-ushinsunine-β-N-oxide (1.16) and
lyscamine (1.17), all of which showed at least partial in vitro cytotoxicity in two different
HCC cell lines. Compounds 1.13 and 1.14 were also previously shown by Wu et al to
possess activity against leukemia as well as lung and colon cancer.35

Figure 2. Cytotoxic constituents of C. odorata fruit extract

Arguably the most stimulating of these compounds is the guaipyridine alkaloid,
cananodine. Its rarely seen guaipyridine structure consisting of a fused pyridine ring and
seven-membered carbocycle, is the most potent among the cytotoxic constituents of the C.
____________________________________________________
34

(a) Wu, Y.C. et al; J. Nat. Prod., 2001, 64, 616-618.
(b) Wu, Y.C. et al; J. Chin. Chem. Soc., 1999, 46, 607-611.
35
Wu, Y.C. et al; Phytochemistry, 1998, 47, 1057-1061.
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odorata extract in inhibitory concentration against HepG2 and HepG2,2,15 cell lines of 0.94
μM and 16 μM respectively.34 The inhibition mechanism, although yet to be confirmed, is
hypothesized to emulate that of sorafenib in that the pyridine nitrogen and hydroxyl
hydrogen form strong hydrogen bond interactions with a backbone cysteine residue of B-Raf
(Figure 3). Because the in vitro IC50 of cananodine is nearly five times less than that
displayed by sorafenib in the HepG2 inhibitory assay, it is also speculated that the large,
aliphatic cycloheptane ring interacts with a hydrophobic site of B-Raf that is not filled by
sorafenib. The extremely limited natural occurence (~3 mg/kg of fruit) of cananodine makes
commercial extraction of the precious material unfeasible, but its potent cytotoxicity and rare
structural motif makes it a worthy, challenging synthetic target.

Figure 3. Hypothesized interactions between cananodine and B-Raf

The Artemisia genus is another collection of plant species known for its variety of
secondary metabolites. With over 260 known species, Artemisia is one of the largest genera
from the Asteraceae family and is found primarily in northern temperate regions of the
world. The genus is comprised of widely recognized plant species including sagebrush (A.
tridenta), wormwood (A. absinthum) and tarragon (A. dracunculus). The last two decades
have witnessed a renewed and growing interest in this genus primarily due to the diverse
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selection of natural products contained within the plants, and also due to the abundance of
plant material and usage in traditional folk remedies.36 Members of this genus have been
utilized for centuries for everything from suppressing coughs to relieving pain.37 More
modern investigations have revealed that many species possess bioactive compounds with
antimalarial, anti-viral, anti-tumor, anti-pyretic, anti-oxidant, and anti-hepatitis properties, to
list a few.36
Some of the most recently discovered compounds isolated from the Artemisia genus
are the rupestines. From 2010-2012, Aisa et al uncovered twelve new guaipyridine alkaloids,
rupestines A-M [1.18-1.29 (Figure 4)].37 Curiously, no compound was designated as
‘rupestine E’ as the molecules were being discovered. These natural compounds were

Figure 4. Rupestines A-D, F-M
____________________________________________________
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(b) Aisa, H.A. et al; Chem. Pharm. Bull., 2012, 60, 213-218.

14

isolated by high-speed counter current chromatography of the extract from Artemisia
rupestris (rock wormwood), which is used in traditional Chinese medicines for detoxification
as well as its anti-viral, anti-bacterial and anti-tumor qualities.38
The rupestines share the same guaipyridine bicyclic core with cananodine, and differ
only in stereochemistry at the 5- and 8-postions and the substituent at the 8-position of the
cycloheptane ring. These structural similarities lead to postulation that the rupestines possess
similar HCC cytotoxic activity and thus the potential benefits of developing a synthetic route
to produce the guaipyridine core could establish these molecules as leads to new and more
effective HCC treatments.

1.5. Previous guaipyridine syntheses
Attempts to synthetically produce members of the guaipyridine family have been few
and far between, likely because their medical potential was long unknown but also due to the
synthetic challenge that they pose. The first reported syntheses were in 1966 by Büchi et
al.39 After isolating two guaipyridine compounds, patchoulipyridine (1.30) and
epiguaipyridine (1.31), from the essential oil extract of Pogostemon patchouli (patchouli oil),
Büchi sought further structural confirmation by producing their synthetic analogs. From βpatchoulene (1.32) starting material, a hydrazoic acid promoted nitrogen incorporation,
followed by palladium catalyzed dehydrogenation produced a mixture of compounds which
convincingly included 1.30, as the observed physical properties very closely correlated with
those of the naturally occurring compound. In their synthesis of 1.31, Büchi et al employed
guaiol (1.33) as the starting material and first performed a reduction of the hydroxyl group.
____________________________________________________
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Chen, X.Y.; Wang, S.H.; Chin. Tradit. Herb. Drugs, 1981, 12, 25.
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The product was then treated with hydrazoic acid to incorporate the nitrogen atom of the
resulting pyridine ring. This reaction series provided dihydroepiguaipyridine (1.34) which
was subsequently used to match physical properties with the dihydro-natural product
derivative.

Figure 5. Compounds from Büchi and Van der Gen isolations and syntheses

Several years later, Van der Gen et al noticed discrepancies in the absolute
configuration that Büchi claimed for their synthetic 1.34 compound and that of the product
that was isolated from the natural source.40 While starting material 1.33 has a wellestablished stereochemistry of 7R, 10S (and thus should the product of his synthetic route),
Büchi et al surprisingly attributed a 7R, 10R stereochemistry to the isolated natural product.
Van der Gen therefore devised independent synthetic schemes from starting materials with
known configurations to produce both C10 epimers of guaipyridine.
Guaiol was again chosen as the starting material to produce the 10S epimer. A
palladium catalyzed alkene isomerization, followed by ozonolysis produced diketone
____________________________________________________
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intermediate 1.35. Treatment with hydroxylamine hydrochloride in ethanol, and dehydration
of the hydroxyl group, produced the desired epimer with spectral properties matching the
natural product isolated by both sets of researchers. The 10R epimer was synthesized from
α-gurjunene (1.36) following a similar ozonolysis and hydroxylamine hydrochloride driven
reaction sequence. A mixture of products was obtained including the anticipated 10R epimer
with clearly differing spectral properties. After producing both stereoisomers, Van der Gen
concluded that Büchi had incorrectly assigned the configuration of the natural product and
had synthetically produced the dihydro C10 epimer of 1.31, guaipyridine (1.37).
In 1987, Okatani and Koyama et al reported two new synthetic methods to produce
1.31 and 1.37 (Schemes 1, 2). In the first route, they applied their recently developed DielsAlder reaction of 1,2,3-triazine with enamines to the synthesis of natural products.41 From 3isopropenyl-l,6-methylcycloheptanone (1.38), the enamine isomers 1.39 and 1.40 were
synthesized, then immediately treated with triazine. Through this hetero-Diels-Alder
reaction, three products were isolated via HPLC, which included 1.31 and 1.37. In the
second publication, the group discovered that treatment of the same 1.38 starting material
with O-(α-methylallyl)hydroxylamine provided oxime 1.42, and following thermal
Scheme 1.

____________________________________________________
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Scheme 2.

decomposition, a mixture of products was obtained which again included 1.31 and 1.37.42
While these syntheses could likely be applied to more recently discovered members
of the guaipyridine family, such as cananodine and the rupestines, several factors keep them
from being commercially viable. Despite the novelty of the routes developed by Büchi and
Van Der Gen, they use precious, naturally occurring starting materials which are generally
difficult to obtain. Also, all of their syntheses are initiated from starting materials that
already possess a seven-membered ring, one of the more synthetically interesting pieces of
the guaipyridines. Not only that but the all of previously mentioned sequences are neither
regioselective nor stereoselective, which can often determine the functionality and toxicity of
compounds used for medicinal purposes. The noticeable flaws in the guaipyridine syntheses
to date leave much to be desired, and an efficient and selective synthesis of these compounds
may ultimately lead to a new class of cancer fighting drugs.

1.6. Total synthesis of cananodine by Craig & Henry
With the isolation of cananodine by Wu et al in 2001, Craig and Henry decided to
employ their recently developed microwave-assisted, decarboxylative Claisen rearrangement
(dCr), to the synthesis of the guaipyridine.43 Their clever approach combined chiral pool and
____________________________________________________
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Koyama, J.; Okatani, T. et al; Heterocycles, 1987, 26, 925-927.
43
Craig, D.; Henry, G.D.; Eur. J. Org. Chem., 2006, 3558-3561.
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chiral auxiliary methods for setting the two stereocenters of cananodine and can be thought
of as possessing four key reaction steps, shown in their retrosynthetic analysis (Scheme 3).
Simple methylation of the ester substituent using MeMgBr provided 1.10, but was preceded
by ozonolysis of the 1,6-diene and ammonia based nitrogen incorporation on substrate 1.50
to provide the bicyclic guaipyridine core. Their microwave assisted dCr reaction on
compound 1.49 proceeded with yields as high as 71% which confirmed that this in-house
developed reaction could be used toward natural product synthesis. Compound 1.49 was the
product of oxazolidinone auxiliary elimination and esterification using 4-methyl-2-(4tolylsulfonyl)-4-pentenoic acid on substrate 1.48. A ring-closing metathesis reaction (RCM)
on compound 1.47 was used to create the seven-membered ring of intermediate 1.48. Both
stereocenters of the final molecule were locked in compound 1.47 as the result of a series of
transformations, including addition of the oxazolidinone chiral auxiliary and nucleophilic
addition between the starting materials 2-methylenepropane-1,3-diol (1.45) and enantiopure
(R)-(-)-citronellene (1.46).
Scheme 3.
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In all, Craig and Henry’s reaction sequence is comprised of 17 steps with an overall
yield of 4%. It should be noted that the specific rotation measured by Craig and Henry for
their synthetic cananodine ([α]21
= +17.4°, c = 1.34, l = 0.25 dm, CHCl3) significantly
𝐷
differed from that which was reported by Wu et al for the naturally occurring product ([α]24
=
𝐷
-76.2°, c = 0.06, l = 0.10 dm, CHCl3). Of particular concern is the difference in the sign of
the measured optical rotation. However, Craig and Henry claim that a more concentrated
sample solution and thus greater order of magnitude of the observed rotation makes their
sample less susceptible to experimental error. Regardless, a synthetic route that is designed
to select for a particular desired stereoisomer should settle the discrepancy, while shortening
the overall reaction sequence may lead to a method of producing the guaipyridine alkaloids
more suited for larger scales.
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2. Total Synthesis of Cananodine via Epoxide-Opening Route
2.1. Original synthetic routes
Our original plan for the synthesis of cananodine varied drastically from that
published by Craig and Henry. Not only did the projected synthetic routes shorten the
overall number of reaction steps, but it was also anticipated that the sequence would allow
for selection of specific configurations at both stereocenters in the target. The Vyvyan
group’s proposed plan for preparation of the bicyclic core of cananodine (1.10) was centered
on an intramolecular sulfone-epoxide-opening under strongly basic conditions (Scheme 4).
In general, preparation of carbocycles by base-promoted picolyl anion attack has historically
been under-utilized. Intermolecular reactions of this type are far more prevalent than the
intramolecular variety that we propose as majority of the research involving intramolecular
ring formation by this method has generally focused on construction of 3, 4 and 5 membered
rings.
Scheme 4.
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The sulfone-epoxide cyclization precursor (2.1) could be synthesized through two
different routes. In the first route (Scheme 4, Path A) a Suzuki-Miyaura cross-coupling
reaction between functionalized pyridine derivative 2.2 with either a vinyl boronate ester
(2.3) or triflate (2.4) side-chain was suggested to create the carbon-carbon bond that forms
the backbone of the final product. Alternatively (Scheme 4, Path B), a Negishi-style crosscoupling between the metalated pyridyl species 2.5 (derived from an appropriately
disubstituted pyridine 2.6) and vinyl triflate 2.4 would also ultimately lead to the desired
epoxide intermediate.
Once synthesized, the sulfone-epoxide intermediate would be subjected to basic
conditions thereby producing a picolyl anion. This anion would be expected to attack the
less-substituted epoxide carbon in the side-chain, opening the epoxide and forming the
cycloheptane ring of the guaipyridine core. The picolyl sulfone group shown in compound
2.1 was expected to dramatically decrease the pka (increase the acidity) of the picolyl protons
from ~34 to ~21, thus stabilizing the deprotonated intermediate and allowing cyclization to
occur more readily.44
Important to our reaction sequence is the ability to selectively set the configuration of
the stereocenters at the 5- and 8-postions of the final guaipyridine products. The
configuration at the 8-position can be set through a Sharpless asymmetric dihydroxylation
(AD), which was named after K. Barry Sharpless who won the Nobel Prize in 2001 for his
work in asymmetric chemistry.45 The reaction uses a clever mixture of commercial
compounds (AD mix-α or β) which includes the osmium catalyst, potassium osmate (K2Os4),
and one of two chiral auxillaries, dihydroquinine phthalazine [(DHQ)2PHAL] or
____________________________________________________
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Figure 6. AD mix stereoselectivity mnemonic

dihydroquinidine phthalazine [(DHQD)2PHAL], depending on the desired stereochemistry of
the product. A mnemonic is commonly used to decide which of the two forms of AD mix
should be used to obtain the desired stereochemistry in the product (Figure 6). By following
this mnemonic and visualizing our substrate with the largest alkene substituent (RL) in the
‘SW quadrant’ we should be able to select for either enantiomer by using the appropriate AD
mix variety. This in turn should settle the discrepancy of cananodine’s absolute
stereochemistry debated by Wu and Craig.
Transition metal-mediated hydrogenation is a likely method of stereoselectivity at the
5-position and several catalysts were identified as possible reagents to affect the desired
transformation. Wilkinson’s catalyst and Crabtree’s catalyst, two well-known
hydrogenation reagents, were chosen to attempt the terminal alkene reduction. We were
especially hopefully that Crabtree’s catalyst could perform the task, as literature precedent
dictates that ligating groups such as hydroxyl, alkoxyl, ester, and other carbonyl groups
____________________________________________________
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attached to an olefinic substrate in a 6-membered ring make effective directors of Crabtree’s
catalyst and promote the hydrogentation.46 No example of this directing effect has been
reported on 7-membered rings, however, which is present is our target compounds.

2.2. Previous work by Meyer, Ligon and Yarbrough
The first Vyvyan group member to explore these synthetic routes was Jennifer
Meyer.47 In her research, she first investigated directed ortho-metalation of substituted
pyridine derivatives with expectations of utilizing the products in palladium-catalyzed
Negishi cross-coupling.48 A number of pyridine derivatives activated at the 2-position (2.6)
were synthesized for use in model studies to determine the viability of metalation at the
desired aromatic carbon (Scheme 5). Three activating groups at the 2-picolyl positon were
used in these models studies including methoxymethyl ether (MOM), benzamide (CONHPh)
and a carboxylic acid. Three lithium bases were also employed over the course of these
reactions in hopes of in situ generation of the appropriate aryl lithium intermediate (2.7).
Several different known trapping agents were used to test if indeed the expected lithium
intermediate was being formed. Using iodine or D2O would presumably give the
corresponding iodo- or deuterated pyridine derivative, while the use of DMF or dry ice
would be expected to provide the aldehyde and carboxylic acid derivatives respectively.
Unfortunately, none of the attempts ever resulted in 3-substituted products (2.8), bringing
into question the formation of 2.7. In fact, deprotonation at the 6-aryl and picolyl positions
was often observed and led to a butyl addition derivate 2.9 when n-BuLi was used as the
base, and the iodo-derivative 2.10 when I2 was used as the trapping agent.
____________________________________________________
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Scheme 5.

Due to the difficulties in functionalizing the 3-position of the pyridine ring, directed
ortho-metalation and Negishi coupling was deemed an ineffective method of synthesizing
coupled cananodine intermediates. Meyer then turned her attention to synthesizing
intermediates for testing in Suzuki cross-coupling reactions (Scheme 4, Path A). From 2,6lutidine-α-2,3-diol (2.11), several activated pyridyl triflate compounds (2.13-2.15) were
synthesized to provide a variety of substrates for testing in the coupling reactions (Scheme
6). Pinacolboronate ester 2.18 was synthesized from 6-methyl-5-hepten-2-one (2.16) via
palladium catalyzed borylation of triflate 2.17. The aforementioned pyridyl triflate species
Scheme 6.
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and boronate 2.18 were then used in combination under varying conditions to determine the
most effective coupling method.
Her research indicated that the use of pyridyl triflate 2.15, containing a pivaloate ester
protecting group on the primary alcohol, and an excess of pinacolboronate 2.18 gave the best
results (79% yield) when using Pd(PPh3)4 and potassium carbonate (K2CO3) in dioxane at
100 °C.49 This reaction was a noteworthy achievement given the importance of successfully
synthesizing the coupled intermediate 2.19 to the overall reaction sequence, and the fact that
no examples of cross-coupling pyridyl triflates and vinyl boronates had previously been
reported. Meyer’s next endeavor was to convert the pivaloate group in the newly synthesized
Suzuki coupling product to the phenyl sulfonate, as well as convert the trisubstituted alkene
in the side-chain to the corresponding epoxide (Scheme 7). The Suzuki coupling product
2.20 containing the derived acetonide side-chain was carried through a series of
transformations including deprotection and epoxidation procedures to create the side-chain
epoxide and coversion of the pivolate group to the electron donating sulfone in cyclization
precursor 2.21.
Scheme 7.

The stage was then set to test sulfone-anion cyclization reactions and attempt to
produce the cyclized precursor 2.22. Ten different reaction conditions were devised,
____________________________________________________
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including various bases for deprotonation at the picolyl position, as well as several solvents,
additives, and reaction temperatures. Despite the extensive experimentation, no cyclized
material was ever found. There was, however, clear evidence that sulfone-anion formation
occurred during the reactions as a drastic color change to yellow/orange upon addition of the
base to the sulfone-epoxide indicated picolyl anion creation. It was therefore speculated that
the sulfone group actually over stabilized the generated anion, reducing its nucleophilicity,
and dissuading attack on the epoxide to form the seven-membered carbocycle.
Learning from Meyer’s work, Toby Ligon continued the epoxide-opening route
towards the synthesis of cananodine.50 Ligon first pursued construction of a 2.21 analog
containing a sulfide activating group (as opposed to the sulfone used by Meyer), confident
that it would be slightly less stabilizing of the picolyl anion, and allow cyclization to proceed.
Ligon also envisioned significantly shortening the overall number of steps in the sequence by
performing dihydroxylation of the side-chain double bond after the Suzuki coupling step in
order to avoid acetonide protection and deprotection procedures. Literature examples
indicated that the sulfide would be able to withstand the asymmetric dihydroxylation
conditions, and not oxidize to the corresponding sulfoxide or sulfone, which was indeed the
case.51
The most pressing issue of course was developing the cyclization reaction conditions.
To do this, model compound 2.23 was prepared through Suzuki cross-coupling. This
compound contains only a monosubstituted terminal alkene in the side-chain and lacks
functionality at the 2-picolyl position. The pyridine ring also lacks the methyl substituent at
the 6-position to suppress competitive deprotonation at a second picolyl site. These
____________________________________________________
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simplifications allowed for a reduced number of transformations before the cyclization
reactions could be attempted, and lessened the complexity of the test substrates. Although it
is known that under basic conditions a nucleophile will generally attack the less substituted
carbon of an epoxide, this approach hinged on the idea that the large negative entropy
associated with forming the 8-membered ring will outweigh the usual reactivity preferences
and form the 7-seven membered ring instead.52 After asymmetric dihydroxylation and
subsequent conversion of the diol to the epoxide, 2.25 was used as the test substrate in
various new cyclization reactions (Scheme 8).
In the first reaction, 2.25 was treated with just the lithium base, lithium
diisopropylamine (LDA), in THF at a reduced temperature. These conditions only provided
the corresponding 8-membered ring derivative, 2.26. Ligon next employed the Lewis acids
boron trifluoride diethyl etherate (BF3∙OEt2) and diethylaluminum chloride (Et2AlCl) in
Scheme 8.
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hopes of inducing a partial positive charge on the epoxide oxygen and promote cyclization at
the less substituted carbon. When the reaction was treated with BF3∙OEt2, Ligon observed
what appeared to be very strong coordination to the epoxide oxygen, promoting
isomerization to an aldehyde in situ. The picolyl anion then apparently attacked the resulting
aldehyde to give a different 8-member ring in compound 2.27. Using Et2AlCl did not appear
to fare any better as the generated chloride ions in solution appeared to add to the epoxide
and upon work-up with acetic anhydride, the chloroacetate 2.28 was obtained.
Clearly, cyclization using monosubstituted epoxides was not a viable option. These
results prompted Ligon to test a trisubstituted epoxide substrate to take advantage of the
inherent preference of the nucleophile to attack the less substituted carbon and yield the 7membered ring. Using test substrate 2.29, standard cyclization conditions were used and
cyclized compound 2.30 was finally obtained and characterized. Regardless of the poor
overall yield, this reaction was monumental to the viability of the overall reaction sequence.
This reaction also showed that cyclization could be accomplished without the aid of an
activating group. In fact, performing the reaction without additional picolyl functionality
(e.g. sulfone or sulfide) might actually be a necessary condition for cyclization to occur.

Knowing that this cyclization could work on model substrates, Loagan Yarbrough
was the next researcher to work on the synthesis of the actual target compound.53 Following

____________________________________________________
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the procedures developed by Meyer and Ligon, Yarbrough successfully synthesized the
epoxide precursor 2.31, and then performed the cyclization reaction to produce cyclized
material 2.32 (Scheme 9). The only remaining step was the stereoselective hydrogenation of
the remaining 1,1-disubstituted alkene. Yarbrough was only able to attempt one
hydrogenation, using Pd/C as a catalyst at atmospheric hydrogen pressure. Unfortunately,
the reaction did not provide the desired synthetic cananodine, and only a small amount of
organic material was recovered from the reaction and it hypothesized that the palladium
catalyst coordinated strongly to the pyridine nitrogen, rather than to the alkene.
Scheme 9.

2.3. Suzuki-Miyaura cross-coupling and optimization
2.3.1. Preparation of coupling partners
Although much of the epoxide-opening route had been explored by past researchers,
many reactions still provided unsatisfactory yields and the stereoselective hydrogenation was
yet to be completed; a significant amount of work was left to be completed. Using already
successful procedures for synthesizing the Suzuki coupling partners, aryl triflate 2.35 and
vinyl boronate ester 2.18, special care was taken to improve the yields of each reaction as
much as possible (Scheme 1). From the starting material 6-methyl-5-hepten-2-one (2.16),
the usually low-yielding triflation reaction using the triflating agent bistrifluoromethanesulfonimide (phenyl triflimide, PhNTf2) and NEt3, has now been completed
30

with yields as high as 57% of triflate 2.17. The palladium catalyzed borylation reaction,
using bis(pinacolato)diboron (B2pin2) boron source, was also optimized to give yields as high
as 92% of boronate ester 2.18. The synthesis of pyridyl triflate 2.34 is fairly straight forward,
using NEt3 and triflic anhydride (OTf2) and proceeds in 55-70% yields. These intermediates
have all been prepared successfully in gram-scale reactions.
Scheme 10.

One of the more obviously flawed reactions was the Suzuki coupling stage. Past
research had indicated that the use of Pd(PPh3)4 with K3PO4 in dioxane at elevated
temperatures provided the best results when coupling aryl triflates and vinyl boronates.
Attempts at reproducing the already successful reaction provided low yields, ranging
between 15-30% of the coupled product 2.35, although former researchers working on this
project were only able to achieve yields as high as about 50% when performing coupling
reactions similar to this one (without the aid of picolyl activating groups). Given the
importance of this reaction to the overall sequence, further optimization of the reaction was
undertaken to improve the mass recovery in the Suzuki cross-coupling.

31

2.3.2. Coupling optimization
The poor yields obtained from Suzuki coupling prompted further examination into
optimizing the reaction conditions. In order to fully investigate this reaction, a number of
coupling partners, both nucleophiles and electrophiles (Figure 7), were either prepared or
purchased to use in a wide variety of coupling conditions.

Figure 7. Compounds used in Suzuki coupling optimization

Three different nucleophilic coupling partners were obtained for use in the coupling
optimizations. Pyridyl boronic acid 2.39 was commercially available. Pinacolboronate ester
2.18 is the product of already successful reactions (Scheme 10) and is the nucleophilic
substrate that has been used in previous Suzuki coupling attempts. Pinacolboronate ester
2.40 has been prepared through two different synthetic methods (Scheme 11). In one route,
Scheme 11.
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dienyl bromide 2.36 is first synthesized through a Grignard coupling of 2,3-dibromopropene
(2.41) with allylmagnesium chloride, which was isolated and characterized. The bromide
was then converted to the boronate ester 2.40 using t-BuLi and isopropoxypinacolboron. The
same boronate ester can also be prepared through another known two stage synthesis.54 The
first stage consists of an identical Grignard reaction in which bromide 2.36 is not purified,
but rather magnesium turnings, elemental iodine and pinacolborane are subsequently added
to yield 2.40.
The presumed lack of reactivity of pyridyl triflate 2.34 in the Suzuki coupling
reactions up to this point prompted further examination of different electrophilic coupling
partners as well and four different compounds were gathered (Figure 7). Pyridyl triflate 2.34
and dienyl bromide 2.36 are the products of already successful reaction sequences (Scheme
10 and 11 respectively). Pyridyl bromide 2.37 was commercially available and pyridyl
iodide 2.38 was successfully synthesized through three different methods (Scheme 12). The
first method that was used involved a new take on the classical Finkelstein reaction. This
reaction, named after the German chemist Hans Finkelstein who discovered the procedure in
1910, is used for easily replacing one halide with another on alkyl substrates using readily
available halide salts.55 In 2002, Buchwald and Klapers devised the aromatic Finkelstein
reaction in which this substitution could be performed on aromatic halides.56 We enjoyed a
great deal of success using this reaction to synthesize 2.38, achieving yields as high as 85%,
but quickly realized its limitations. The reaction itself requires an expensive
cyclohexyldiamine ligand for activating the copper catalyst. Together with the relatively
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Scheme 12.

high cost of pyridyl bromide rendered this method unfeasible for large scale preparation.
Another method uses 2,6-lutidine [2,6-dimethylpyridine (2.41)], that is much less expensive
than the functionalized pyridine derivatives.57 Despite the accessibility of the reagents and the
ability to perform macro-scale preparations, this reaction employs extremely harsh, acidic
conditions and a laborious work-up procedure consisting of basification, steam distillation,
extraction and chromatography to isolate the pure product. Furthermore, the reaction has
typically only yielded 10-15% of the expected product while in our hands. A more balanced
approach is initiated from moderately priced 3-amino-2,6-dimethylpyridine (2.42) using
another classical reaction known as the Sandmeyer reaction, after the Swiss chemist that
discovered it.58 This reaction proceeds through acid-catalyzed diazonium salt formation,
followed by nucleophilic attack by the desired halide anion, in relatively mild conditions.59
Using this method, yields between 37-58% have been achieved. The balance of moderate
starting material costs, overall ease of performing the reaction and the mass yield has
____________________________________________________
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established the Sandmeyer reaction as the preferred method to synthesize 2.38.
All of the coupling compounds were procured and tested in combination with each
other under a wide variety of reactions conditions, both novel and from relevant literature
sources (Table 1).60 Several different variables were tested including the use of three
different palladium catalysts as well as several different Lewis bases and solvents. A number
of different reaction times and temperatures were also experimented with and in some cases
additives such as exotic phosphine ligands (entries 17 and 18) were used in hopes of inducing
greater reaction efficiency. The table clearly demonstrates that the vast majority of
conditions that were tried resulted in little, if any, of the anticipated coupled product. Under
the conditions that were originally used (Scheme 10), pyridyl bromide 2.37 and dienyl
boronate 2.40 provided slightly increased yields (entry 8) initially leading to the belief that
using an aryl halide may be more efficient in this particular reaction. However, when the
presumably more reactive aryl iodide 2.38 was used under the same conditions, none of the
corresponding coupled product was observed (entries 10-12) even with varying time lengths
of the reaction. In a method described by Falck and co-workers, silver (I) oxide (Ag2O) was
used as an additive to significantly enhance palladium catalyzed Suzuki-like cross-couplings
between alkylboronic acids and a variety of alkyl and alkenylhalides and triflates.61 This
idea was translated to our reaction, first testing pyridyl bromide 2.37 and boronate ester 2.18
(entry 7). Under these conditions a modest 38% yield was observed, only a slight
improvement upon our original conditions. When both of our original coupling partners,
triflate 2.34 and boronate 2.18, were used under these conditions (entry 16) a 76% yield was
____________________________________________________
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(a) Occhiato, E.G.; Lo Galbo, F.; Guarna, A.; J. Org. Chem., 2005, 70, 7324-7230.
(b) Liebscher, J.; Yin, L.; Chem. Rev., 2007, 107, 133-173.
61
Falck, J.R.; Zou, G.; Reddy, K.; Tetrahedron Lett., 2001, 42, 5817-5819.
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Table 1. Attempted Coupling Reactions

Entry

Nuc.

Elec.

Pd Catalysta

Base

Solvent

Additive

Time (h)/Temp. (°C)

1

2.39

2.36

Pd(PPh3)4

K3PO4

toluene

-

24/100

2

2.39

2.36

Pd(PPh3)4

K3PO4

DMSO

-

24/100

3

2.39

2.36

Pd(PPh3)4

NaOH

toluene

-

24/100

4

2.40

2.43

Pd(PPh3)4

K3PO4

toluene

-

24/100

5

2.40

2.37

Pd(OAc)2

dioxane

PPh3

18/100

6

2.40

2.37

Pd(OAc)2

dioxane

PPh3

48/100

7

2.18

2.37

Pd(dppf)Cl2

K2CO3

THF

Ag2O

6/90

8

2.40

2.37

Pd(PPh3)4

K3PO4

dioxane

-

48/100

9

2.40

2.37

Pd(PPh3)4

K3PO4

toluene

-

48/100

10

2.40

2.38

Pd(PPh3)4

K3PO4

dioxane

-

7.5/80

11

2.40

2.38

Pd(PPh3)4

K3PO4

dioxane

-

24/100

12

2.40

2.38

Pd(PPh3)4

K3PO4

dioxane

-

48/100

13

2.18

2.38

Pd(PPh3)4

K3PO4

dioxane

-

24/90

14

2.18

2.38

Pd(dppf)Cl2

K2CO3

THF

Ag2O

6/80

15

2.18

2.34

Pd(dppf)Cl2

K2CO3

THF

Ag2O

2/80

16

2.18

2.34

Pd(dppf)Cl2

K2CO3

THF

Ag2O

7/80

17

2.40

2.34

Pd(OAc)2

K2CO3

dioxane

BrettPhos

22/100

18

2.40

2.34

Pd(OAc)2

K2CO3

dioxane

XPhos

22/100

a

K3PO4
·H2O
K3PO4
·H2O

5 mol% bIsolated yields cContains inseparable starting material dSome starting triflate recovered
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Yield (%)b

8-10
8-13
15
29
15c
32
38
37-43
32c
0
0
0
0
50-81
0
76c
0d
0d

observed, although the obtained organic material was identified as an inseparable ~7:1
mixture of product and starting triflate through proton nuclear magnetic resonance
spectroscopy (1H NMR) analysis. Despite the mixture, these results were extremely
encouraging, and compelled further investigation of these conditions. It was hoped that the
pyridyl iodide 2.38 would be reactive enough so that no starting material would remain upon
isolating the coupled product, or that it could be separated from the product by
chromatography. These conditions proved highly successful (entry 14), as the iodide and
boronate ester 2.18 reacted together to provide the desired coupled product 2.36 in isolated
yields as high as 81%, while generally ranging from 70-75% yields, and no observed starting
material remaining. The success of this reaction can be attributed to the relatively high
reactivity of the iodopyridine species and the additive Ag2O, which acts as a halide scavenger
to precipitate iodide as AgI, and in turn drives the equilibrium of the reaction toward the
product. These conditions marked a drastic improvement in our ability to efficiently and
consistently perform the Suzuki coupling reaction and we are now able to prepare larger
quantities of the coupled precursor 2.35 for continuation through the proposed synthetic
sequence.

2.4. Synthetic route continuation
2.4.1. Preparation of the guaipyridine core
With optimized cross-coupling conditions in hand, it was concluded that the use of
pyridyl iodide 2.38 was imperative to achieving high yields and purity in the reaction. As
previously discussed, 2.38 was used in the optimized coupling conditions using the Ag2O
additive to produce 2.35. The coupled material was then carried through the next several
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reactions in the synthetic route to produce the bicyclic guaipyridine core (2.39) of the final
molecule (Scheme 13). After the Suzuki coupling, dihydroxylation of the trisubstituted
alkene afforded the 1,2-diol 2.43 by Sharpless asymmetric dihydroxylation. Depending on
which of the two AD mix varieties that is used, either stereochemistry can be selected at the
trisubstituted alkene. At this stage it was determined that Ligon and Yarbrough had been
using the incorrect AD mix (β) and thus the stereochemistry at the 8-position (S) was
opposite of that which was desired. In the end, we prepared both enantiomers of the
dihydroxylation reaction, which could ultimately lead us to all four diastereomers of the
target, cananodine. AD mix-α would lead to stereochemistry matching the naturally
occurring cananodine with 5R, 8R configuration by first inducing (S) stereochemistry at the
sp2 internal alkene carbon of 2.35.
Scheme 13.

Yields as high as 71% were achieved for this dihydroxylation reaction and the next
step was epoxidation of the diol. Past researchers had obtained nearly quantitative yields in
the subsequent epoxidation reaction, although reproducing these results was difficult.
Meticulous care was taken in preparing and purifying the necessary reagents before use and
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yields as high as 71% were achieved, although they have typically been much lower.
Important to the stereochemistry in sequence is that the epoxidation mechanism involves an
SN2 like susbstitution to displace a mesylate leaving group. In doing so, the configuration is
inverted at the stereocenter of 2.31. Chiral GC of the epoxide products demonstrated
enantiomeric excess of 96% when selecting (S) configuration with AD mix-α, and 95% when
selecting for (R) configuration with AD mix-β in the dihydroxylation reaction. Despite the
lower yields, the epoxide precursor 2.31 was obtained, purified and successfully cyclized
through base-promoted picolyl anion epoxide-opening to give guaipyridine 2.32. Low yields
are generally observed in this reaction which is attributed the fact that deprotonation can
occur on both of the methyl groups at the 2- and 6-positions. Deprotonation of a picolyl
hydrogen at the 6-position will obviously lead to no epoxide-opening and cyclization, but
could possibly lead to side product formation although none have been specifically isolated.
In producing the cyclized guaipyridine core, compound 2.32, only one stereoselective
hydrogenation reaction remained before the total synthesis of cananodine was completed.

2.4.2. Terminal alkene hydrogenation and reduction reactions
The last step in the total synthesis of cananodine is conversion of the remaining 1,1disubstituted alkene at the 5-position of the cycloheptane ring to the corresponding methyl
with (R) stereochemistry. One hydrogenation reaction was already attempted by Yarbrough
and it demonstrated that the non-selective hydrogenation catalyst, 10% Pd/C, did not provide
any recognizable organic product, let alone 1.10. Two different transition metal
hydrogenation catalysts were also thought to be able to perform the desired transformation:
Wilkinson’s catalyst (2.44) and Crabtree’s catalyst (2.45).62,63 Wilkinson’s catalyst, named
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after Sir Geoffrey Wilkinson, is a rhodium complex containing three triphenylphosphine
ligands and one chloride. Crabtree’s catalyst, named after the British chemist, Robert
Crabtree, possesses an iridium central metal ion with tris(cyclohexyl)phosphine, 1,5cyclooctadiene, and pyridine ligands. Based on previously reported directed Ir
hydrogenations it was hypothesized that the hydroxyl substituent would direct the iridium
metal into position for hydrogenation of the double bond (Figure 8). We were also, however,

Figure 8. Proposed directed hydrogenation of 2.32

aware that the tertiary hydroxyl substituent at the 8-position on the cycloheptane ring of 1.10
may be too sterically hindered or too far away from the alkene at the 5-position to direct such
action. Several distinct conditions were initially attempted in using these hydrogenation
____________________________________________________
62
63

Wilkinson, G.; Young, J.F.; Osborn, J.A.; Jardine, F.H.; J. Am. Chem. Soc., 1966, 1711-1732.
Crabtree, R.H.; Acc. Chem. Res., 1979, 12, 331-337.
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catalysts (Scheme 14). The hydrogenations at one atmosphere were performed using a
hydrogen balloon, while pressurized hydrogenations reactions were performed using a
Fischer-Porter apparatus. The hydrogenation using Crabtree’s catalyst was attempted under
two different hydrogen pressures, using dichloromethane as the solvent. To our
disappointment, reactions at both 1 atmosphere and 50 psi hydrogen pressure yielded no
product, and the starting material was recovered. It is speculated that the tertiary hydroxyl
group is in fact too far away from the alkene to support hydrogenation. Wilkinson’s catalyst
proved to be slightly more successful. Although no product was obtained from reactions
Scheme 14.

using 1 atmosphere of hydrogen, elevated pressures between 30-50 psi did provide modest
yields of the pure products. Both NMR and gas chromatography-mass spectrometry (GCMS) analyses indicated that the isolated products were actually a diastereotopic mixtures
consisting of either 1.10 and 1.10a or 1.10b and 1.10c. Initially it was believed that the
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reaction produced a slight diastereomeric excess of one of the two diastereomers. However,
noticeable broadening in one of the two peaks prompted further GC-MS analysis, and upon
changing the thermal conditions a small starting material (2.32) peak with mass-to-charge
ratio (m/z) of 231 was separated. It is possible that this peak could also correlate to the
unreduced internal alkene isomer of 2.32). The result was a near 1:1 ratio of the two
cananodine diastereomers (Figure 9), eluting at approximately 21.8 and 24.4 minutes, both
with m/z = 233. Hydrogenation of the 2.32 (S) enantiomer afforded at best a ~2:1 mixture of
diastereomers which allowed for specific NMR chemical shift correlation and thus
identification of cananodine resonances by comparing to literature values (see 2.4.3, Tables
2, 3).

PSC264 Gas Chromatogram
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Figure 9. Wilkinson’s hydrogenation crude gas chromatogram

Although the lack of reactivity when using Crabtree’s catalyst and the lack of
selectivity displayed by Wilkinson’s catalyst were disappointing, it was not entirely
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unexpected as largely unhindered, 1,1-disubstituted alkenes have been remarkably understudied and few enantioselective hydrogenation methods exist.64 Encouraged to isolate at
least one of the two pure diastereomers, two additional hydrogenation catalysts were
obtained and used in similar hydrogenation attempts. The norbornadiene (nbd) rhodium
catalyst 2.46, developed by John Kenneth Stille, (well known for the Stille cross-coupling
using alkyl tin and alkyl halides reagents), has been commonly used in hydrogenations of
1,1-disubstituted alkenes.65,66 The exotic threonine-derived phosphinite iridium catalyst, 2.47,
developed by Andreas Pfaltz et al, has also displayed remarkable selectivity in reducing
activated styrene derivatives.67 Both catalysts are commercially available.

The hydrogenations using 2.46 and 2.47 were run using 50 psi hydrogen pressure in a
Fischer-Porter tube. Again, to our disappointment, the Ir catalyst provided a very small
amount of a diastereotopic mixture by GC-MS analysis, but mostly starting material. The
Rh(nbd) catalyst also provided unsatisfactory results as only the starting material was
recovered by NMR analysis. GC-MS analysis of the crude reaction product did indicate that
____________________________________________________
64

Burgess, K.; Cui, X.; Chem. Rev., 2005, 105, 3272-3296.
Stille, J. K.; Amma, J. P.; J. Org. Chem. 1982, 47, 468.
66
(a) Evans, D.A.; Morrissey, M.M.; J. Am. Chem. Soc., 1984, 106, 3866-3868.
(b) Paquette, L.A.; Long, Y.O.; Yang, J.; J. Am. Chem. Soc., 2003, 125, 1567-1574.
67
Pfaltz, A. et al; Adv. Synth. Catal., 2005, 347, 282– 288.
65
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a small amount of product had been formed, and only a single diastereomer was observed.
Literature sources for this Rh catalyst indicate that hydrogen pressures between 600-900 psi
have significantly enhanced overall yields and selectivity, but we lack the appropriate
equipment and instrumentation necessary to perform reactions with such extreme pressure
requirements. Being able to perform this hydrogenation at elevated pressures may result in
higher selectivity for 1.10.
As the extent of practical hydrogenation methods had seemingly been reached, our
attention was turned to alternate alkene reduction procedures. In 2012, Prabhu et al
described a novel guanidine salt catalyzed styrene reduction in the presence of aqueous
hydrazine.68 They believe that the hydrogen bonding capability of guanidine with hydrazine
forms the reductive catalyst and releases nitrogen gas as a by-product. Unfortunately, even
with excessive amounts of both guanidine salt and hydrazine, the reaction was never
successful in our hands. Two lithium metal mediated reductions on a compound related to
2.32 were also were also attempted (see 3.5.) with little success.

All hydrogenation and reduction methods to date have so far been ineffective in
performing the desired reduction of the terminal alkene to produce a single diastereomer of
the target compound. Although standard flash chromatography has proven ineffective in
separating the mixture of diastereomers that are obtained from Wilkinson’s hydrogenation,
other separation methods were explored in hopes of isolating the pure stereoisomers.
____________________________________________________
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Prabhu, K.M. et al; Chem. Comm., 2012, 48, 6583-6585.
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2.4.3. Attempted diastereomer separation
As the number of hydrogenation/reduction methods available had become virtually
exhausted and have proven ineffective in providing just a single cananodine diastereomer, we
turned our attention to high-performance liquid chromatography (HPLC) methods of
separating the diastereotopic mixtures that are obtained from the Wilkinson’s
hydrogenations. It had already been established that the diastereomers 1.10 and 1.10a were
inseparable by standard flash chromatography on both silica and alumina solid phases.
Reverse phase thin-layer chromatography (TLC) also indicated no separation, dampening our
hopes that reverse phase HPLC could achieve the separation.
Despite this, analytical scale reverse phase HPLC was conducted to attempt the
separation and determinate the feasibility of performing HPLC on a preparative scale. The
crude hydrogenation product displayed a sharp peak with retention time of 15 minutes under
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Figure 10. Attempted HPLC separation of diastereomers
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the given solvent conditions, indicating no separation of the two stereoisomers (Figure 10).
Another small peak was observed at approximately 19 minutes in the crude hydrogenation
sample which corresponded to 2.32, verified by matching peaks in a control chromatogram
of just the terminal alkene starting material. Incorporation of 0.1% formic acid into the
solvent system, as suggested by Aisa et al, did not improve separation of the stereoisomers,
or even show any broadening the diastereomer peak at 15 minutes.39 These results indicate
that reverse phase HPLC is not an effective method for separating the cananodine
diastereomers on an analytical scale with the current solvent system.
Although exhaustive efforts to obtain just a single cananodine diastereomer through
multiple hydrogenation and reduction attempts, and HPLC failed to provided just a single
cananodine diastereomer, it can still be confidently said that the desired cananodine
stereoisomer was produced through comparison of 1H NMR and 13C NMR chemical shifts
with previously reported results (Tables 2, 3). Spectral data from both Wu’s naturally
occurring 1.10 and the synthetic 1.10 produced by Craig and Henry were used to assess
chemical shift correlations with our synthetic cananodine.34,43 Resonances from the 5S
epimer, 1.10a, were also deduced based on the known chemical shifts for the naturally
occurring 5R epimer 1.10. The tables show generally close agreement in chemical shifts
between our 1.10 and literature values for both proton and carbon NMR spectra. Some
incongruities can be seen in 1H NMR coupling constants (J values), but all appear to be
within instrumental error. Two curious chemical shift discrepancies are observed at the 8position stereocenter as well as the 7β hydrogen when comparing to the natural product
isolated by Wu. These chemicals shifts, however, both closely match those reported by
Craig and Henry, although they failed to discuss these discrepancies in their own publication.
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Table 2. Cananodine 1H NMR Comparison
δH, multiplicity (J in Hz)
position

3
4
5
6α
6β
7β
7α
8
9β
9α
8-C(CH3)2OH
Me-2
Me-5

Natural product
(400 MHz)

6.97, d (8.0)
7.39, d, (8.0)
3.00, m
1.35, m
1.90, m
1.61, m
2.07, m
1.42, m
2.88, dd (13.2, 6.4)
3.32, d (13.2)
1.24, s
1.24, s
2.51, s
1.32, d (6.8)

Vyvyan et al
(500 MHz)

ΔδH

Craig & Henry
(300 MHz)

5S Epimer

6.94, d (7.8)
7.36, d (7.8)
3.00, m
1.44, (tt, 11.7, 3.9)
1.90, m
1.79, m
2.12, m
1.61, qd (12.2, 3.4)
2.89, dd (12.2, 11.7)
3.22, dd (13.6, 3.9)
1.29, s
1.27, s
2.51, s
1.35, d (7.3)

0.03
0.03
0.00
0.11
0.00
0.18
0.05
0.21
0.01
0.10
0.05
0.03
0.00
0.00

6.93, d (8.0)
7.34, d (8.0)
2.97, m (7.0)

6.95, d
7.30, d
3.00, m
1.44, m
1.89, m
1.73, m
2.02, m
1.61, qd
2.89, dd
3.24, dd
1.28, s
1.26, s
2.50, s
1.33, d

1.92-1.87
2.12-2.07, m
1.59, qd (12.0, 3.5)
2.87, dd (13.5, 10.5)
3.23, dt (13.5, 1.5)
1.25, s
1.24, s
2.49, s
1.31, s

Table 3. Cananodine 13C NMR Comparison
δC, multiplicity
position

2
3
4
5
6
7
8
9
4a
4b
8-C(CH3)2OH
8-C(CH3)2OH
Me-2
Me-5

Natural Product
(100 MHz)

Vyvyan et al
(125 MHz)

153.8, s
121.0, d
133.0, d
35.2, d
36.0, t
32.7, t
47.9, d
38.9, t
138.3, s
160.6, s
73.2, s
27.8, q
25.7, q
23.3, q
20.6

154.3
120.6
132.3
35.3
36.1
32.5
48.0
39.9
137.8
161.0
73.3
27.5
26.2
24.0
20.7

ΔδC

0.5
0.4
0.7
0.1
0.1
0.2
0.1
1.0
0.5
0.4
0.1
0.3
0.5
0.7
0.1
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Craig & Henry
(75 MHz)

154.2
120.7
132.5
35.2
36.2
32.8
48.0
39.4
138.0
160.9
73.3
27.9
25.6
23.7
20.7

5S Epimer

154.7
120.9
135.6
36.5, br
36.5, br
33.8
47.3
39.4
137.4
159.4
73.8
27.3
25.9
26.8
18.6

To our satisfaction, the 13C chemical shifts of our synthetic cananodine match remarkably
well with the already reported values, all within 1.0 ppm. It should be noted that Professor
Craig provided our lab with the actual NMR spectra of their synthetic cananodine as well as
the natural product for visual comparison. The unsettled specific rotation of cananodine can
also be confirmed as the the hydrogenation precursor 2.32 was measured to have [α]20
=
𝐷
+16.3°. In assuming that the sign of the optical rotation does not change after the final
hydrogenation, this experimental evidence suggests that the naturally occurring guaipyridine
exists as (+)-cananodine, which agrees with the data reported by Craig and Henry.

2.5. Progress toward the syntheses of rupestines B-D
We have demonstrated that the epoxide-opening route is an effective method of
producing the bicyclic guaipyridine core, although we have yet to perfect the final method of
reducing the 1,1-disubstituted alkene at the 5-position of the 7-membered carbocycle. The
success in this route led us to believe that a similar synthetic sequence (Scheme 15) could be
used to construct members of the rupestine family. Access to the final rupestines products
Scheme 15.
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could again be achieved through hydrogenation of the terminal alkene in 2.48, which is the
product of a familiar epoxide-opening reaction on 2.49, demonstrated in the synthesis of
cananodine. Compound 2.49 is the likely product of optimized cross-coupling conditions
between 2.38 and 2.50 followed by dihydroxylation and epoxidation procedures. Boronate
ester 2.50 could be prepared from the appropriate heptenone and octenone starting materials.
Rupestines B-D were chosen as target molecules because they contain methyl and ethyl
ketone substituents at the 8-position and were thought to be more easily synthesized than
other rupestine compounds. Rupestines B (1.20) and C (1.21) possess ethyl ketone
substituents and are C5 epimers of one another. Rupestine D (1.22) contains a methyl ketone
substituent at the 8-position.
To synthesize these compounds, additional preparation of the boronate ester Suzuki
coupling partners is required due to the scarcity of commercial suppliers of the alkenones
2.57 and 2.58 (Scheme 16). Inexpensive, commercially available alkynols are first subjected
to chlorination through an SN2 reaction using thionyl chloride (SOCl2) and pyridine to
provide chloro-alkynes 2.56 and 2.57 in good yields. Substitution at the α-position of 2,4pentanedione using K2CO3 in ethanol (EtOH) gave alkynones 2.60 and 2.61. Following
Scheme 16.
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facile semi-hydrogenation, the usual triflation method using PhNTf2 provided dienyl triflates
2.62 and 2.63. It was originally thought that selecting for the (Z) configuration in the internal
alkene could provide higher reactivity in the eventual epoxide opening stage as rotation about
the C3 and C4 carbons would bring the epoxide into a closer proximity to the picolyl anion.
Curiously, after subjecting the newly formed triflates to borylation conditions, none of the
boronate ester products 2.59 and 2.60 were observed upon extraction of the organic material.
It is speculated that the palladium catalyst that is used in this reaction strongly coordinates to
the now less-hindered 1,2-disubstituted alkene, rather than the trisubstituted alkene substrate
used in the cananodine route. This steric relief likely causes side product formation rather
than the expected boronate ester products.
The unsuccessful borylation reaction caused us to make slight adjustments to the
synthetic route. In order to suppress interaction of the palladium catalysts with the internal
Scheme 17.
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double bond of the substrates, Sharpless asymmetric dihydroxylation and protection with an
acetonide group was performed prior to borylation and coupling attempts (Scheme 17). The
dihydroxylation and protection procedures proceeded smoothly to provide protected products
2.63 and 2.64. From there, the borylation procedure was repeated and this time provided the
boronate esters 2.65 and 2.66 in moderate to good yields indicating that functionalization and
protection procedures were necessary for borylation to occur. The optimized coupling
conditions using aryl iodide 2.38 again allowed for easy access to the subsequent coupled
products 2.67 and 2.68, and following deprotection of the diol, compounds 2.69 and 2.70
were obtained for epoxidation attempts. The epoxidation procedure using MsCl and NEt3
followed by K2CO3 and MeOH provided 2.72 (R = Et) in moderate yields, although the small
amount of product obtained was only enough for characterization, and the cyclization
reaction could not be attempted. The same epoxidation procedure was not successful in
providing 2.71 (R = Me), but rather the corresponding bis-mesylate product was observed.
These results suggest that the lack of steric hindrance surrounding the 1,2-diol in 2.71 allows
for fast mesylate bond formation at both hydroxyl sites, and thus the preferential mesylate
formation, elimination and cyclization does not appear to occur. Other routes will need to be
explored for the epoxidation of 2.71.
Later investigation of the enantiopurity of the substrates unfortunately revealed that
the protected diols 2.63 and 2.64 were essentially racemic mixtures by chiral GC analysis and
therefore all of the isolated products after the dihydroxylation stage were also racemic
mixtures. Although disappointing, these results were not entirely unexpected as literature
references indicate very poor enantioselectivity of cis-olefins in the asymmetric
dihydroxylation reaction.60 The importance of enantiopure products in synthetic chemistry,

51

especially when designing potential pharmaceuticals is paramount, as selection of the wrong
stereoisomer commonly leads to limited or no activity, or unwanted side effects.
Consequently, the rupestine B-D synthetic route required further alteration to achieve
improved selectivity at the stereocenters.
The most obvious way to improve the enantioselectivity was to change the geometry
of the internal double bond of the dihydroxylation substrates 2.62 and 2.63. trans-Olefins
have been shown to have a higher degree of selectivity in the dihydroxylation reaction than
their cis-olefin counterparts, and so construction of the trans-analogs of the compounds in
Scheme 17 was envisioned as new synthetic targets (Scheme 18).
Crotyl chloride (2.77) a widely available commercial compound was chosen as the
starting point for the rupestine D synthetic scheme. Using 2.77 as starting material
Scheme 18.
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eliminates the thionyl chloride driven chlorination reaction that was previously a part of the
sequence. This is balanced by the fact that (E)-1-chloropent-2-ene [2.78 (R = Et)] is
extremely difficult to find commercially, and so it was necessary to first reduce 2-pentyn-1-ol
(2.75) with lithium aluminum hydride (LAH) to the analogous trans-alkenol 2.76, and then
convert to the chloro-derivative by the previously mentioned procedure. Both routes also
eliminate down-stream Pd catalyzed hydrogenation of the internal alkyne from the previous
synthetic route which was used to introduce the cis-alkene. Unfortunately, initial
chlorination attempts on substrate 2.76 have only provided the SN2’ product. However,
familiar carbonylation and triflation procedures have been used on 2.77 to provide triflate,
2.80 which then allowed for the Sharpless dihydroxylation. Upon completing the reaction
chiral GC showed vastly improved enantiomeric excess of 61% for 2.82, however still not at
a desirable level of enantiopurity. Despite this, the subsequent three reactions were
attempted which proceeded smoothly as diol 2.85 was isolated for further epoxidation/
cyclization attempts.
It was already established that one epoxidation attempt using NEt3, MsCl, K2CO3,
and MeOH failed to convert the 2.85 substrate to the corresponding product. Although the
number of ways to form reactive intermediates (such as epoxides) from diols is limited, other
methods were attempted in hopes of obtaining a cyclized guaipyridine core (Scheme 19). An
epoxidation method described by Sharpless goes through a cyclic intermediate to form a
halohydrin, and is followed with elimination of the halide by the remaining hydroxyl oxygen
acting as the nucleophile. Trimethyl orthoacetate was first used to form the orthoester
derivative of the starting diol. Two different halide sources, acetyl bromide and
trimethylsilyl chloride, were used to try and induce halohydrin formation. Although
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Scheme 19.

following the reactions by TLC seemed to clearly indicate formation of the cyclic
orthoesters, upon addition of the halide sources TLC analysis became inconclusive. After
completion and work-up of the reaction, spectral analysis indicated only starting material
retention in both cases. Another method to convert diols to more reactive intermediates
described by Sharpless involves formation of a cyclic sulfate form the starting diol.59 Cyclic
sulfates are more reactive (for better or worse) than their oxirane analogs, thus it was thought
if cyclic sulfate 2.88 could be obtained, the efficiency of the subsequent cyclization reaction
could be improved. To make this cyclic sulfate, the cyclic sulfite must first be prepared. The
reaction to produce cyclic sulfite 2.87 was unsuccessful, the starting material was recovered
and the thus cyclic sulfate was never prepared.
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3. Access to the Guaipyridine Core via Intramolecular Heck Reaction
3.1. The Heck cross-coupling reaction
As is common in target oriented synthesis, multiple strategies for producing the same
compound can often be envisaged by the researcher and can potentially lead to surprising
discoveries. A second route to access the guaipyridine core hinges on a late stage
intramolecular Heck cross-coupling reaction between a side-chain monosubstituted terminal
alkene and an aryl halide or triflate. It was hypothesized that this reaction could form the 7membered ring of the final molecule and provide the bicyclic core, inherent to all
guaipyridines. From there, numerous transformations at the 8-position can be envisioned to
eventually synthesize a variety of guaipyridine compounds.

3.1.1. History of the Heck coupling reaction
The Heck reaction itself is a well-established and important tool in organic chemistry
and natural products synthesis for the formation of carbon-carbon bonds, dating back over
four decades. The palladium catalyzed reaction between olefins and aryl halides through
vinylic hydrogen substitution was first reported by Mizoroki et al in 1971, but independently
discovered and refined into a more convenient and practical form by Richard F. Heck (for
whom the reaction is named after) less than a year later.69,70 Palladium catalyzed crosscoupling reactions in general have since become increasingly ubiquitous as a synthetic tool
and arguably the most widely recognized and useful method of forming carbon-carbon
bonds. The importance of these reactions to organic chemistry was recognized in 2010
____________________________________________________
69
70

Mizoroki, T.; Mori, K.; Ozaki, A.; Bull. Chem. Soc. Jap., 1971, 4, 581.
Heck, R.F.; Nolley, Jr., J.P.; J. Org. Chem., 1972, 37, 2320-2322.

55

when Heck shared the Nobel Prize in chemistry with Akira Suzuki and Ei-ichi Negishi (who
soon after Heck developed organoboron and organozinc Pd coupling reactions, respectively)
for their work in developing cross-coupling chemistry.
Like other coupling reactions, the Heck reaction follows a catalytic cycle mechanism
in forming the products (Figure 11).71 Both Pd (0) and Pd (II) catalysts have been shown to
be effective for this transformation, but regardless of the catalyst, it must initially proceed
through a pre-activation step in which the metal center is ultimately reduced to Pd (0).
Standard oxidative addition then occurs, in which the palladium inserts itself between the
alkyl or aryl halide bond, then simultaneously breaks the C-X bond while forming Pd-X and

Figure 11. General Heck reaction catalytic cycle
____________________________________________________
71

Beletskaya, I.P.; Cheprakov, A.V.; Chem. Rev., 2000, 100, 3009-3066.

56

Pd-R bonds. The olefinic substrate then also coordinates to the palladium and is thought to
displace the labile halogen or pseudo-halide from the metal center. The π-electrons from the
olefinic substrate then donate to the metal center forming a transient carbocation, which
allows for migratory insertion of the alkyl or aryl group into the positively charged alkene
substrate and forms the new C-C bond. The palladium then binds a hydrogen atom from the
substrate and the resulting PdH species is eliminated to reform the double bond and release
the product. A last reductive elimination step (not shown) requires a base to regenerate the
active Pd (0) catalyst from the hydridopalladium (II) species.
As widely used as this process has become, the overwhelming majority of literature
references cite reactions of the intermolecular variety involving di- and trisubstituted olefins.
Several years after the initial work by Mizoroki and Heck the first instances of the
intramolecular version of the reaction were reported by Heck and elaborated on by Shibasaki
and other researchers when they began to properly explore the potential and utility of this
transformation.72 Since the late 1980’s and early 1990’s this reaction in general has
flourished in the fields relating to target-oriented synthesis. Overman and Dounay have
reviewed numerous applications of the asymmetric intramolecular Heck reaction from this
era including the synthesis of a variety of alkaloids, terpenoids, polyketides and many other
classes of natural products.73
While the overwhelming majority of cyclizations that the Heck coupling has been
used for involve the formation of 5- and 6-membered ring systems, relatively few examples
of 7-membered ring formation exist. Even fewer publications describe 7-membered
____________________________________________________
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carbocycle formation, although multiple syntheses of 7-membered N-heterocycles have been
reported.74 One of the few examples of 7-membered carbocycle formation through Heck
cyclization was demonstrated by Banerjee et al in their synthesis of the analgesics (±)komaroviquinone and (±)-faveline methyl ether in 2005.75 The group first synthesized
intermediate 3.1 and used an intramolecular Heck reaction to perform the 7-exo cyclization in
forming the tricyclic core (3.2) of the naturally occurring products.

Our guaipyridine targets share similarities in the fused aryl and carbocycle motif with
the substrates used by Banerjee et al in their intramolecular Heck cyclization, which gave us
confidence that the guaipyridine core could be constructed in this manner. Despite the
similarities, the subtle differences in structure, including the presence of a pyridine ring
rather than a benzene ring, made it difficult to say with certainty that a Heck reaction would
be successful. Model studies on simple, less-precious substrates were needed in order fully
validate a Heck reaction mediated synthetic pathway.

____________________________________________________
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3.1.2. Intramolecular Heck reaction model studies
To assess whether the Heck reaction was a viable method for forming our particular
guaipyridine bicyclic system, a series of model substrates were prepared for intramolecular
cyclization testing (Scheme 20). Commercially available 3-bromo-2-methylpyridine (3.3)
was chosen as the test substrate. This compound contains both the aryl halide needed for
Heck cyclization, as well as the 2-methyl functionality needed for constructing alkenyl sidechains of various lengths. The lack of a methyl group at the 6-position made this compound
Scheme 20.

a simpler test substrate. The compounds 3.4 and 3.6 containing butenyl and hexenyl sidechains at the 2-position were prepared with relative ease using a strong lithium base to
deprotonate the picolyl position, and the appropriate alkenyl bromide reagent. To our
disappointment, the corresponding pentenyl derivative, 3.5, could never be formed under the
same conditions and thus no 6-exo Heck cyclization was attempted. This is likely explained
by the strong preference of 4-bromo-1-butene to undergo elimination and form the
conjugated 1,3-butadiene under basic conditions. Even after synthesis of the butenyl ptoluenesulfonate, 3.11, containing a more electronically stable leaving group, the addition
product could not be isolated. Regardless, subsequent Heck cyclization on substrates 3.4 and
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3.6 proved successful. The 5-exo cyclopentylpyridine compound, 3.7, was obtained as the
only product from Heck coupling under standard conditions. The intramolecular coupling of
3.6 provided a 3:1 mixture of 7-exo and 7-endo cyclization products (3.9) by NMR
integration of identifiable vinyl resonances. These results were encouraging as they
presented evidence that the Heck reaction could be used to form the guaipyridine core.
As previously mentioned, the test substrate 3.3 lacked the necessary methyl group at
the 6-position of the pyridine ring. The substrates that will be used to construct our target
molecules contain methyl substituents at both the 2- and 6- positions, and so another model
study was necessary to indicate whether an activating group (such as a halide or sulfide) was
needed to selectively alkylate only the 2-picolyl position (Scheme 21). It was hoped that
functionalizing the phenol with a MOM protecting group would be enough to dictate the
needed selectivity by loosely coordinating a lithium ion to produce a reactive organo-lithium
intermediate in situ. In this competitive lithiation experiment, the 2,6-dimethylated pyridinol
3.12 was chosen as the starting material and chloromethyl methyl ether (MOMCl) was used
to protect the phenol (3.13). From there, a strong lithium base and allyl bromide quenching
Scheme 21.
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agent was used to determine which picolyl site would be deprotonated and subsequently
alkylated. The two expected products were compounds 3.14 and 3.15 which could be
generated by deprotonation at either picolyl site. What was actually observed after isolation
of the organic material and NMR analysis was product 3.16, a somewhat surprising result
stemming presumably from directed ortho metalation (3.13a).76 While neither of the
expected products were observed in this model study, insightful information was nonetheless
gathered as the results clearly indicated that some sort of activating group was needed to
selectively alkylate at the 2-picolyl position.

3.2. Initial synthetic plan
The results obtained from the Heck reaction and competitive lithiation model studies
were encouraging and revealing enough to begin construction of synthetic intermediates.
Our initial synthetic plan was envisaged to consist of two central reaction steps (Scheme 22).
In the first, an intermolecular variant of the epoxide-opening demonstrated in the synthesis of
cananodine could be used to deprotonate the activated picolyl position of compound 3.19 and
Scheme 22.
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add to the electrophilic epoxide ring of 3.20. After halogenation or triflation at the 3-position
of the pyridine ring, the Heck reaction substrate 3.18 would be obtained. The important
intramolecular Heck cyclization would then close the 7-membered ring to provide bicyclic
3.17 and from there multiple transformations on the 8-position substituent and hydrogenation
of the terminal alkene can be envisioned to access a variety of different guaipyridine
compounds. With our synthetic route in mind, the preparation of the epoxide opening
partners was commenced (Scheme 23).
Starting from cheap, commercially available 3-hydroxy-6-methylpyridne (3.21)
aromatic substitution using formaldehyde afforded pyridyl diol 2.11, previously used by
Meyer in her Suzuki coupling optimization attempts (See 2.2). Acid catalyzed substitution
with 48% hydrobromic acid and thiophenol afforded the pyridyl thioether 3.22. The
noticeably poor yields observed in this reaction are thought to stem from the inherent pH
sensitivity of the product. In the work-up procedure, a crude aqueous solution that is too
basic tends to deprotonate the phenol group, while increased acidity protonates the nitrogen
of the pyridine ring. Both scenarios result in water soluble compounds which cannot be
extracted into the organic phase. Even after work-up at multiple pH levels, additional pure
Scheme 23.
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product could not be obtained. Unfortunately, the phenol group of 2.11 cannot first be
protected because the extremely acidic conditions of the subsequent thioetherication step
would likely cleave any protecting group. Despite a poor yield, the large scale reaction
provided a useable amount of product and the ensuing protection of the phenol group
provided the first epoxide-opening partner, 3.19.
Next was the synthesis of alkenyl epoxide 3.20 [(R = Me) Scheme 24]. The reaction
sequence first involved synthesis of the appropriate phosphonium bromide salt 3.24. This salt
was then used as a ylide in the following Wittig reaction (a C-C bond forming reaction
named after the German chemist, Georg Wittig) with acetone to produce diene 3.25.
Unfortunately, no pure diene 3.25 product was ever isolated. Although at least some product
formation did appear to occur by NMR, the inherent volatility of the compound made
isolation of the pure product difficult if not impossible. Distillation of the material was an
unfeasible purification method due to the relatively small scale of the reactions.
Scheme 24.

The difficulties associated with producing either of the initial epoxide opening
partners 3.19 and 3.20 (R = Me) required us to adjust our synthetic plans and look elsewhere
for compounds that could be used to construct the Heck coupling precursor. In doing so, a
different approach was taken when considering the roles of the alkylation partners that we
hoped could be used to synthesize the desired Heck coupling precursor (Scheme 25). Rather
than using a sulfide activating group, it was hypothesized that the bromide derivative (3.26)
of compound 3.22 could be easily prepared based on past research by Meyer. Performing a
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triflation of the phenol group (3.28) would then serve to both protect the phenol during the
subsequent nucleophilic alkylation and act as the electrophilic site during Heck cyclization.
Preparation of ester 3.29 through simple acid catalyzed esterification with MeOH and the
appropriate carboxylic acid (3.27) would then replace epoxide 3.20 as the second addition
partner. Deprotonation of the carbon α-carbonyl would allow 3.29 to act as the nucleophile
in the reaction as opposed to the electrophilic epoxide. Heck precursor 3.30 could thus be
constructed through nucleophilic addition/bromide elimination between 3.28 and 3.29.
Scheme 25.

3.3. Preparation of precursors and the bromide elimination reaction
Multiple routes for synthesizing pyridyl bromide 3.28 were suggested and initially
pursued (Scheme 26). Acid catalyzed bromination was first attempted by refluxing pyridyl
diol 2.11 in HBr and H2SO4, which resulted in no product formation and isolation of only a
small amount of organic material. Bromination using N-bromosuccinimide (NBS) and PPh3
did not fare any better as very little product was observed in the reaction. The pH sensitivity
of the compound was again thought to be an important factor in isolating the desired product,
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as was the case in the synthesis sulfide 3.22. With this is mind, 2.11 was again refluxed with
HBr and upon concentration and cooling of the reaction mixture thick white crystals formed
at the bottom of the flask. These crystals were isolated and identified as the hydrobromo-salt
of 3.26, compound 3.31, with an observed melting point of 222 °C closely matching the
literature value of 224 °C.77 Although the hydrobromo-salt was easily synthesized,
subsequent triflation of the phenol using two equivalents of NEt3 and O(TF)2 did not result in
any of the desired pyridyl triflate 3.37 and no identifiable NMR resonances were observed.
Scheme 26.

These results led us to two conclusions. First, the difficulty in brominating the
picolyl position indicated that perhaps the phenol group needed to first be protected before
bromination, as suggested by past researchers in the Vyvyan group. Also, because we have
successfully activated phenol groups in the past, activation of both of the hydroxyl groups in
2.11 with either triflate or mesylate groups seemed to be a reasonable supposition. The latter
proposal would also eliminate protection and deprotection procedures in the total synthesis,
as the aryl triflate or mesylate would be used as a leaving group in the Heck cyclization.
____________________________________________________
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Bis-triflation was first attempted by reacting 2.11 with excess NEt3 and Tf2O at a
reduced temperature (Scheme 27) and mixed results were observed from three separate
attempts at synthesizing the bis-triflate 3.32. While the product certainly appeared to have
been synthesized by NMR analysis, it was isolated after chromatography as viscous red oil,
indicating significant inseparable impurities which included a large amount of the monotriflate species. The amount of mono-triflate that was produced and the overall amount of
organic material that was isolated from the reaction appeared to vary drastically with each
attempt. Regardless, the apparent bis-trilfate mixture was used in the ensuing alkylation
reaction which successfully resulted in compound 3.30, although in a poor overall yield and
purity.
Scheme 27.

The mixed results displayed by the bis-triflation route incited experimentation with
mesylate activating groups. The expected product in a reaction between 2.11 and excess
NEt3 and MsCl was the bis-mesylate 3.33. However, the chloride ions generated in the
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mixture appeared to undergo a substitution reaction at the picolyl position instead, as
evidenced by GC-MS data (m/z = 236) for the isolated product and only one mesylate singlet
at 3.30 ppm in the 1H NMR spectrum. This result, although unexpected, was not
unwelcomed as the chloride substituent at the picolyl position could still potentially be used
as the leaving group in the following nucleophilic substitution. However, when this
transformation was attempted a disappointing 13% of impure Heck precursor 3.35 was
obtained.
The poor efficiency of the bis-activation routes and the overall impurity of the
products obtained from them forced us to take a step back and consider protecting the phenol
group before any further transformations on the substrate (Scheme 28). After protection of
2.11 with an allyl group, bromination of the 2-picolyl position became a simple task resulting
in bromide 3.37. Although the methyl ester 3.29 was somewhat successful in previous
Scheme 28.
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nucleophilic addition reactions, it was also changed to the tert-butyl ester derivative (3.38) in
hopes that the increased steric bulk would suppress self-condensation of the ester in the
strongly basic conditions. Increased reactivity was indeed observed as the bromide
elimination reaction between 3.37 and 3.38 proceeded smoothly in satisfactory yields to
synthesize the first important intermediate in the sequence, 3.39. Subsequent Pd catalyzed
phenol deprotection was the next course of action. Initial fears that the Pd(PPh3)4 catalyst
would interact with the side-chain alkene rather than the allyl protecting group were quickly
dismissed when the reaction resulted in very good yields of phenol 3.49 as the only product.
Triflation of the newly formed phenol group was also achieved in good yields, culminating a
series of highly successful reactions to produce the Heck coupling precursor 3.41.

3.4. Intramolecular Heck reactions
After successful synthesis of the Heck precursor 3.41, the stage was set to test
intramolecular Heck coupling reaction conditions in hopes of constructing the bicyclic
guaipyridine core 3.42. Several different conditions were used before successful conversion
of the starting alkenyl triflate to the corresponding 7-membered ring was observed (Table 3).
Pd(OAc)2, a Pd (II) species, was the first catalyst that was tried because of the success that
was achieved when this catalyst was used in the model Heck reaction studies, providing 5and 7-membered carbocycles from intramolecular cyclization. Despite the earlier success of
these conditions, two reactions under roughly the same time and temperature conditions, but
employing different bases, provided no product and starting material was recovered (entries
1, 2). Changing the palladium (II) species to Pd(dppf)2Cl2, again under the same conditions,
did not result in any of the desired product (entry 3). It was not until Pd(PPh3)4 was used as
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the catalyst that any product was observed (entry 4). After letting the mixture stir for about
one day with K2CO3 and PPh3 in acetonitrile at elevated temperatures, the product 3.42 was
isolated in very good yields after separation from impurities via chromatography.

Table 4. Survey of Heck Pd Catalysts and Bases

Entry

Pd. Catalysta

Lewis Base

Solvent

Additive

Time (h)/
Temp. (°C)

Yield (%)b

1

Pd(OAc)2

K2CO3

MeCN

PPh3

20/90

0c

2

Pd(OAc)2

K3PO4

MeCN

PPh3

22.5/90

0c

3

Pd(dppf)Cl2

K2CO3

MeCN

PPh3

23/90

0

4

Pd(PPh3)4

K2CO3

MeCN

PPh3

23/90-100

75-84

a

25 mol% bIsolated yields cSome starting material recovered.

To our satisfaction 3.42 was the only product that was isolated, even though model
studies indicated the potential for both 7-exo and 7-endo cyclization mechanisms. Also of
note is the fact that while neither of the palladium (II) catalysts provided cyclized products of
any kind, switching to the Pd (0) catalyst readily gave the desired product and in very
acceptable yields. One rationale for this is that the PPh3 that is used to displace the
monoanionic acetate or chloride ligands of the Pd (II) catalysts and reduce the metal center to
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the zero oxidation state may not have had the desired effect. It has yet to be seen in our lab
whether this reaction would proceed without the use of PPh3 when using a Pd (0) catalyst.

3.5. Attempted hydrogenation and reduction reactions
Synthesis of the guaipyridine core compound 3.51 can be accomplished in seven
steps in a 13% overall yield. Still, the issue at hand was whether the 1,1-disubstituted alkene
at the 5-position could be stereoselectively reduced. It was hoped that the larger ester
coordinating group would be able to better assist in a hydrogenation using Crabtree’s Ir
catalyst, and it was yet to been seen what effect the already semi-successful Wilkinson’s
catalyst would have during hydrogenation. Subjecting 3.42 to Crabtree’s hydrogenation
conditions, again, appeared to have no effect and starting material was recovered from the
reaction. Wilkinson’s catalyst had essentially the same effect on 3.42 that it did on the
cananodine precursor 2.32. NMR and GC-MS analysis, for a second time, revealed a 1:1
ratio of the diastereomers 3.43 and 3.43a.

Several alternative reduction attempts were also tried on this substrate. The
previously attempted guanidine nitrate catalyzed reduction fared no better in reducing the
alkene in 3.42 than it did in the reaction with 2.32 (See 2.4.2.). Even with a significant
excess of the guanidine salt catalyst and hydrazine, no product could be isolated.
Two lithium metal mediated reductions were also attempted. In the first, lithium and
____________________________________________________
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dimethylaminonaphthalene (DMAN) were reacted together to form a green radical-anion
‘LDMAN’ solution (Scheme 29).78 This solution was then added to 3.42 and after a series of
one-electron and proton donations at the double bond (mediated by the proton donor, tBuOH), 3.43 would be the expected product. Again, this reduction did not appear to have
reduced the double bond as only a miniscule amount of product was observed by NMR and
GC-MS analysis. Distinctive color changes were, however, observed during the course of
the reaction suggesting that some reaction was in fact occurring. Upon addition of LDMAN
to 3.42, the solution turned bright orange. Then, quenching with the first equivalent of tBuOH changed the solution to colorless. These visual indicators suggested that the radical
anion of 3.42 was initially generated and that quenching with 1 eq. of t-BuOH provided the
corresponding methyl radical. However, any further addition of LDMAN/t-BuOH failed to
effect noticeable change in the solution, and in the end the starting material was recovered.
This color change could also be caused by deprotonation at the 2-picolyl position.
Scheme 29.

The last reduction attempt was derived from a well-known procedure known as the
Birch reduction, named after the Australian chemist Arthur Birch who published a series
articles describing his work with metal mediated reductions from 1944-1949.79 This reaction
employs liquid ammonia at reduced temperatures along with the lithium metal to generate
free electrons and ammonia anions, which are powerful reducing agents. Although this
____________________________________________________
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method has traditionally been used for reducing aromatic compounds to their corresponding
1,4-cyclohexadiene counterparts, we were hopeful it could have the same effect on the
conjugate alkene of 3.42. After successful generation of ammonia anions, the solution was
added to the 3.42 substrate. Spectroscopic analysis of the crude reaction product again
indicated only a very small amount of product 3.43 formation. These results concluded three
largely unsuccessful alkene reduction attempts as well as three different hydrogenation
attempts resulting in little to no product formation. Only the Rh based Wilkinson’s catalyst
provided products of any kind although, as noted, in ~1:1 diastereotopic mixtures.

3.6. Attempted reductive-Heck reactions
To try and avoid the hydrogenation and reduction procedures all together, we
consulted appropriate literature sources to assess whether a reductive-Heck reaction was
feasible in our system. This type of reaction would reduce the terminal double bond through
hydride addition while simultaneously forming the 7-membered ring of the guaipyridine
core. Although the first instance of hydride ion capture by a vinylpalladium species was
reported in 1988 by Grigg et al, very few references are available for this type of reaction and
no reports of 1,1-disubstututed alkene reduction during Heck coupling could be found.80
Recent total syntheses have, however, demonstrated precedence for using the reductive Heck
____________________________________________________
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reaction to form both 7-membered carbocycles and heterocycles. For instance, in 2012 Sinha
et al used the reductive-Heck reaction to synthesize members of the iboga alkaloid family.81
By submitting the azabicyclooctene indolamine 3.44 with indolyl iodide to reductive-Heck
conditions they were able to synthesize the 7-membered N-heterocycle 3.45.
The conditions for reductive-Heck couplings are generally very similar to those used
in standard Heck reactions. In order to induce the desired reductive effects, a hydride ion
source must be made available within in the reaction system to reduce the vinylpalladium
intermediate. Commonly used hydride sources for this reaction are formic acid or sodium
formate due to their willingness to act as hydride donor and because unreactive carbon
dioxide is generally the only by-product that is produced. Nitrogen-containing bases are also
frequently used in these reactions. Several different conditions were surveyed in hopes of
producing the reduced guaipyridine core 3.52 (Table 4). To our disappointment, standard
conditions using both formic acid and sodium formate as the hydride source did not provide
the reduced product (entries 1, 2). Adding the nitrogen base, piperidine, was also
unsuccessful under similar conditions (entry 3). Employing the ammonium salt,
tetrabutylammonium bromide (Bu4NBr), as the base provided an interesting mixture of
products (entry 4). Although 3.52 was still not observed, the standard Heck reaction product
3.51 as well as the internal alkene isomer 3.53 were initially isolated in a 44% yield as an
inseparable 3:1 mixture. Re-subjecting the material to the same conditions did not enhance
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the ratio of either isomer indicating that the isomerization occurred before cyclization. A
repeated trial of this reaction demonstrated inconsistent yields, and thus was abandoned.
Table 5. Reductive Heck Coupling Conditions

Entry

Pd cat.

Hydride
Source

Base

Additive

Solvent

Time (h)/
Temp. (°C)

Product

1

Pd(PPh3)4

HCO2H

-

PPh3

DMF:MeCN

6/60

-

2

Pd(PPh3)4

HCO2Na

-

PPh3

DMF:MeCN

6/60

-

3

Pd(PPh3)4

HCO2Na

piperidine

-

DMF

5/75

-

4

Pd(OAc)2

HCO2Na

Bu4NBr

-

DMF

24/r.t.

3.42, 3.46

With a second, efficient route for accessing the bicyclic guaipyridine core in hand,
continued pursuit of an efficient hydrogenation or reduction method for the final terminal
alkene must be continued. Despite the inability to effectively perform such a reaction thus
far, numerous transformations can be envisioned at the 8-position to create many rupestine
analogs and other synthetic guaipyridine compounds.
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4. Conclusions
Overall, two different methods of accessing the bicyclic guaipyridine core was
successfully demonstrated and may lead to future guaipyridine syntheses. The first synthetic
route employs base-promoted epoxide-opening to form the 7-membered ring of the
guaipyridine core while the second route makes use of an intramolecular Heck cyclization to
form the same bicyclic core. In doing so, many synthetic challenges were overcome and key
products were isolated, leaving well-defined goals for future synthetic aspirations.
Much of the epoxide-opening cyclization route had already been accomplished by
past researchers, but the remaining terminal alkene hydrogenation and low yields from key
synthetic steps left much to be desired. Optimization of the important Suzuki cross-coupling
reaction led to a much needed improvement of the mass recovery of the coupled
intermediate, and thus the synthetic route was continued to the final stereoselective
hydrogenation step. The best results stemming from exhaustive hydrogenation and reduction
attempts provided disappointing diastereotopic mixtures of the target compound, cananodine.
The desired product and the three other cananodine diastereomers were, however, confirmed
by several characterization techniques including NMR, HRMS and GC-MS analyses.
After much initial toil, a second synthetic route was developed to efficiently produce
the guaipyridine core. A key reactions in this sequence was alkylation of a pyridyl bromide
which provided an important intermediate. After two additional steps, the Heck precursor
was isolated and employing intramolecular Heck reaction conditions gave the guaipyridine
bicyclic core. Although hydrogenation and reduction attempts were also tried on the terminal
alkene of this compound, no improvement in selectivity was observed. Future
transformations of the functional group at the 8-position could lead to a variety of
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guaipyridine compounds. For instance, treating the ester substituent with excess MeMgBr
would provide the 2-propyl substituent of cananodine, while conversion of the ester to the
aldehyde followed by treatment with 1 eq. MeMgBr or EtMgBr and then oxidation of the
resulting secondary alcohol would be expected to give the methyl and ethyl ketones of
rupestines B-D.
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5. Experimental Section
General Experimental Procedures
All reactions were performed following all necessary safety procedures, including the
use of nitrile gloves and UVEX splash-proof safety goggles. All reactions involving air- or
moisture-sensitive materials were carried out in oven and/or flame dried glassware under
argon. All reactions were stirred using a magnetic stir bar at room temperature unless
otherwise noted. Diethyl ether, THF, CH2Cl2, MeCN, and toluene were dried before use by
passing through a column of activated alumina using an Innovative Technology Pure Solv™
400 Solvent Purification System. All solutions were concentrated by rotary evaporation
under reduced pressure.
All chromatography was performed with mixtures of hexanes and ethyl acetate unless
otherwise noted. For materials purified by chromatography, parameters are reported using
the following format: (column diameter, solvent reservoir volume, solvent mixture ratio).
Flash chromatography (~10 psi) was carried out with hand-packed columns of silica
(Silicycle, 230-400 mesh). All TLC analysis was performed using Sorbent Technologies 200
µm silica layer fluorescence UV254 TLC plates.
1

H NMR spectroscopy experiments were performed on a Varian Unity Inova 500

MHz FT-NMR spectrometer and plotted and processed by VnmrJ 3.2 and/or Spinworks 3
software. Between eight and 32 scans were performed on each sample and referenced to the
tetramethylsilane (TMS) peak (0.00 ppm). Chemical shifts are reported using the following
format: chemical shift (ppm) [multiplicity (s = singlet, d = doublet, t = triplet, q = quartet,
quin. = quintet, br = broad), coupling constant(s) (J in Hz), integral, proton assignment].
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13

C NMR spectroscopy experiments were performed on a Varian Unity Inova 500

MHz FT-NMR Spectrometer and processed by the VnmrJ 3.2 software. Between 256-1026
scans were performed on each sample and referenced to the CDCl3 triplet resonace (77.0
ppm). Chemical shifts are reported using the following format: chemical shift (ppm).
Infrared spectroscopy experiments were performed on a ThermoNicolet Nexus 470
FT-IR Spectrophotometer (Diamond ATR) and plotted and processed by the OMNIC
software. Absorptions are reported using the following format: absorption (cm-1) [intensity
(s = strong, m = medium, w = weak, br = broad)].
Gas chromatography-mass spectrometry was performed using a Varian CP3800 GC
with Saturn 2000 Ion Trap MS with the help of Charles Wandler and WWU Scientific
Technical Services. Gas chromatograms and mass spectra were processed using Varian MS
Data Review Version 6.9 and plotted using Microsoft Excel 2010. High resolution mass
spectrometry was performed by the Dr. John Greaves lab at the University of CaliforniaUrvine. Chiral gas chromatography was performed on a Varian 3900 gas chromatograph
using an Agilent Cyclosil-B 30 m × 0.256 µm ID × 0.25 µm column. Data was processed
with the Interactive Graphics 6.9 software and plotted using Microsoft Excel 2010. High
performance liquid chromatography was performed using a Varian 240 Prostar HPLC with
programmable UV/Vis detector with the help of Erin Macri and WWU Scientific Technical
Services. HPLC spectra were processed with the Interactive Graphics 6.9 software and
plotted using Microsoft Excel 2010. Polarimetry experiments were performed using a
Rudolph Digital digital polarimeter and calibration was checked with a d-menthol standard
(+50°, c = 10, l = 0.10 dm, EtOH).
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General Procedure A: Triflation
Preparation of 6-methylhepta-1,5-dien-2-yl trifluoromethanesulfonate82

Notebook Entry: PSA143, PSB030, PSB130, PSB162, PSB234, PSC032, PSC126, PSC235,
PSC280, PSD010, PSD017
LHMDS (1.06 M, 30.1 mL, 32.5 mmol) and THF (60 mL) were added to a 250 mL round
bottom flask under Ar atmosphere brought to -78 ˚C in a dry ice/isopropanol bath. Alkenone
2.16 (3.16 g, 25 mmol) was added drop-wise to the reaction flask over the course of 30 min
in a solution THF (13 mL). The solution was stirred an additional 15 min before quick
addition of PhNTf2 (9.38 g, 26.3 mmol) was added via cannula in a solution of THF (23 mL)
and the mixture warmed to room temperature overnight. The reaction was quenched with
sat. NaHCO3 solution (50 mL) and diluted with hexanes (50 mL). The combined organic
layers were washed with H2O (2 × 50 mL) and sat. NaCl (1 × 50 mL) and combined organic
layers were dried over anhydrous MgSO4. The solution was filtered and concentrated using
rotary evaporation. Dienyl triflate 2.17 was isolated via flash chromatography (2¾” diameter
column, 1 L reservoir, 19:1 hexanes:EtOAc) (3.71 g, 57%) as a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.10 (d, J = 3.4, 1 H, CH2=C), 5.08 (tt, J = 7.3, 1.5, 1 H,

CH2-CH), 4.93 (dt, J = 3.4, 1.0, 1 H, CH2=C), 2.36 (t, J = 7.4, 2 H, C-CH2), 2.23 (app. q, J =
6.8, 2 H, C-CH2-CH2), 1.70 (s, 3 H, CH3), 1.62 (s, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 133.7, 121.5, 104.3, 33.9, 25.63, 25.59, 24.6, 17.7.

FT-IR (Diamond ATR): 3092 (w), 2961 (w), 1715 (m), 1525 (m), 1350 (s), 1290 (s), 1268
(s), 1194 (m), 1135 (m), 823 (m), 718 (s).
____________________________________________________
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General Procedure B: Pd Catalyzed Borylation
Preparation of 4,4,5,5-tetramethyl-2-(6-methylhept-5-en-2-yl)-1,3,2-

dioxaborolane

Notebook Entry: PSB034, PSB045, PSB117, PSB133, PSB140, PSB166, PSB270, PSC040,
PSC236, PSC281, PSD012, PSD019
Bis(pinacolato)diboron (0.917 g, 3.61 mmol), PdCl2(PPh3)2 (0.115 g, 0.164 mmol), KOPh
(0.651 g, 4.93 mmol) and PPh3 (0.0516 g, 0.197 mmol) were loaded into 100 mL round
bottom flask and brought under Ar atmosphere. Toluene (35 mL) and dienyl triflate 2.17
(0.848 g, 3.28 mmol) were then added to reaction flask and the mixture was stirred at 60°C
for 6 h. DI H2O was added to the flask and the aqueous layer was extracted with hexanes (3
× 20 mL). The combined organic layers were washed with sat. NaCl (1× 20 mL) and dried
over anhydrous MgSO4. The solution was filtered, concentrated and purified by radial
chromatography (4 mm plate, 8 mL/min, 6:1 hexanes:EtOAc) to give dienyl boronate ester
2.18 (0.464 g, 92%).
1H

NMR (CDCl3, 500 MHz): δ 5.77 (d, J = 3.4, 1 H, CH2=C-Bpin), 5.60 (d, J = 3.4, 1 H,

CH2=C-Bpin), 5.14 (t, J = 7.3, 1 H, CH2CH), 2.17 (m, 2H,), 2.11 (t, J = 7.8, 2 H, CH2-CH2),
1.61 (s, 3 H, CH3), 2.57 (s, 3 H, CH3), 1.27 (s, 12 H, Bpin).
13C

NMR (CDCl3, 125 MHz): δ 131.4, 129.0, 124.4, 83.3, 35.6, 27.0, 25.7, 24.9, 24.82,

24.78, 17.7.
FT-IR (Diamond ATR): 2977 (m), 2926 (w), 1370 (m), 1306 (m), 1143 (s).
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Preparation of 6-dimethylpyridin-3-yl trifluoromethanesulfonate

Notebook Entry: PSA135, PSA147
A two-neck, 100 mL round bottom flask was charged with pyridinol 2.33 (0.839 g, 6.80
mmol) and equipped with an addition funnel and rubber septum and brought under Ar
atmosphere. CH2Cl2 (30 mL) and NEt3 (1.07 mL, 7.70 mmol) were added to the reaction
vessel and the solution was cooled in an ice/H2O bath. The solution was allowed to stand for
30 min before OTf2 (1.23 mL, 7.32 mmol) was added drop-wise to the mixture. The reaction
was warmed to room temperature overnight. The solution was washed with sat. NH4Cl and
the aqueous layer was extracted with CH2Cl2 (1 × 20 mL). The combined organic layers
were dried over Na2SO4, filtered, concentrated and purified by radial chromatography (6 mm
plate, 1:2 hexanes:EtOAc) to give pyridyl triflate 2.34 (1.22 g, 70%).
1H

NMR (CDCl3, 500 MHz): δ 7.45 (d, J = 8.3, 1H, Ar-H), 7.08 (d, J = 8.3, 1H, Ar-H), 2.58

(s, 3H, CH3), 2.56 (s, 3H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 158.0, 150.6, 143.5, 129.0, 122.1, 117.3, 24.0, 19.5.

FT-IR (Diamond ATR): 1462 (m), 1421 (s), 1209 (s), 1136 (s), 1091 (s).
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Preparation from pyridyl triflate of 2,6-dimethyl-3-(6-methylhepta-1,5dien-2-yl)pyridine

Notebook Entry: PSB021, PSB023
A two-neck, 100 mL round bottom flask was charged with K3PO4 (1.25 g, 5.9 mmol) and
Pd(PPh3)4 (0.1132 g, 0.098 mmol) and equipped with reflux condenser and septum. The
reaction flask was flushed with Ar, then dioxane (25 mL) and pyridyl triflate 2.35 (0.503 g,
1.96 mmol in 5 mL dioxane) were added to reaction flask with stirring. The solution allowed
to stand for 15 min. Dienyl boronate 2.18 (0.557 g, 2.35 mmol in 10 mL dioxane) was added
to the reaction flask and the mixture was stirredstirred at 90 °C overnight. The mixture was
filtered over Celite®, concentrated under vacuum and purified by flash chromatography (1½”
column, 500 mL reservoir, 3:1 hexanes:EtOAc) to produce coupled product 2.35 (0.905 g,
4.45 mmol, 22.5%).
1H

NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 7.6, 1 H, Ar-H), 6.92 d, J = 7.6, 1 H, Ar-H), 5.20

(d, J = 1.8, 1 H, Ar-C=CH2), 5.07 (t, J = 7.3 1 H, CH2-CH), 4.88 (d, J = 1.8, 1 H, ArC-CH2),
2.50 (s, 3 H, Ar-CH3), 2.47 (s, 3 H, Ar-CH3), 2.34 (t, J = 7.6, 2 H, CH2-CH2), 2.04 (m, 2 H,
CH2-CH2), 1.66 (s, 3 H, CH3), 1.52 (s, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 155.9, 154.6, 148.1, 136.4, 134.8, 132.0, 123.6, 120.1,

115.0, 37.6, 26.3, 25.7, 24.2, 22.8, 17.7.
FT-IR (Diamond ATR): 2967 (m), 2925 (m), 2856 (m), 1590 (s), 1465 (s), 1437 (s, br), 1375
(s), 902 (s), 829 (s).
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General Procedure C: Suzuki Coupling58
Preparation 2 of 2,6-dimethyl-3-(6-methylhepta-1,5-dien-2-yl)pyridine

Notebook Entry: PSB122, PSB125, PSB134, PSB137, PSB148, PSB160, PSB182, PSB241,
PSB291, PSC152, PSC223, PSC239, PSD016, PSD020
A flame dried, 100 mL round bottom flask was charged with K2CO3 (3.41 g, 24.7 mmol),
Ag2O (4.77 g, 20.6 mmol) and Pd(dppf)Cl2 (0.672 g, 0.823 mmol) equipped with septum and
stir bar, and brought under Ar atmosphere. Aryl iodide 2.38 (1.92 g, 8.23 mmol) and dienyl
boronate 2.18 (2.04 g, 8.64 mmol) were added to the stirring solution which was then heated
at 90 °C for 6 h. The solution was filtered over Celite® and concentrated. The crude organic
solution was purified by flash chromatography (1 ½” diameter column, 500 mL reservoir, 3:1
hexanes:EtOAc) to provide pyridyl diene 2.35 (1.43 g, 81%).
(For characterization data, see page 79)
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Preparation of 2-bromohexa-1,5-diene83

Notebook Entry: PSB051, PSB089
A three-neck, 100 mL round bottom flask was equipped with a reflux condenser, addition
funnel and septum and brought under Ar atmosphere. The flask was charged with
allylmagnesium chloride (2.0 M in THF, 20.0 mL, 40.0 mmol) and brought to rapid reflux.
After reflux was established, 2,3-dibromopropene 2.41 (85%, 3.25 mL, 30.0 mmol) was
added over the course of 1 h. The reaction stirred under reflux for 2.5 h and then let stirred at
room temperature overnight. The reaction was quenched with 10% HCl solution slowly
drop-wise (CAUTION! vigorous reaction) and the aqueous phase was extracted with diethyl
ether (3 × 30 mL). The combined organic layers were dried over anhydrous CaCl2. The
crude organic solution was filtered, concentrated, and purified by vacuum distillation (bp =
40-43 °C at 39 mmHg) to provide dienyl bromide 2.36 (2.40 g, 50%).
1H

NMR (CDCl3, 500 MHz): δ 5.79 (ddt, J = 10.0, 6.5, 1.8, 1 H, CH2-CH), 5.58 (d, J = 1.2,

1 H, CH=CH2), 5.42 (d, J = 1.2, 1 H, CH=CH2), 5.07 (dd, J = 10.6, 1.2, 1 H, C=CH2), 5.01
(dd, J = 17.0, 1.8, 1 H, C=CH2), 2.51 (t, J = 6.8, 2 H, C-CH2), 2.32 (dt, J = 7.1, 2 H, CH2CH2).
13C

NMR (CDCl3, 125 MHz): δ 138.0, 135.7, 118.5, 117.6, 42.1, 33.8.

____________________________________________________
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Preparation 1 of 2-(hexa-1,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane

Notebook Entry: PSB074, PSB094
A two-neck, 50 mL round bottom flask was equipped with a stir bar, thermometer and
septum and brought under Ar atmosphere. Dienyl bromide 2.36 (0.805 g, 5.00 mmol) in a
solution of THF (9 mL) was added to the flask and cooled with a dry ice/isopropanol bath.
The solution allowed to stir for 0.5 h before drop-wise addition of t-BuLi (1.6 M, 6.25 mL,
10.0 mmol) followed by an additional 0.5 h of stirring. pinBi-OPr (1.40 g, 7.50 mmol) was
added in a solution of THF (6 mL) and the reaction flask was allowed to slowly warm to
room temperature overnight. The reaction was quenched with H2O (10 mL), the aqueous
layer extracted with CH2Cl2 (3 × 15 mL), and combined organics layers were dried over
anhydrous MgSO4. The crude organic solution was filtered through a Celite® plug and
concentrated. The product was purified by flash chromatography (1½” diameter column, 500
mL reservoir, 9:1 hexanes:EtOAc) to provided boronate ester 2.40 (0.589 g, 57%).
1H

NMR (CDCl3, 500 MHz): δ 5.82 (m, 1 H, CH=CH2), 5.79 (d, J = 3.9, 1 H, C=CH2), 5.62

(s, 1 H, C=CH2), 5.0 (dd, J = 17.1, 2.0, 1 H, CH=CH2), 4.94 (dd, J = 10.3, 1.5, 1 H,
CH=CH2), 2.22 (m, 4 H, CH2-CH2), 1.27 (s, 12 H, Bpin).
13C

NMR (CDCl3, 125 MHz): δ 138.8, 129.4, 114.4, 83.3, 82.9, 34.8, 33.5, 26.9, 24.7, 24.6.
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Preparation 2 of 2-(hexa-1,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane

Notebook Entry: PSB092, PSB105
A 50 mL round bottom flask was charged with Mg turnings (0.350 g, 14.4 mmol) and
sublimed I2 (7 crystals) and equipped with a stir bar and septum. The flask then brought
under Ar atmosphere at which time THF (20 mL) was added. The solution stirred until most
of the original color had disappeared. HBpin (3.15 g, 24.6 mmol) was then added followed
by addition of dienyl bromide 2.36 (1.93 g, 12.0 mmol) over 5 min and the mixture stirred
for 3 h. The reaction was quenched with 10% HCl (5 mL) and extracted with diethyl ether (2
x 10 mL). The combined organic layers washed were with sat. NaCl (1 x 15 mL) and dried
over MgSO4. The crude organic solution was then filtered and concentrated under vacuum.
Purification by radial chromatography (4 mm plate, 8 ml/min, 3:1 hexanes:EtOAc) provided
boronate 2.40 (0.857 g, 34%).
(For characterization data, see page 85)

86

Preparation from pyridyl bromide of 3-iodo-2,6-dimethylpyridine53

Notebook Entry: PSB103, PSB112, PSB129, PSB154
A 25 mL screw-top culture tube was equipped with stir a bar and septum and brought under
Ar atmosphere. The flask was charged with pyridyl bromide 2.37 (1.13 g, 6.00 mmol) and
dioxane (6 mL). The septum was briefly removed and copper (I) iodide (0.059 g, 0.300
mmol), NaI (1.88 g, 12.0 mmol) and N,N-(dimethyl)cyclohexyldiamine (0.084 g, 0.600
mmol) were quickly added to the stirring solution. The septum was replaced with a screw
cap and the reaction was heated at 110 °C for 24 h. The reaction was allowed to cool to
room temperature before dilution with sat. NH4Cl (5 mL). The solution was poured into H2O
(20 mL), followed by extraction of the aqueous layer with CH2Cl2 (3 × 15 mL). The
combined organic layers were dried over anhydrous Na2SO4. The crude organic solution was
filtered and concentrated, then purified by radial chromatography (6 mm plate, 10 mL/min
1:1 hexanes:EtOAc) to provide pyridyl iodide 2.38 (1.19 g, 85%).
1H

NMR (CDCl3, 500 MHz): δ 7.90 (d, J = 7.9, 1 H, Ar-H), 6.70 (d, J = 7.9, 1 H, Ar-H),

2.70 (s, 3 H, Ar-CH3), 2.48 (s, 3 H, Ar-CH3).
13C

NMR (CDCl3, 125 MHz): δ 159.3, 157.4, 146.5, 122.2, 92.4, 28.9, 23.9.

FT-IR (Diamond ATR): 2918 (w), 1557 (m), 1420 (s), 1016 (s), 811 (s).
HRMS (CI+) Calculated for C7H9IN: 233.9780. Found: 233.9786.
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Preparation from 2,6-lutidine of 3-iodo-2,6-dimethylpyridine54

Notebook Entry: PSB158, PSB163, PSB165, PSB271
A flame dried, 250 mL, three-neck round bottom flask was equipped thermometer/adapter
and reflux condenser. Fuming sulfuric acid (oleum; 60%, 35 mL) was added to the flask and
cooled in an ice/H2O bath. 2,6-Lutidine 2.41 (7.28 mL, 62.5 mmol) was added to the flask in
portions as to not exceed a solution temperature of 40 °C. The solution was then heated to 50
°C at which time sublimed I2 (19.8 g, 78.1 mmol) was added. The reaction was heated to
200 °C and stirred for 4 h. The reaction was cooled to room temperature and poured over
400 mL crushed ice in a 1 L Erlenmeyer flask. The flask was cooled in an ice bath followed
by quenching with NaOH pellets (~50 g, ~10 g/5 min with swirling) (CAUTION: highly
exothermic reaction). Steam distillation of the crude mixture was performed and the
collected distillate was extracted with ether (2 × 100 mL). The combined organic layers
dried were over anhydrous MgSO4, filtered and concentrated. Purification via flash
chromatography (1½” diameter column, 500 mL reservoir, 3:1 hexanes:EtOAc) provided
pyridyl iodide 2.38 (2.10 g, 15%).
(For characterization data, see page 87)
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Preparation from pyridyl amine of 3-iodo-2,6-dimethylpyridine55

Notebook Entry: PSC142, PSC147, PSC170, PSC196, PSC218, PSD014, PSD018
A two-neck, 100 mL round bottom flask was equipped with a stir bar and thermometer/
adapter and charged with p-TsOH∙H2O (4.69 g, 24.6 mmol) and MeCN (35 mL). The
solution was cooled in an ice/H2O bath at which time aryl amine 2.42 (1.00 g, 8.18 mmol)
was added and a suspension of amine salt precipitated. Meanwhile, a solution of NaNO2
(1.14 g, 16.4 mmol) and KI (3.96 g, 20.5 mmol) in DI H2O (5.25 mL) was prepared. This
solution was added to the amine salt solution drop-wise as to keep the internal temperature
below 10 °C. The solution was stirred for 10 min in the ice-bath and stirred at rt for 1 h. The
reaction mixture was diluted with DI H2O (50 mL) and diethyl ether (30 mL). The obtained
organic layer was washed with sat. NaHCO3 (1 × 30 mL) and sat. Na2S2O3 (2 × 30 mL)
solutions. The combined organic layers were dried over anhydrous Na2SO4, then filtered
and. The crude material was purified by flash chromatography (1½” diameter column, 500
mL reservoir, 3:1 hexanes:EtOAc) to give pyridyl iodide 2.38 (1.10 g, 58%) as light yellow
oil.
(For characterization data, see page 87)
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General Procedure D: Sharpless Asymmetric Dihydroxylation
Preparation of (S)-6-(2,6-dimethylpyridin-3-yl)-2-methylhept-6-ene-2,3diol

Notebook Entry: PSD025
A 250 mL round bottom flask containing pyridyl diene 2.35 (1.33 g, 6.16 mmol) was charged
with AD mix-α (8.63 g, 1.4 g/mmol), MeSO2NH2 (0.762 g, 8.01 mmol), DI H2O (31 mL)
and t-BuOH (31 mL). The solution was initially stirred in an ice/H2O bath and allowed to
warm gradually to rt for 24 h. The reaction was quenched with Na2SO3 (~8 eq.) and stirred
for 15 min before removal of t-BuOH by rotary evaporation under vacuum. The solution was
diluted with H2O and extracted with EtOAc (2 × 50 mL). The combined organic layers were
dried over MgSO4, concentrated and purified by flash chromatography (1½” diameter
column, 500 mL reservoir, 5% EtOH in EtOAc) to provide pyridyl diol 2.43 (0.80 g, 52%).
1H

NMR (CDCl3, 500 MHz): δ 7.25 (d, J = 8.22, 1 H, Ar-H), 6.93 (d, J = 7.6, 1 H, Ar-H),

5.24 (s, 1 H, C=CH2), 4.92 (s, 1 H, C=CH2), 3.38 (dd, J = 10.6, 2.4, 1 H, CH-OH), 2.65 (m,
1 H, C-CH2), 2.51 (s, 3 H, Ar-CH3), 2.49 (s, 3 H, Ar-CH3), 2.40 (m, 2 H, C-CH2), 1.87 (s, br,
1 H, OH), 1.50 (m, 1 H, CH2-CH2), 1.41 (m, 1 H, CH2-CH2), 1.16 (s, 3H, CH3), 1.12 (s, 3H,
CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.3, 154.8, 148.0, 136.6, 134.8, 120.6, 115.7, 73.2, 34.8,

29.9, 26.7, 24.3, 23.2, 22.8, 14.2.
FT-IR (Diamond ATR): 3355 (w, br), 2952 (w), 2668 (w), 1394 (w), 831 (s)
HRMS (ESI, M+Na) Calculated for C15H23NNaO2: 272.1627. Found: 272.1623.
[α]𝟐𝟎
= -18.0° (c = 0.50, l = 0.10 dm, CHCl3).
𝑫
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Preparation of (R)-6-(2,6-dimethylpyridin-3-yl)-2-methylhept-6-ene-2,3diol

Notebook Entry: PSB124, PSB126, PSB150, PSB161, PSB188, PSB242, PSB292, PSC153,
PSC225, PSC240
In accordance with General Procedure D, a 250 mL round bottom flask containing pyridyl
diene 2.35 (1.07 g, 4.95 mmol) was charged with AD mix-β (4.85 g, 1.0 g/mmol),
MeSO2NH2 (0.612 g, 6.34 mmol), DI H2O (50 mL) and t-BuOH (50 mL). The solution was
stirred at rt for 24 h. Purification by flash chromatography (1½” diameter column, 500 mL
reservoir, 5% EtOH in EtOAc) provided pyridyl diol 2.43 (1.22 g, 70%).
(For spectroscopic characterization data, see page 90)
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General Procedure E: Epoxidation
Preparation of (R)-3-(4-(3,3-dimethyloxiran-2-yl)but-1-en-2-yl)-2,6dimethylpyridine

Notebook Entry: PSD026
Pyridyl diol 2.43 (0.72 g, 2.88 mmol), NEt3 (0.80 mL, 5.76 mmol) and CH2Cl2 (29 mL) were
charged to a 100 mL round bottom flask and brought under Ar atmosphere. The solution was
cooled in an ice/H2O bath before MsCl (0.42 mL, 4.32mmol) was added drop-wise. The
mixture was allowed to warm to room temperature while being monitored by TLC. After
~30 min, MeOH (29 mL) and K2CO3 (1.59 g, 11.52 mmol) were added and the mixture was
stirred at rt overnight. The reaction was then filtered over Celite® and washed with sat.
NaCl (1 × 100 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic layers
were dried over anhydrous MgSO4, filtered and concentrated. Purification by flash
chromatography (2 ¾” diameter column, 1 L reservoir, 1:1 hexanes:EtOAc) provided
epoxide 2.31 (0.38 g, 57%).
NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.8, 1 H, Ar-H), 6.95 (d, J = 7.8, 1 H, Ar-H),
5.28 (app. dd, J = 2.7, 1.46, 1 H, C=CH2), 4.94 (d, J = 1.5, 1 H, C=CH2), 2.74 (dd, J = 7.3,
5.4, 1 H, CH2-CH-C) 2.42 (s, 3 H, Ar-CH3), 2.41 (s, 3 H, Ar-CH3), 2.40 (m, 2 H, C-CH2),
1.60 (m, 2 H, CH2-CH2), 2.24 (s, 3 H, CH3), 2.21 (s, 3 H, CH3).
13C NMR (CDCl , 125 MHz): δ 156.2, 154.5, 147.3, 136.4, 134.4, 120.2, 115.4, 63.8, 58.3,
3
34.4, 27.2, 24.8, 24.2, 22.8, 18.7.
FT-IR (Diamond ATR): 2961 (m), 2925 (m), 1590 (m), 1458 (m), 1174 (m), 839 (s)
HRMS (CI+) Calculated for C15H22NO: 232.1701. Found: 232.1700.
[α]𝟐𝟎
= +10.3° (c = 0.32, l = 0.10 dm, CHCl3).
𝑫
Chiral GC analysis: Hold at 140 °C for 120 min. Retention times: 63.650 (major
enantiomer) and 61.847(minor enantiomer) min. 96.4%.
1H
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Preparation of (S)-3-(4-(3,3-dimethyloxiran-2-yl)but-1-en-2-yl)-2,6dimethylpyridine

Notebook Entry: PSB128, PSB142, PSB146, PSB157, PSC157, PSC227, PSC241
In accordance with General Procedure E, pyridyl diol 2.43 (1.08 g, 4.31 mmol), NEt3 (0.84
mL, 6.03 mmol) and CH2Cl2 (43 mL) were charged to a 25 mL round bottom flask and
brought under Ar atmosphere. The solution was cooled in an ice/H2O bath before MsCl
(0.55 mL, 5.60 mmol) was added drop-wise. The mixture was allowed to warm to room
temperature while being monitored by TLC. After ~1 h, MeOH (43 mL) and K2CO3 (2.38 g,
17.2 mmol) were added and the mixture was stirred at rt overnight. Purification by flash
chromatography (1” diameter column, 250 mL reservoir, 5% EtOH in EtOAc) provided
epoxide 2.31 (0.707 g, 71%).
(For spectroscopic characterization data, see page 92)
[α]𝟐𝟎
= -6.9° (c = 0.34, l = 0.10 dm, CHCl3).
𝑫
Chiral GC analysis: Hold at 140 °C for 120 min. Retention times: 61.714 (major
enantiomer) and 63.491 (minor enantiomer) min. 94.9% ee.
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General Procedure F: Intramolecular Epoxide-Opening
Preparation of (R)-2-(2-methyl-5-methylene-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)propan-2-ol

Notebook Entry: PSD030
A 100 mL round bottom flask was charged with pyridyl epoxide 2.31 (0.28 g, 1.22 mmol)
and brought under Ar atmosphere. The epoxide was dissolved in THF (24.5 mL) and the
solution was cooled in a dry ice/isopropanol bath before n-BuLi (1.6 M, 2.29 mL, 3.67
mmol) was added drop-wise. One additional 1.0 eq. aliquot of n-BuLi was added 15 min
later. The solution was allowed to gradually warm to room temperature with stirring and
then quenched with sat. NaHCO3. The aqueous layer was extracted with diethyl ether (3 x 50
mL), dried over anhydrous MgSO4, filtered and concentrated. Purification by flash
chromatography (1” diameter column, 250 mL reservoir, 5% EtOH in EtOAc) provided the
cyclized material 2.32 (0.092 g, 33%) as a light yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 7.44 (d, J = 7.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H),

5.12 (app. s, 1 H, C=CH2), 5.10 (d, J = 2.0, 1 H, C=CH2), 3.19 (app dt, J = 15.1, 2.0, 1 H,
Ar-CH2), 2.87 (dd, J = 14.7, 9.3, 1 H, Ar-CH2), 2.63 (ddd, J = 13.7, 7.8, 4.9, 1 H, Ar-CCH2), 2.51 (s, 3 H, Ar-CH3), 2.40 (ddd, J = 13.2, 8.8, 3.9, 1 H, Ar-C-CH2), 1.87 (s, br, 1 H,
OH), 1.78 (dddd, J = 11.2 9.3, 3.9, 2.0, 1 H, CH2-CH-CH2), 1.60 (m, 2 H, C-CH2-CH2)
13C

NMR (CDCl3, 125 MHz): δ 158.0, 156.2, 148.6, 135.7, 120.9, 114.2, 110.0, 73.4, 47.2,

39.4, 34.3, 30.9, 27.8, 26.3, 24.1.
HRMS (CI+) Calculated for C15H22NO: 232.1701. Found: 232.1709.
[α]𝟐𝟎
= +16.3° (c = 0.92, l = 0.10 dm, CHCl3).
𝑫
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Preparation of (R)-2-(2-methyl-5-methylene-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)propan-2-ol

Notebook Entry: PSB221, PSB248, PSB250, PSC023, PSC029, PSC161, PSC215 PSC231,
PSC243
In accordance with General Procedure F, a 50 mL round bottom flask was charged with
pyridyl epoxide 2.31 (0.108 g, 0.467 mmol) and brought under Ar atmosphere. The epoxide
was dissolved in THF (9.3 mL) and the solution was cooled in a dry ice/isopropanol bath
before n-BuLi (1.6 M, 0.29 mL, 0.467 mmol) was added drop-wise. Two additional 1.0 eq.
aliquots of n-BuLi were added at 15 min intervals. Purification by flash chromatography (1
½” diameter column, 500 mL reservoir, 5% EtOH in EtOAc) provided the cyclized material
2.32 (0.037 g, 35%) as a light yellow oil.
(For spectroscopic characterization data, see page 95)
[α]𝟐𝟎
= -7.2° (c = 0.32, l = 0.10 dm, CHCl3).
𝑫
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General Procedure G: Wilkinson’s Hydrogenation
Preparation of 2-((5R,8R)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)propan-2-ol (cananodine) & 2-((5S,8R)-2,5dimethyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-8-yl)propan-2-ol
(5-epi cananodine)

Notebook Entry: PSB231, PSB264, PSC219
All reagents and equipment were initially brought under nitrogen atmosphere in a glovebox.
Wilkinson’s catalyst (0.018 g, 0.020 mmol) was charged to a 90 mL Fischer-Porter tube.
Cananodine precursor 2.32 (0.092 g, 0.40 mmol) was dissolved in a 9:1 THF:EtOH (8 mL)
solution and added to the Fischer-Porter tube, followed by NEt3 (83 µL, 0.59 mmol). The
Fischer-Porter tube pressure regulator and adapter were then assembled, brought outside the
glovebox, charged with 50 psi H2 gas and allowed to stir overnight. The pressure was
released from the vessel and the solution was filtered through a plug of silica and
concentrated under vacuum to provide a crude mixture of 1.10 and 1.10a (0.045 g, 49%, ~1:1
mixture).
1H

NMR 1.10 (CDCl3, 500 MHz): δ 7.39 (d, J = 7.8, 1 H, Ar-H), 6.94 (d, J = 7.8, 1 H, Ar-),

3.22 (dd, J = 13.6, 3.9, 1 H, Ar-CH2), 3.00 (m, 1 H, Ar-CH), 2.92 (dd, J = 12.2, 11.7, 1 H,
Ar-CH2), 2.51 (s, 3 H, Ar-CH3), 2.14 (m, 1 H, Ar-CH-CH2-CH2), 1.90 (m, 1 H, Ar-CHCH2), 1.79 (m, 1 H, Ar-CH-CH2-CH2), 1.61 (qd, J = 12.2, 3.4, 1 H, Ar-CH2-CH), 1.44 (m, 1
H, Ar-CH-CH2), 1.32 (d, J = 6.1, 3 H, Ar-CH-CH3), 1.29 (s, 3 H, C-(CH3)2-OH), 1.27 (s, 3
H, C-(CH3)2(OH)).
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13C

NMR 1.10 (CDCl3, 125 MHz): δ 161.0, 154.3, 137.8, 132.3, 120.6, 73.3, 48.0, 39.9,

36.1, 35.3, 32.5, 27.5, 26.2, 24.0, 20.7.
1H

NMR 1.10a (CDCl3, 500 MHz): δ 7.30 (d, 1 H, Ar-H), 6.95 (d, 1 H, Ar-H), 3.24 (dd, 1

H, Ar-CH2), 3.00 (m, 1 H, Ar-CH), 2.90 (dd, 1 H, Ar-CH2), 2.50 (s, 3 H, Ar-CH3), 2.02 (m,
1 H, Ar-CH-CH2-CH2), 1.89 (m, 1 H, Ar-CH-CH2), 1.73 (m, 1 H, Ar-CH-CH2-CH2), 1.61
(m, 1 H, Ar-CH2-CH), 1.44 (m, 1 H, Ar-CH-CH2), 1.33 (d, 3 H, Ar-CH-CH3), 1.28 (s, 3 H,
C-(CH3)2(OH)), 1.26 (s, 3 H, C-(CH3)2-OH).
13C

NMR 1.10a (CDCl3, 500 MHz): δ 159.4, 154.6, 133.7, 127.7, 120.9, 73.7, 47.3, 39.5,

36.5, 36.5, 33.8, 27.4, 26.8, 25.9, 18.6.
HRMS 1.10 and 1.10a (CI+) Calculated for C15H24NO: 234.1858. Found: 234.1867 &
234.1865.
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Preparation of 2-((5R,8S)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridin-8-yl)propan-2-ol (8-epi cananodine) & 2-((5S,8S)-2,5dimethyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-8-yl)propan-2-ol

Notebook Entry: PSB231, PSB264, PSC219
In accordance with General Procedure G, all reagents and equipment were initially brought
under nitrogen atmosphere in a glovebox. Wilkinson’s catalyst (0.0023 g, 0.0025 mmol) was
charged to a 90 mL Fischer-Porter tube. Cananodine precursor 2.32 (0.011 g, 0.049 mmol)
was dissolved in a 9:1 THF:EtOH (1 mL) mixture and added to the Fischer-Porter tube,
followed by NEt3 (10 µL, 0.074 mmol). The Fischer-Porter tube pressure regulator and
adapter were then assembled, brought outside the glovebox, charged with 50 psi H2 gas and
allowed to stir overnight. The pressure was released from the vessel and the solution was
filtered through a plug of silica and concentrated under vacuum to provide a crude mixture of
1.10b and 1.10c (0.015 g, 23%, ~2:1 mixture).
(For spectroscopic characterization data, see page 96)
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General Procedure H: Alkynol Chlorination
Preparation of 1-chlorobut-2-yne84

Notebook Entry: PSA011, PSA026, PSA034, PSA044, PSA070, PSA118, PSB061, PSC035,
PSC177
SOCl2 (10.9 mL, 0.150 mol), pyridine (14 drops), and diethyl ether (50 mL) were added to a
three neck, 100 mL round bottom flask, equipped with a reflux condenser and addition
funnel, and brought to reflux. 2-Butyn-1-ol (7.48 mL, 0.100 mol) was added over the course
of 1 h. The solution refluxed for 5 h. The ether was then distilled off and the remaining
solution transferred to a 25 mL round bottom flask. The remaining solution was then
distilled (bp = 101 °C at 760 mmHg) to provide 2.51 as a colorless oil (8.06 g, 91%).
1H

NMR (CDCl3, 500 MHz): δ 4.12 (q, J = 2.9, 2 H, Cl-CH2), 1.85 (t, J = 2.9, 3 H, C-CH3).

13C

NMR (CDCl3, 125 MHz): δ 83.3, 74.1, 31.6, 3.9.

____________________________________________________
84

Crombie, L.; Harper, S.H.; Stedman, R.E.; Thompson, D.; J. Chem. Soc., 1951, 2445-2449.
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Preparation of 1-chloropent-2-yne84

Notebook Entry: PSA020, PSA035, PSA045, PSA048, PSA051, PSA117, PSB072, PSB267,
PSC139, PSC178
In accordance with General Procedure H, SOCl2 (10.9 mL, 0.150 mol), pyridine (14 drops),
and ether (50 mL) were brought reflux with stirring, and 2-pentyn-1-ol (9.19 mL, 0.100 mol)
was added over the course of 1 h. After work-up, the product 2.52 was isolated by
distillation (bp = 121 at 760 mmHg) as a colorless oil (9.14 g, 90%).
1H

NMR (CDCl3, 500 MHz): δ 3.56 (t, J = 7.5, 2 H, Cl-CH2), 2.59 (qt, J = 7.5, 2.3, 2 H,

CH2-CH3), 1.79 (t, J = 2.3, 3 H, CH2-CH3).
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General Procedure I: α-Substitution with 2,4-pentanedione85
Preparation of hept-5-yn-2-one84

Notebook Entry: PSA014, PSA032, PSA036, PSA046, PSA072, PSA120, PSB067, PSC042,
PSC181
Chloroalkyne 2.51 (4.40 g, 49.0 mmol), K2CO3 (7.45 g, 54.0 mmol), 2,4-pentanedione (5.50
mL, 54.0 mmol), and EtOH (50 mL) were combined and refluxed for 24 h in a 100 mL round
bottom flask with stirring. After reflux the excess EtOH, and formed EtOA were distilled
off. The remaining salt solution was dissolved in 60 mL ice H2O, extracted with diethyl
ether (4 × 10 mL) and the combined organic layers were washed with sat. NaCl (2 × 10 mL).
The organic solution was then dried over anhydrous K2CO3, filtered and concentrated.
Alkynone 2.53 was isolated by vacuum distillation (B.P. = 79-82 °C at 30 mmHg) as a clear
colorless liquid (5.22 g, 64%).
1H

NMR (CDCl3, 500 MHz): δ 2.63 (t, J = 7.0, 2 H, C-CH2), 2.39 (tq, J = 5.1, 2.6, 2 H, CH2-

CH2), 2.17 (s, 3 H, H3C-C=O), 1.76 (t, J = 5.1, 3 H, C≡C-CH3).
13C

NMR (CDCl3, 125 MHz): δ 207.0, 58.3, 42.8, 29.9, 13.4, 3.4.

FT-IR (Diamond ATR): 2921 (w), 1716 (s), 1366 (m), 1163 (m), 878 (m).

____________________________________________________
85

Barbot, F.; Mesnard, D.; Miginiac, L.; Org. Prep. Proc. Int., 1978, 10, 261-266.
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Preparation of oct-5-yn-2-one84

Notebook Entry: PSA022, PSA038, PSA047, PSA049, PSA052, PSA119, PSB079, PSC144,
PSC182
In accordance with General Procedure I, chloro-alkyne 2.52 (7.77 g, 0.0770 mol), K2CO3
(11.6 g, 0.0841 mmol), 2,4-pentanedione (8.63 mL, 0.0841 mol), and EtOH (50 mL) were
combined and refluxed for 24 h in a 100 mL round bottom flask with stirring. After work-up
and distillation (B.P. = 85-94 °C at 36 mmHg), alkynone 2.54 was isolated as a clear,
colorless oil (6.37 g, 67%).
1H

NMR (CDCl3, 500 MHz): δ 2.64 (t, J = 6.9, 2 H, O=C-CH2), 2.41 (tt, J = 7.7, 2.2, 2 H,

CH2-CH2), 2.17 (s, 3 H, O=C-CH3), 2.13 (qt, J = 7.7, 2.2, 2 H, CH2-CH3), 1.01 (t, J = 7.7, 3
H, CH2-CH3).
13C

NMR (CDCl3, 125 MHz): δ 207.1, 82.2, 77.8, 43.0, 29.9, 14.2, 13.4, 12.3.

FT-IR (Diamond ATR): 2976 (w), 1716 (s), 1364 (m), 1162 (m).
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General Procedure J: Pd/BaSO4 Semi-Hydrogenation of Alkynes
Preparation of (Z)-hept-5-en-2-one86

Notebook Entry: PSA042, PSA053, PSA074, PSC048, PSC184
Alkynone 2.53 (3.22 g, 29.0 mmol), Pd/BaSO4 catalyst (0.643 g, 20 wt%), quinoline (0.294
mL, 10 wt.%) and EtOAc (100 mL) were combined in a 250 mL round bottom flask with
stirring. The flask was fitted with a rubber septum and flushed with Ar for 5 min. The flask
was then flushed with H2 gas using a hydrogen balloon. Another hydrogen balloon attached
to the flask and the mixture was stirred for 1.5 h. The flask was then flushed with Ar, and
filtered over Celite®. Alkenone 2.55 was obtained after rotary evaporation (3.28 g, 99%).
1H

NMR (CDCl3, 500 MHz): δ 5.48 (dqt, J = 9.9, 6.74, 1.6, 1 H, CH=CH), 5.33 (dtq, J =

9.9, 7.3, 1.6, 1 H, CH=CH), 2.48 (t, J = 7.3, 2 H, O=C-CH2), 2.32 (app. q, J = 7.3, 2 H CH2CH), 2.16 (s, 3 H, CH3-C=O), 1.62 (dd, J = 6.74, 1.0, 3 H, CH-CH3)\
13C

NMR (CDCl3, 125 MHz): δ 208.6, 128.5, 125.1, 43.4, 29.9, 21.3, 12.6.

FT-IR (Diamond ATR): 1718 (s), 1360 (m), 1162 (m), 699 (m).

____________________________________________________
86

Cologne, J.; Descoles, G.; Mugnier, R.; Bulletin de la Societe Chimique de France, 1965, 10, 2733-2738.
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Preparation of (Z)-oct-5-en-2-one87

Notebook Entry: PSA054, PSA055, PSA064, PSA139, PSB091, PSC146, PSC185
In accordance with General Procedure J, alkynone 2.54 (2.39 g, 19.2 mmol), Pd/BaSO4
catalyst (0.478 g, 20 wt.%), quinoline (0.24 mL, 2.1 mmol, 10 wt.%) and EtOAc (75 mL)
were combined in a 250 mL round bottom flask with stirring under H2 atmosphere.
Alkenone 2.56 was obtained after work-up and concentration (2.40 g, 99%).
1H

NMR (CDCl3, 125 MHz): δ 5.40 (dtt, J = 10.7, 7.3, 1.5, 1 H, CH=CH), 5.28 (dtt, 10.7,

7.3, 1.5, 1 H, CH=CH), 2.48 (t, J = 7.8, 2 H, O=C-CH2), 2.31 (app. q, J = 7.3, 2 H CH2CH2), 2.14 (s, 3 H, H3C-C=O), 2.05 (dqd, J = 7.3, 7.3, 1.5, 2 H, CH2-CH3), 0.96 (t, J = 7.3, 3
H, CH2-CH3).
13C

NMR (CDCl3, 500 MHz): δ 208.5, 132.9, 127.0, 43.6, 29.9, 21.6, 20.4, 14.3.

____________________________________________________
87

Crombie, L.; Hemesley, P.; Pattenden, G.; J. Chem. Soc., 1969, 6, 1016-1024.
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Preparation of (Z)-hepta-1,5-dien-2-yl trifluoromethanesulfonate

Notebook Entry: PSA060, PSA114, PSB102, PSC053, PSC186
In accordance with General Procedure A, LHMDS (1.06 M, 33.0 mL, 34.9 mmol) and THF
(60 mL) were added to a 250 mL round bottom flask under Ar atmosphere and cooled in a
dry ice/isopropanol bath with stirring for 15 min. Heptenone 2.55 (3.02 g, 26.9 mmol) was
added drop-wise to the reaction flask over the course of 0.5 h in a solution THF (15 mL).
The solution was stirred for an additional 15 min before quick addition of PhNTf2 (10.1 g,
28.2 mmol) was added via cannula and the mixture warmed to room temperature overnight.
Dienyl triflate 2.57 (2.92 g, 44%) was isolated via flash chromatography (1½” diameter
column, 500 mL reservoir, 19:1 hexane:EtOAc) as a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.57 (dqt, J = 10.7, 7.3, 1.5 Hz, 1 H, CH=CH), 5.36 (dtq, J =

10.7, 7.2, 1.5, 1 H, CH=CH), 5.14 (d, J = 3.4, 1H, CH2=C-OTf), 4.97 (dt, J = 3.4, 1.0, 1 H,
CH2=C-OTf), 2.42 (t, J = 7.3, 2 H, TfO-C-CH2), 2.33 (app. q, J = 7.3, 2 H, CH2-CH2), 1.66
(m, 3 H, CH2CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.4, 127.6, 126.2, 120.2, 104.3, 34, 24, 13.

FT-IR (Diamond ATR): 3020 (w), 2923 (w), 1670 (w), 1416 (m), 1248 (w) 1205 (s), 1140
(m), 883 (m), 693 (m).
HRMS (CI, M+NH3) Calculated for C8H14NF3O3S: 262.0725. Found: 262.0735.
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Preparation of (Z)-octa-1,5-dien-2-yl trifluoromethanesulfonate

Notebook Entry: PSA063, PSA073, PSA144, PSB042, PSB102, PSC154, PSC187
In accordance with General Procedure A, LHMDS (1.06 M, 46.2 mL, 49.0 mmol) and THF
(90 mL) were added to a 500 mL round bottom flask under Ar atmosphere and stirred while
cooling in a dry ice/isopropanol bath for 15 min. Octenone 2.56 (4.76 g, 37.7 mmol) was
added drop-wise to the reaction flask over the course of 0.5 h in a solution of THF (20 mL).
The solution stirred an additional 15 min before quick addition of PhNTf2 (14.1 g, 39.6
mmol) was added via cannula and the mixture warmed to room temperature overnight.
Dienyl triflate 2.58 (4.04 g, 41%) was isolated via flash chromatography (2¾” diameter
column, 1 L reservoir, 19:1 hexane:EtOAc) as a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.50 (dtt, J = 7.4, 3.4, 2.0 1 H, CH=CH), 5.30 (dtt, J = 7.3,

3.4, 2.0, 1 H, CH=CH), 5.14 (d, J = 3.9, 1 H, CH2=C-OTf), 4.95 (dt, J = 3.4, 1.0, 1 H,
H2C=C-OTf), 2.40 (t, J = 6.8, 2 H, TfO-C-CH2), 2.30 (app. q, J = 7.8, 2 H, CH2-CH2), 2.05
(m, 2 H, CH2-CH2), 0.97 (t, J = 7.8, 3 H, CH2-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.3, 133.9, 125.8, 104.5, 33.9, 23.7, 20.5, 14.2.

FT-IR (Diamond ATR): 3014 (w), 2967 (w), 1669 (w), 1415 (m), 1204 (s), 927 (m), 892
(m).
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Preparation of (5R,6S)-5,6-dihydroxyhept-1-en-2-yl
trifluoromethanesulfonate

Notebook Entry: PSC190
In accordance with General Procedure D, AD mix-α (4.09 g, 1.00 g/mmol),
methanesulfonamide (0.506 mg, 5.32 mmol), dienyl triflate 2.57 (1.01 g, 4.09 mmol), DI
H2O (20 mL) and t-BuOH (20 mL) were added to a 100 mL round bottom flask containing
2.57, and stirred while cooling in an ice/H2O bath. The crude organic material was purified
by flash chromatography (1½” diameter column, 500 mL reservoir, 1:1 hexanes:EtOAc) to
give diol 2.61 (0.607 mg, 53%) as a viscous, light yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.15 (d, J = 3.4, 1 H, C=CH2), 5.02 (d, J = 3.9, 1 H, C=CH2),

3.86 (m, 1 H, CH-CH), 3.65 (m, 1 H, CH-CH), 2.66 (ddd, J = 15.6, 9.3, 4.9, 1 H, CH2-CH2),
2.46 (ddd, J = 16.6, 9.3, 7.3, 1 H, CH2-CH2), 1.95 (s, 2 H, OH), 1.72 (m, 1 H, CH2-CH2),
1.65 (m, 1 H, CH2-CH2), 1.20 (d, J = 6.3, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.5, 118.4, 74.0, 73.4, 70.4, 30.6, 27.8, 17.1.

FT-IR (Diamond ATR): 3374 (w, br), 2977 (w), 1671 (w), 1411 (m), 1204 (s), 1139 (s), 895
(s), 611 (s).
HRMS (ESI, M+Na) Calculated for C8H13F3NaO5S: 301.0334. Found: 301.0323.
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Preparation of (5S,6R)-5,6-dihydroxyoct-1-en-2-yl
trifluoromethanesulfonate

Notebook Entry: PSA133, PSA149, PSB110, PSC160, PSC191
In accordance with General Procedure D, AD mix-β (2.95 g, 1g/mmol), MeSO2NH2 (0.201 g,
2.11 mmol) dienyl triflate 2.58 (0.544 g, 2.11 mmol), DI H2O (10 mL) and t-BuOH (10 mL)
and were combined in a 50 mL round bottom flask. Light yellow oil, diol 2.62 (0.412 g,
63%) was obtained after work-up and flash chromatography (1½” diameter column, 500 mL
reservoir, 1:1 hexanes:EtOAC).
1H

NMR (CDCl3, 500 MHz): δ 5.15 (d, J = 3.9, 1 H, C=CH2), 5.02 (d, J = 3.9, 1 H, C=CH2),

3.66 (m, 1 H, CH-CH), 3.60 (m, 1 H, CH-CH), 2.66 (ddd, J = 15.6, 9.3, 5.4, 1 H, CH2-CH2),
2.46 (ddd, J = 16.1, 9.3, 7.3, 1 H, CH2-CH2), 1.71 (m, 2 H, CH-CH2), 1.52 (m, 2 H, CH2CH2), 1.03 (t, J = 7.3, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.6, 118.6, 76.1, 75.8, 72.8, 30.5, 27.4, 24.7, 10.2.

FT-IR (Diamond ATR): 3382 (w, br), 2969 (w), 1670 (w), 1412 (m), 1204 (s), 1139 (m),
897 (m), 610 (m).
HRMS (ESI, M+Na) Calculated for C9H15F3NaO5S: 315.0490. Found: 315.0482.
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General Procedure K: 1,2-Diol Protection
Preparation of 4-((4R,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)but-1-en-2-yl
trifluoromethanesulfonate

Notebook Entry: PSC194
Diol 2.61 (0.567 g, 2.04 mmol), R-(-)-camphorsulfonic acid (0.0388 g, 0.204 mmol),
dimethoxypropane (5.00 mL, 40.8 mmol), and acetone (4 mL) were combined in a 25 mL
round bottom flask equipped with a stir bar, and the solution was stirred at room temperature
for 30 min. The mixture was then concentrated and purified by flash chromatography (2½”
diameter column, 1 L reservoir, 12:1 hexanes:EtOAc) to give compound 2.63 (0.495 g,
76%).
1H

NMR (CDCl3, 500 MHz): δ 5.16 (d, J = 3.4, 1 H, C=CH2), 5.02 (d J = 3.9, 1 H, C=CH2),

4.32 (m, 1 H, CH-CH), 4.05 (m, 1 H, CH-CH), 2.63 (ddd, J = 15.1, 9.8, 5.4, 1 H, CH2-CH2),
2.42 (ddd J = 16.1, 9.3, 6.3 Hz, 1 H, CH2-CH2), 1.67 (m, 2 H, CH2-CH2), 1.46 (s, 3 H, CCH3) 1.36 (s, 3 H, C-CH3), 1.21 (d, J = 6.3, 3 H, CH-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.3, 118.2, 107.8, 104.6, 76.8, 76.5, 73.4, 30.8, 28.3, 26.8,

15.2.
FT-IR (Diamond ATR): 2986 (w), 1670 (w), 1415 (m), 1205 (s), 1139 (m), 897 (m).
HRMS (ESI, M+Na) Calculated for C11H17F3NaO5S: 341.0646. Found: 341.0638.
Chiral GC analysis: 120 °C for 60 min. Retention times: 22.12 (minor enantiomer) and
23.11 (major enantiomer) minutes. 8.2% ee.
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Preparation of 4-((4S,5R)-5-ethyl-2,2-dimethyl-1,3-dioxolan-4-yl)but-1-en2-yl trifluoromethanesulfonate

Notebook Entry: PSC166, PSC195
In accordance with General Procedure K, diol 2.62 (1.19 g, 4.06 mmol, R-(-)-CSA acid
(0.0773 g, 0.406 mmol, 10 mol %), dimethoxypropane (9.95 mL, 81.2 mmol, 20 eq.), and
acetone (7.75 mL) were combined in a 25 mL round bottom flask. Purification by flash
chromatography (1½” diameter column, 500 mL reservoir, 3:1 hexanes:EtOAc) gave
compound 2.64 (1.22 g, 90%).
1H

NMR (CDCl3, 500 MHz): δ 5.15 (d, J = 3.9, 1 H, C=CH2), 5.01 (d, J = 3.4, 1 H, C=CH2),

4.05 (m, 2 H, CH-CH), 2.63 (ddd, J = 15.6, 9.8, 4.9, 1 H, CH2-CH2), 2.42 (ddd, J = 16.1, 9.8,
6.8, 1 H, CH2-CH2) 1.64 (m, 4 H, CH2-CH3 & CH2-CH2), 1.43 (s, 3 H, C-CH3), 1.35 (s, 3 H,
C-CH3) 1.03 (t, J = 7.3 , 3 H, CH2-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.1, 118.4, 107.8, 104.6, 79.3, 76.6, 76.3, 30.7, 28.5, 26.6,

22.4, 10.7.
FT-IR (Diamond ATR): 2984 (w), 1670 (w), 1416 (m), 1205 (s), 1141(m), 899 (m).
HRMS (ESI, M+Na) Calculated for C12H19F3NaO5S: 355.0803. Found: 355.0804.
Chiral GC analysis: 120 °C for 120 min. Retention times: 82.5239 (major enantiomer) and
83.7040 (minor enantiomer) min. 2.9% ee.
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Preparation of 4,4,5,5-tetramethyl-2-(4-((4R,5S)-2,2,5-trimethyl-1,3dioxolan-4-yl)but-1-en-2-yl)-1,3,2-dioxaborolane

Notebook Entry: PSC198
In accordance with General Procedure B, B2pin2 (0.397 g, 1.57 mmol), Pd(PPh3)2Cl2 (0.050
g, 0.071 mmol), KOPh (0.282 g, 2.14 mmol) and PPh3 (0.224 g, 0.085 mmol) were charged
to a 25 mL round bottom flask. An argon atmosphere was established, followed by addition
of anhydrous toluene (10 mL). Protected diol 2.63 was added to the mixture which was then
stirred at ~60 °C for 5.5 hrs. The crude organic material was purified by flash
chromatography (1” diameter column, 250 mL reservoir, 6:1 hexanes:EtOAc) to give
boronate 2.65 (0.256 g, 61%) as a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.82 (d, J = 3.41, 1 H, C=CH2), 5.66 (d, J = 2.93 Hz, 1 H,

C=CH2), 4.26 (app. dq, J = 13.2, 7.3, 1 H, CH-CH), 4.06 (ddd, J = 10.7, 8.8, 5.4, 1 H,
C=CH2), 2.36 (ddd, J = 14.7, 10.7, 5.4, 1 H, CH2-CH2), 2.16 (ddd, J = 14.7, 9.8, 5.4, 1 H,
CH2-CH2), 1.68 (m, 1 H, CH2-CH2), 1.55 (m, 1 H, CH2-CH2), 1.47 (s, 3 H, C-CH3), 1.38 (s,
3 H, C-CH3), 1.30 (s, 12 H, (CH3)4), 1.18 (d, J = 6.4, 3 H, CH-CH3).
13C

NMR (CDCl3, 125 MHz): δ 142.7, 129.4, 107.3, 84.4, 77.3, 73.8, 31.8, 29.3, 28.5, 26,

24.8, 22.7, 15.7, 14.1.
FT-IR (Diamond ATR): 2979 (m), 1369 (s), 1307 (m), 1214 (m), 1141 (s), 1083 (m), 858
(m).
HRMS (ESI, M+Na) Calculated for C16H29NaBO4: 319.2060. Found: 319.0247.
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Preparation of 2-(4-((4S,5R)-5-ethyl-2,2-dimethyl-1,3-dioxolan-4-yl)but-1en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Notebook Entry: PSC167, PSC199
In accordance with General Procedure B protected diol 2.64 (0.597 g, 1.80 mmol), B2pin2
(0.501 g, 1.98 mmol, 1.1 eq.), Pd(PPh3)2Cl2 (0.068 g, 0.0898 mmol), KOPh (0.363 g, 2.69
mmol), PPh3 (0.0287 g, .1077 mmol) and toluene (12 mL) were combined in a 25 mL round
bottom flask and heated at 60 °C under Ar atmosphere. Flash chromatography purification
(1” diameter column, 250 mL, 6:1 hexanes:EtOAc) provided boronate 2.66 (0.431 g, 83%) as
a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.81 (d, J = 2.9, 1 H, C=CH2), 5.66 (d, J = 2.9 Hz, 1 H,

C=CH2), 4.07 (app. dt, J = 9.8, 5.6, 1 H, CH-CH), 3.98 (app. dt, J = 8.8, 4.9, 1 H, CH-CH),
2.40 (ddd, J = 14.2, 10.8, 5.4, 1 H, CH2-CH2), 2.16 (ddd, J = 15.1, 9.8, 5.4, 1 H, CH2-CH2),
1.67 (m, 2 H, CH-CH2), 1.56 (m, 2 H, CH2-CH2), 1.47 (s, 3 H, C-CH3), 1.36 (s, 3 H, CCH3), 1.28 (s, 12 H, (CH3)4), 1.00 (t, J = 7.3, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 143.5, 129.6, 107.7, 83.2, 79.7, 77.8, 32.1, 29.2, 28.5, 26.3,

24.5, 22.7, 10.4.
FT-IR (Diamond ATR): 2979 (w), 1367 (m), 1307 (m), 1141 (s), 862 (m).
HRMS (CI+) Calculated for C17H32BO4: 311.2397. Found: 311.2391.
[α]𝟐𝟎
= +2.0° (c = 0.51, l = 0.10 dm, CHCl3).
𝑫
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Preparation of 2,6-dimethyl-3-(4-((4S,5R)-2,2,5-trimethyl-1,3-dioxolan-4yl)but-1-en-2-yl)pyridine

Notebook Entry: PSC202
In accordance with General Procedure C, Pd(dppf)Cl2 (0.073 g, 0.083 mmol), K2CO3 (0.343
g, 2.48 mmol) and Ag2O (0.481 g, 2.07 mmol) were charged to a 50 mL screw-top culture
tube was equipped with a stir bar and rubber septum. The flask was brought under Ar
atmosphere and THF (16.5 mL) was added. The solution was stirred for 5 min before
addition of boronate 2.65 (0.257 g, 0.867 mmol) and pyridyl iodide 2.38 (0.192 g, 0.825
mmol). The reaction was stirred at 100 °C 6 h. Purification via flash chromatography (1”
diameter column, 250 mL reservoir, 3:1 hexanes:EtOAc) provided coupled product 2.72
(0.096 g, 42%) as a light yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 8.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H),

5.28 (d, J = 1.5, 1 H, Ar-C=CH2), 4.94 (d, J = 1.0, 1 H, Ar-C=CH2), 4.24 (app. quin., J = 6.3,
1 H, CH-CH), 4.04 (ddd, J = 9.3, 5.4, 4.0, 1 H, CH-CH), 2.59 (ddd, J = 15.1, 10.7, 4.9, 1 H,
CH2-CH2), 2.53 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.36 (ddd, J = 16.1, 11.2, 5.9, 1 H,
CH2-CH2), 1.60 (m, 1 H, CH2-CH2), 1.47 (m, 1 H, CH2-CH2), 1.42 (s, 3 H, C-CH3), 1.34 (s,
3 H, C-CH3), 1.13 (d, J = 6.4, 3 H, CH-CH3)
13C

NMR (CDCl3, 125 MHz): δ 156.2, 154.3, 147.8, 136.3, 120.2, 115.2, 110.0, 107.4, 77.5,

73.6, 34.1, 28.6, 28.1, 25.9, 24.9, 2.8, 15.4.
FT-IR (Diamond ATR): 2983 (w), 2933 (w), 1590 (w), 1454 (m), 1377 (m), 1245 (m), 1216
(m), 1082 (s), 858 (m).
HRMS (ESI+) Calculated for C17H25NO2: 276.1964. Found: 276.1960.
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Preparation of 3-(4-((4R,5S)-5-ethyl-2,2-dimethyl-1,3-dioxolan-4-yl)but-1en-2-yl)-2,6-dimethylpyridine

Notebook Entry: PSC172, PSC203
In accordance with General Procedure C, boronate 2.66 (0.399 g, 1.29 mmol) pyridyl iodide
2.68 (0.286 g, 1.23 mmol), Pd(dppf)Cl2 (0.100 g, 0.123 mmol), K2CO3 (0.508 g, 3.68 mmol),
Ag2O (0.710 g, 3.07 mmol) and anhydrous THF (24.5 mL) were combined in a 50 mL screwtop culture rube and heated at 100 °C for 6 h while stirring. After work-up, purification via
flash chromatography (1½” diameter column, 250 mL reservoir, 3:1 hexanes:EtOAc) gave
coupled product 2.73 (0.254 g, 72%) as a light yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 7.27 (d, J = 7.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H),

5.27 (d, J = 2.0, 1 H, Ar-C=CH2), 4.94 (d, J = 1.5, 1 H, Ar-C=CH2), (ddd, J = 9.3, 5.4, 3.5, 1
H, CH-CH), 3.96 (app. quin., J = 4.9, 1 H, CH-CH), 2.61 (ddd, J = 15.1. 10.7, 4.9 , 1 H,
CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.36 (ddd, J = 15.6, 10.3, 5.9, 1 H,
CH2-CH2), 1.52 (m, 4 H, CH2-CH2 & CH2-CH3), 1.41 (s, 3 H, C-CH3), 1.34 (s, 3 H, C-CH3),
0.98 (t, J = 7.3, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.1, 154.1, 147.9, 136.3, 134.6, 120.1, 115.2, 107.5, 79.5,

77.3, 34.1, 28.6, 28.0, 26.0, 24.2, 22.7, 10.6.
FT-IR (Diamond ATR): 3053 (m), 2937 (m), 1591 (m), 1461 (m), 1378 (m), 1216 (m), 1048
(m), 692 (m).
HRMS (ESI+) Calculated for C18H28NO2: 290.2120. Found: 290.2119.
[α]𝟐𝟎
= +2.2° (c = 0.56, l = 0.10 dm, CHCl3).
𝑫
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General Procedure L: Deprotection
Preparation of (2R,3S)-6-(2,6-dimethylpyridin-3-yl)hept-6-ene-2,3-diol

Notebook Entry: PSC204
A 25 mL round bottom flask containing coupled product 2.67 (0.0859 g, 0.312 mmol) was
cooled in an ice/H2O bath. A second 25 mL round bottom flask was charged with TFA (3
mL) and DI H2O (3 mL) and cooled in an ice/H2O bath before being added to the reaction
flask. The solution was stirred for 1 h in an ice bath. The reaction was quenched slowly at
reduced temperature with sat. NaHCO3 solution (10 mL) and extracted with diethyl ether (2
× 10 mL). Combined organic layers were dried over anhydrous MgSO4, filtered and
concentrated to provide diol 2.69 (0.034 g, 46%) as a viscous, colorless oil.
1H

NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.8, 1 H, Ar-H), 6.95 (d, J = 7.8, 1 H, Ar-H),

5.26 (d, J = 1.5, 1 H, Ar-C=CH2), 4.92 (s, 1 H, Ar-C=CH2), 3.79 (m, 1 H, CH-CH), 3.62 (m,
2 H, CH-CH), 2.62 (s, br, 2 H, OH), 2.60 (m, 2 H, CH2-CH2), 2.52 (s, 3 H, Ar-CH3), 2.49 (s,
3 H, Ar-CH3), 2.37 (m, 1 H, CH2-CH2), 1.50 (m, 2 H, CH2-CH2), 1.12 (d, J = 6.4, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.0, 154.4, 147.8, 136.6, 134.8, 120.3, 115.4, 74.3, 70.3,

34.0, 29.8, 24.0, 22.6, 16.9.
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Preparation of (3S,4R)-7-(2,6-dimethylpyridin-3-yl)oct-7-ene-3,4-diol

Notebook Entry: PSC175, PSC176, PSC205
In accordance with General Procedure L, coupled product 2.68 (0.240 g, 0.830 mmol), TFA
(8 mL) and DI H2O (8 mL) were combined in a 50 mL round bottom flask and cooled in an
ice/H2O bath with stirring for 1 h.

After work-up, concentration of the organic layer

provided diol 2.70 (0.144 g, 70%).
1H

NMR (CDCl3, 500 MHz): δ 7.30 (d, J = 5.9, 1 H, Ar-H), 6.97 (d, J = 7.8, 1 H, Ar-H),

5.29 (d, J = 1.0, 1 H, Ar-C=CH2), 4.95 (d, J = 1.0, 1 H, Ar-C=CH2), 3.64 (ddd, J = 10.3, 6.4,
3.4, 1 H, CH-CH), 3.53 (app. quin., J = 3.9, 1 H, CH-CH), 2.64 (app. quin., J = 7.8, 1 H,
CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.40 (m, 1 H, CH2-CH2), 1.90 (s,
br, 2 H, OH), 1.55 (ddd, J = 13.7, 8.3, 6.4, 2 H, CH2-CH2), 1.46 (m, 2 H, CH2-CH3), 1.00 (t,
J = 7.8, 3 H, CH2-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.1, 154.5, 147.9, 136.5, 134.7, 120.2, 115.4, 76.2, 73.9,

33.9, 29.3, 24.4, 24.1, 22.8, 10.4.
FT-IR (Diamond ATR): 3346 (br), 2925 (m), 1591 (m), 1463 (m), 1065 (m), 972 (m), 905
(m), 831 (m), 702 (s).
HRMS (ESI, M+Na) Calculated for C15H23NaNO2: 272.1627. Found: 272.1623.

116

Preparation of 3-(4-((2S,3R)-3-ethyloxiran-2-yl)but-1-en-2-yl)-2,6dimethylpyridine

Notebook Entry: PSC183
In accordance with General Procedure E, diol 2.70 (0.043 g, 0.172 mmol) NEt3 (31 µL, 0.224
mmol) and CH2Cl2 (3.5 mL) were combined in a 10 mL pointed bottom flask under argon
atmosphere. The solution was cooled in an ice/H2O bath at which time MsCl (19 µL, 0.190
mmol) was added drop-wise in 0.5 mL anhydrous CH2Cl2. The solution warmed to room
temperature and the reaction progress was monitored by TLC. After ~30 min, an additional
0.5 eq. of NEt3 and MsCl were added. After an additional 30 min the reaction was deemed
complete by TLC and MeOH (4 mL) and K2CO3 (0.222 g, 1.60 mmol) were added to the
flask and the reaction was stirred overnight. After work-up, the organic layer was filtered
and concentrated to give epoxide 2.72 (0.018 g, 44%).
1H

NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.3, 1 H, Ar-H), 6.6 (d, J = 7.8, 1 H, Ar-H), 5.28

(d, J = 1.5, 1 H, Ar-C=CH2), 4.96 (d, J = 1.5, 1 H, Ar-C=CH2), 2.72 (ddd, J = 6.9, 4.5, 2.4, 1
H, CH-CH), 2.67 (app. td, J = 5.4, 2.0, 1 H, CH-CH), 2.52 (s, 3 H, Ar-CH3), 2.49 (s, 3 H,
Ar-CH3), 1.60 (m, 4 H, diastereotopic CH2), 0.99 (t, J = 7.8, 3 H, CH2-CH3).
13C

NMR (CDCl3, 125 MHz): δ156.2, 154.5, 147.3, 136.4, 134.4, 120.2, 115.4, 59.9, 58.1,

57.9, 33.9, 30.4, 25.1, 24.2, 22.8, 9.9.
FT-IR (Diamond ATR): 3382 (w, br) 3074 (w), 2967 (m), 1649 (m), 1450 (m), 1328 (m).
HRMS (ESI, M+Na) Calculated for C15H21NaNO: 254.1521. Found: 254.1528.
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Preparation of (E)-hept-5-en-2-one83

Notebook Entry: PSC206, PSC211. PSC232, PSC238
In accordance with General Procedure H, crotyl chloride 2.77 (4.77 mL, 50.0 mmol) 2,4pentanedione (5.64 mL, 55.0 mmol), K2CO3 (7.60 g, 55.0 mmol) and EtOH (33 mL) were
combined in a 100 mL round bottom and refluxed for 24 h with stirring. After work-up, the
product was purified by vacuum distillation (bp = 54-60 °C at 33 mmHg) to provide
alkenone 2.79 (3.24 g, 60%) as a clear, colorless liquid.
1H

NMR (CDCl3, 500 MHz): δ 5.45 (m, 2 H, CH=CH), 2.50 (t, J = 7.3, 2 H, CH2-CH2),

2.28 (dt, J = 13.7, 6.3, 2 H, CH2-CH2), 1.66 (dd, J = 5.9, 1.0, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 208.6, 129.5, 125.9, 43.5, 29.9, 26.8, 17.9.

FT-IR (Diamond ATR): 2919 (w), 1714 (s), 1359 (m), 1162 (m), 966 (m).
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Preparation of I-hepta-1,5-dien-2-yl trifluoromethanesulfonate

Notebook Entry: PSC209, PSC214, PSC234, PSC242
In accordance with General procedure A, a 250 mL, a three-neck round bottom flask was
equipped with addition funnel and septa and brought under argon atmosphere. THF (58 mL)
and LHMDS (1.06 M, 30 mL) were charged to the flask and cooled in a dry ice/isopropanol
bath. Alkenone 2.79 (2.62 g, 23.3 mmol) was added to the addition funnel in a solution of
THF (10 mL) and added drop wise to the solution over 30 min. After complete addition, the
solution was stirred for 15 min. PhNTf2 (8.75 g, 24.5 mmol) was added to a 50 mL flask and
brought under argon atmosphere. The solid was dissolved in THF (20 mL) and quickly
added to the solution via cannula. After work-up, purification via flash chromatography (2
¾” column, 1 L reservoir, 19:1 hexanes:EtOAc) provided semi-pure product 2.80 (2.16 g,
38%) as a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 5.54 (m, 1 H, CH=CH), 5.40 (m, 1 H, CH=CH), 5.13 (d, J =

3.9,1 H, C=CH2), 4.96 (d, J = 3.4, 1 H, C=CH2), 2.42 (t, J = 7.3, 2 H, CH2-CH2), 2.25 (app.
q, J = 6.8, CH2-CH2), 1.69 (dd, J = 6.4, 1.0, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.4, 128.2, 127.1, 120.3, 104.5, 33.9, 28.9, 17.9.

FT-IR (Diamond ATR): 3027 (w), 2923 (w), 1669 (w), 1415 (m), 1204 (s), 1140 (s), 914
(m) 609 (m).
HRMS (ESI, M+NH4) Calculated for C7H15NF3O3S: 262.0725. Found: 262.0731.
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Preparation of (5S,6S)-5,6-dihydroxyhept-1-en-2-yl
trifluoromethanesulfonate

Notebook Entry: PSC210, PSC220, PSC237, PSC244
In accordance with General Procedure D, AD mix-α (3.97 g, 1g/mmol), MeSO2NH2 (0.768 g,
5.16 mmol), DI H2O (31 mL) and t-BuOH (31 mL) were added to a 100 mL round bottom
flask. The solution was cooled in an ice/H2O bath at which time triflate 2.80 (1.52 g, 6.21
mmol) was added. After work up, the product was purified by flash chromatography (2 ¾”
column, 1 L reservoir, 1:1 hexanes:EtOAc) to provide diol 2.81 (0.115 g, 66%) as a viscous,
light brown oil.
1H

NMR (CDCl3, 500 MHz): δ 5.16 (d, J = 3.9, 1 H, C=CH2), 5.10 (d, J = 3.4, 1 H, C=CH2),

3.66 (app. quin., J = 6.3, 1 H, CH-CH), 3.41 (ddd, J = 9.3, 5.9, 2.9, 1 H CH-CH), 2.63 (ddd,
J = 14.6, 9.3, 4.9, 1 H, CH2-CH2), 2.50 (ddd, J = 16.1, 9.3, 6.8, 1 H, CH2-CH2), 2.00 (s, br,
OH), 1.78 (m, 1 H, CH2-CH2), 1.67 (m, 1 H, CH2-CH2), 1.26 (d, J = 6.4, 3 H, CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.4, 118.3, 104.6, 74.8, 70.8, 30.2, 29.8, 19.7.

FT-IR (Diamond ATR): 3364 (w, br), 2976 (w), 1670 (w), 1412 (m), 1203 (s), 1138 (s), 894
(s), 605 (m).
HRMS (ESI, M+Na) Calculated for C8H13F3NaO5S: 301.0334. Found: 301.0320.
[α]𝟐𝟎
= -6.0° (c = 6.0, l = 0.10 dm, CHCl3).
𝑫
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Preparation of 4-((4S,5S)-2,2,5-trimethyl-1,3-dioxolan-4-yl)but-1-en-2-yl
trifluoromethanesulfonate

Notebook Entry: PSC212, PSC221
In accordance with General Procedure J, diol 2.81 (0.578 g, 2.08 mmol), R-(-)-CSA (0.040 g,
0.208 mmol), dimethoxypropane (5.10 mL, 41.6 mmol) and acetone (4 mL) were combined
in a 25 mL round bottom flask and stirred for 1 h. After work-up, purification via flash
chromatography (1½” diameter column, 500 mL reservoir, 12:1 hexanes:EtAOc) provided
2.82 (0.566 g, 86%).
1H

NMR (CDCl3, 500 MHz): δ 5.16 (d, J = 3.4, 1 H, CH2=C), 5.02 (d, J = 3.9, 1 H, CH2=C),

3.76 (m, 1 H, CH-CH), 3.55 (app. td, J = 8.3, 3.0, 1 H, CH-CH), 2.61 (ddd, J = 15.6, 9.8, 4.9,
1 H CH2-CH2), 2.48 (ddd, J = 16.1, 9.8, 6.3, 1 H, CH2-CH2), 1.82 (dddd, J = 13.2, 9.3, 6.4,
3.0, 1 H, CH2-CH2), 1.71 (dddd, J = 13.7, 9.8, 8.8, 4.9, 1 H, CH2-CH2), 1.41 (s, 3 H, C(CH3)2), 1.40 (s, 3 H, C-(CH3)2), 1.29 (d, J = 5.9, 3 H, CH-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.2, 117.4, 108.2, 104.6, 80.8, 76.5, 30.7, 28.5, 23.3, 23.2,

17.3.
FT-IR (Diamond ATR): 2918 (w), 1415 (m), 1206 (s), 899 (m).
HRMS (ESI, M+Na) Calculated for C11H17F3NaO5S: 341.0646. Found: 341.0640.
[α]𝟐𝟎
= -4.9° (c = 5.4, l = 0.10 dm, CHCl3).
𝑫
Chiral GC analysis: 120 °C for 60 min. Retention times: 16.0917 (minor enantiomer) and
16.9078 (major enantiomer) minutes. 61.4% ee.
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Preparation of 4,4,5,5-tetramethyl-2-(4-((4R,5R)-2,2,5-trimethyl-1,3dioxolan-4-yl)but-1-en-2-yl)-1,3,2-dioxaborolane

Notebook Entry: PSC213, PSC222
In accordance with General Procedure B, B2pin2 (0.860 g, 3.39 mmol), Pd(PPh3)2Cl2 (0.107
g, 0.152 mmol), KOPh (0.610 g, 4.62 mmol) and PPh3 (0.048 g, 0.185 mmol) were charged
to a 100 mL round bottom flask and brought under Ar atmosphere. Toluene (21 mL) and
2.82 (0.967, 3.08 mmol) were then added to the flask and stirred at ~60 °C for 6 h. After
work-up, purification via flash chromatography (1½” diameter column, 500 mL column, 6:1
hexanes:EtOAc) provided 2.83 (0.561, 62%).
1H

NMR (CDCl3, 500 MHz): δ 5.82 (d, J = 3.4, 1 H, CH2=C), 5.67 (d, J = 3.4, 1 H, CH2=C),

3.76 (m, 1 H, CH-CH), 3.56 (m, 1 H, CH-CH), 2.38 (app. quin., J = 8.3, 1 H, CH2-CH2),
2.23 (app. quin., J = 8.3, 1 H, CH2-CH2), 1.68 (m, 2 H, CH2-CH2), 1.41 (s, 6 H, C-(CH3)2),
1.29 (s, 12 H, Bpin), 1.28 (s, 3 H, CH-CH3).
13C

NMR (CDCl3, 125 MHz): δ 140.5, 129.4, 107.8, 83.4, 82.0, 31.7, 27.3, 24.8, 17.7.

FT-IR (Diamond ATR): 2979 (m), 1412 (m), 1307 (m), 1141 (s), 1089 (m), 859 (m).
HRMS (ESI+) Calculated for C16H30BO4: 319.2060. Found: 319.2056.
[α]𝟐𝟎
= -4.5° (c = 5.6, l = 0.10 dm, CHCl3).
𝑫
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Preparation of 2,6-dimethyl-3-(4-((4S,5S)-2,2,5-trimethyl-1,3-dioxolan-4yl)but-1-en-2-yl)pyridine

Notebook Entry: PSC217, PSC224
In accordance with General Procedure C, Pd(dppf)Cl2 (0.147 g, 0.180 mmol), K2CO3 (0.746
g, 5.39, mmol) and Ag2O (1.04 g, 4.50 mmol) were charged to a 100 mL round bottom flask
and brought under Ar atmosphere. THF (38 mL) was added, followed by 2.83 (0.559 g, 1.89
mmol), and 2.38 (0.419 g, 1.80 mmol) and the solution was stirred at 90 °C for 6 h. After
work-up, purification via flash chromatography (1½” diameter column, 500 mL reservoir,
3:1 hexanes:EtOAc) provided 2.84 (0.415 g, 84%).
1H

NMR (CDCl3, 500 MHz): δ 7.28 (d, J = 7.8, 1 H, Ar-H), 6.96 (d, J = 7.8, 1 H, Ar-H),

5.28 (d, J = 1.5, 1 H, CH2=C), 4.95 (s, 1 H, CH2=C), 3.71 (m, 1 H, CH-CH), 3.54 (m, 1 H,
CH-CH), 2.57 (m, 1 H, CH2-CH2), 2.54 (s, 3 H, Ar-CH3), 2.52 (s, 3 H, Ar-CH3), 2.43 (m, 1
H, CH2-CH2), 1.62 (m, 2 H, CH2-CH2), 1.40 (s, 3 H, C-(CH3)2), 1.38 (s, 3 H, C-(CH3)2), 1.24
(d, J = 5.9, 3 H, CH-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.2, 154.5, 147.6, 136.4, 120.2, 115.3, 107.8, 81.8, 76.7,

33.9, 30.4, 27.3, 24.2, 22.8, 17.6.
FT-IR (Diamond ATR): 2983, (m), 2931 (m), 1590 (m), 1455 (m), 1377 (m), 1238 (m),
1091 (s), 857 (m).
HRMS (ESI+) Calculated for C17H26NO2: 276.1964. Found: 276.1955.
[α]𝟐𝟎
= -3.9° (c = 4.1 g/mL, l = 0.10 dm, CHCl3).
𝑫
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Preparation of (2S,3S)-6-(2,6-dimethylpyridin-3-yl)hept-6-ene-2,3-diol

Notebook Entry: PSC226
In accordance with General Procedure K, 2.84 (0.539, 1.96 mmol), TFA (12 mL) and H2O
(12 mL) were combined in a 50 mL round bottom flask and stirred for 1 h. After work-up,
concentration of the organic layer provided 2.85 (0.246 g, 53%).
1H

NMR (CDCl3, 500 MHz): δ 7.30 (d, J = 7.8, 1 H, Ar-H), 6.98 (d, J = 7.8, 1 H, Ar-H),

5.28 (d, J = 1.5, 1 H, C=CH2), 4.96 (s, 1 H, C=CH2), 3.62 (app. quin., J = 6.4, 2 H, CH-CH),
3.38 (m, 2 H, CH-CH), 2.60 (ddd, J = 15.1, 10.3, 5.9, 1 H, CH2-CH2), 2.54 (s, 3 H, Ar-CH3),
2.52 (Ar-CH3), 2.45 (m, 1 H, CH2-CH2), 1.73 (s, br, 2 H, OH), 1.59 (dddd, J = 13.7, 9.8, 6.4,
3.4, 1 H, CH2-CH2), 1.52 (m, 1 H, CH2-CH2), 1.19 (d, J = 6.4, 3 H, Ch-CH3).
13C

NMR (CDCl3, 125 MHz): δ 156.1, 154.4, 147.7, 136.6, 136.7, 120.3, 115.5, 75.6, 70.8,

33.5, 31.5, 24.1, 22.7, 19.7.
HRMS (ESI+) Calculated for C14H22NO2: 236.1651. Found: 236.1645.
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General Procedure M: Picolyl Alkylation
Preparation of 3-bromo-2-(but-3-en-1-yl)pyridine88

Notebook Entry: PSB169
A two-neck 25 mL round bottom flask was brought under Ar atmosphere and charged with
3.3 (0.344 g, 2.00 mmol) and THF (7 mL). The solution was cooled in a dry ice/isopropanol
bath at which time LHMDS (1.06 M, 2.36 mL, 2.50 mmol) was added drop-wise stirred for
45 min. Allyl bromide (0.303 g, 2.50 mmol) was added in a solution of THF (1 mL) dropwise and stirred at reduced temperature for an additional 1.5 h. The solution warmed to room
temperature overnight before being quenched with sat. NaHCO3 (10 mL). The solution was
diluted with diethyl ether (10 mL) and the aqueous phase was further extracted with diethyl
ether (1 × 10 mL). The combined organic phases were dried over anhydrous MgSO4, filtered
and concentrated before purification via flash chromatography (½” column, 100 mL
reservoir, 3:1 hexanes:EtOAc) to provide 3.4 (0.197 g, 46%).
1H

NMR (CDCl3, 500 MHz): δ 8.48 (dd, J = 4.4, 1.4, 1 H, Ar-H), 7.82 (dd, J = 7.8, 1.5, 1 H,

Ar-H), 7.02 (dd, J = 7.8, 4.4, 1 H, Ar-H), 5.93 (ddt, J = 13.2, 10.3, 6.8, 1 H, CH=CH2), 5.08
(dd, J = 17.1, 1.5, 1 H, CH=CH2) 5.00 (dd, 10.3, 2.0, 1 H, CH=CH2), 3.06 (t, J = 7.8, 2 H,
Ar-CH2), 2.52 (m, 2 H, CH2-CH2).
13C

NMR (CDCl3, 125 MHz): δ 159.8, 147.8, 140.2, 137.6, 122.5, 121.4, 115.2, 36.9, 32.4.

____________________________________________________
88

Zhang, Z.; Dwoskin, L.P.; Crooks, P.A.; Tetrahedron Lett., 2011, 52, 2667-2669.
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Preparation of 3-bromo-2-(hex-5-en-1-yl)pyridine

Notebook Entry: PSB175
In accordance with General Procedure M, 3.3 (0.344 g, 2.0 mmol) and THF (8 mL) were
cooled in a dry ice/isopropanol bath before drop-wise addition of LHMDS (1.06 M, 2.36 mL,
2.50 mmol). 5-Bromo-1-pentene (0.373 g, 2.50 mmol) was then added drop-wise. After
work-up, purification via flash chromatography (½” column, 100 mL reservoir, 3:1
hexanes:EtOAc) provided 3.6 (0.200 mg, 42%).
1H

NMR (CDCl3, 500 MHz): δ 8.43 (dd, J = 4.9, 1.5, 1 H, Ar-H), 7.80 (dd, J = 8.3, 1.5, 1

H, Ar-H), 7.00 (dd, J = 7.8, 4.4, 1 H, Ar-H), (ddt, J = 13.2, 10.3, 6.8, 1 H, CH=CH2), 5.02
(dd J = 17.1, 2.0, 1 H, CH=CH2), 4.95 (dd, J = 9.3, 2.0, 1 H, CH=CH2), 2.97 (t, J = 7.8, 2 H,
Ar-CH2), 2.12 (q, J = 7.3, 2 H, Ar-CH2-CH2) 1.76 (m, 2 H, CH2-CH2-CH), 1.52 (m, 2 H,
CH2-CH2-CH).
13C

NMR (CDCl3, 125 MHz): δ 160.8, 147.8, 140.2, 138.8, 122.3, 121.3, 114.5, 37.5, 33.6,

28.7, 28.0.
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General Procedure N: Model Intramolecular Heck Cyclization
Preparation of 5-methylene-6,7-dihydro-5H-cyclopenta[b]pyridine

Notebook Entry: PSB178, PSB185
A 25 mL screw-top culture tube was equipped with a stir bar and charged with MeCN (22
mL), PPh3 (0.072 g, 0.280 mmol), K2CO3 (0.550 g, 3.98 mmol) and 3.4 (0.116 g, 0.549
mmol). The culture tube was degassed in a sonicator for 30 min before addition of Pd(OAc)2
(0.031 mg, 0.14 mmol). The culture tube was fitted with a septum and flushed with Ar gas
before replacing septum with screw-cap. The solution was stirred at room temperature for 1
h then at 90 °C for 24 h. The culture tube was allowed to cool to rt before filtering the
solution over Celite®. The solution was concentrated and purified by flash chromatography
(½” column, 100 mL, 3:1 hexanes:EtOAc) to provide cyclized product 3.7 (0.047 g, 65%).
1H

NMR (CDCl3, 500 MHz): δ 8.42 (dd, J = 4.9, 1.5, 1 H, Ar-H), 7.73 (dd, J = 7.8, 2.0, 1 H,

Ar-H), 7.11 (dd, J = 7.8, 4.9, 1 H, Ar-H), (dd, J = 2.9, 2 H, Ar-C=CH2), 5.15 (dd, J = 2.4, 2
H, Ar-C=CH2), 3.10 (m, 2 H, Ar-CH2), 2.84 (m, 2 H, Ar-CH2-CH2).
13C

NMR (CDCl3, 125 MHz): δ 167.3, 149.8, 147.7, 134.4, 128.1, 121.6, 105.6, 32.1, 29.2.
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Preparation of 5-methylene-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
& 5-methyl-8,9-dihydro-7H-cyclohepta[b]pyridine

Notebook Entry: PSB179, PSB184
In accordance with General Procedure N, MeCN (20.5 mL), PPh3 (0.067 g, 0.260 mmol),
K2CO3 (0.513 g, 3.71 mmol) and 3.6 (0.123 g, 0.510 mmol), and Pd(OAc)2 (0.029 g, 0.130
mmol) combined in a screw-top culture tube. After work-up, purification by flash
chromatography (½” column, 100 mL, 3:1 hexanes:EtOAc) provided the cyclized isomeric
mixture of 3.9 and 3.9a (0.035 g, 43%, ~3:1 mixture).
1H

NMR 3.9 (CDCl3, 500 MHz): δ 8.36 (dd, J = 4.9, 2.0, 1 H, Ar-H), 7.48 (dd, J = 7.8, 1.96,

1 H, Ar-H), 7.08 (dd, J = 7.8, 4.9, 1 H, Ar-H), 5.18 (d, J = 2.0, 1 H, Ar-C=CH2), 5.03 (d, J =
2.0, 1 H, Ar-C=CH2), 3.02 (app.t, J = 5.4, 2 H, Ar-CH2), 2.42 (app. t, J = 5.9, Ar-C-CH2),
1.89 (m, 2 H, 1.8, Ar-CH2-CH2), 1.82 (quin, J = 5.4, 2 H, Ar-C-CH2-CH2).
1H

NMR 3.9a (CDCl3, 500 MHz): δ 8.37 (dd, J = 4.9, 1.5, 1 H, Ar-H), 7.54 (dd, J = 7.8, 1.5,

1 H, Ar-H), 7.17 (dd, J = 7.8, 4.9, 1 H, Ar-H), 6.05 (tq, J = 6.8, 1.5, 1 H, Ar-C=CH), 2.83 (t,
J = 6.8, 2 H, Ar-CH2), 2.22 (quin., J = 7.3, 2 H, Ar-CH2-CH2), 2.10 (s, 3 H, Ar-C-CH3), 1.95
(m, 2 H, Ar-C=CH-CH2).
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Preparation of but-3-en-1-yl 4-methylbenzenesulfonate89

Notebook Entry: PSB198
A two-neck 50 mL round-bottom flask was equipped with addition funnel and brought under
Ar atmosphere. The flask was charged with 3.10 (0.721 g, 10.0 mmol) and pyridine (8 mL)
and cooled to 0 °C in an ice/H2O bath. TsCl (2.29 g, 12.0 mmol) was added in a solution of
pyridine (4 mL) drop-wise via addition funnel. The reaction mixture was stirred at 0 °C for
4.5 h. The reaction was quenched with sat. NH4Cl (20 mL) and the aqueous phase extracted
with diethyl ether (2 × 20 mL). Combined organic phases were dried over MgSO4, filtered
and concentrated. The crude organic material was purified by flash chromatography (1”
column, 1:2 hexanes:EtOAc) to provide butenyl tosylate 3.11 (1.01 g, 45%).
1H

NMR (CDCl3, 500 MHz): δ 7.80 (d, J = 7.82, 1.47, 2 H, Ar-H), 7.36 80 (d, J = 7.82,

1.47, 2 H, Ar-H), 5.68 (ddt, J = 13.2, 10.3, 6.35, 1 H, CH2=CH) 5.09 (dd, J = 9.27, 1.46,
CH2=CH), 5.07 (dd, J = 8.79, 1.47, 1 H, CH2=CH), 4.07 (t, J = 6.84, 2 H, CH2-CH2), 2.41
(dt, J = 6.84, 1.47, 2 H, CH2-CH2).
FT-IR (Diamond ATR): 2983 (w), 1735 (w), 1598 (w), 1356 (m), 1174 (s), 954 (m), 901
(m), 814 (m), 771 (m), 623 (s).

____________________________________________________
89

Hanack, M.; Kang, S.; Haeffner, J.; Goerler, K.; Justus Liebigs Annalen der Chemie, 1965, 690, 98-114.
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General Procedure O: MOM Phenol Protection
Preparation of 3-(methoxymethoxy)-2,6-dimethylpyridine

Notebook Entry: PSB167
A 250 mL recovery flask was charged with 3.12 (1.00 g, 8.12 mmol) and NaH in mineral oil
suspension (60%, 0.546 g, 22.7 mmol). The flask was brought under Ar atmosphere and
charged with THF (80 mL) and MOMCl (0.719 g, 8.93 mmol). The reaction mixture was
stirred at rt for 48 h. The solution was diluted with EtOAc (30 mL), washed with sat. NaCl
(2 × 40 mL) and the combined organic phase was dried over anhydrous Na2SO4. The
solution was filtered, concentrated and purified via flash chromatography (1½” column, 500
mL, 1:2 hexanes:EtOAc) to provide 3.13 (0.889 g, 65%).
1H

NMR (CDCl3, 500 MHz): δ 7.24 (d, J = 8.3, 1 H, Ar-H), 6.91 (d, J = 8.3, 1 H, Ar-H),

5.17 (s, 2 H O-CH2-O), 4.61, 3.48 (s, 3 H, O-CH3), 2.47 (s, 3 H, Ar-CH3), 2.46 (s, 3 H, ArCH3).
13C

NMR (CDCl3, 125 MHz): δ 150.1, 149.6, 148.2, 121.7, 121, 121.3, 94.6, 56.0, 23.5,

19.3.
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Preparation of 4-allyl-3-(methoxymethoxy)-2,6-dimethylpyridine

Notebook Entry: PSB176
A 25 mL round-bottom flask was equipped with a stir bar brought under inert atmosphere.
Compound 3.13 (0.200 g, 1.20 mmol) and THF (10 mL) were charged to the flask. The
solution was cooled in a dry ice/isopropanol bath and n-BuLi (~1.28 M, 0.82 mL, 1.32
mmol) was added drop-wise. The solution stirred for 15 min at which time allyl bromide
(0.217 g, 1.79 mmol) was added all at once. The solution stirred at rt for 48 h before being
quenched with sat. NaHCO3 (10 mL). The aqueous phase was extracted with diethyl ether (2
× 10 mL) and the combined organic phases were dried over anhydrous Na2SO4. The crude
material was filtered, concentrated, and then purified by flash chromatography (1” column,
250 mL reservoir, 1:1 hexanes:EtOAc) to provide 3.16 (0.093 mg, 38%).
1H

NMR (CDCl3, 500 MHz): δ 6.83 (s, 1 H, Ar-H), 5.93 (ddt, J = 17.1, 10.3, 1.5, 1 H,

CH=CH2), 5.14 (dd, J = 10.3, 1.5, 1 H, CH=CH2), 5.11 (dd, J = 17.1, 1.5, 1 H, CH=CH2),
4.94 (s, 2 H O-CH2-O), 3.61 (s, 3 H, O-CH3), 2.50 (s, 3 H, Ar-CH3), 2.45 (s, 3 H, Ar-CH3).
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Preparation of 2-(hydroxymethyl)-6-methylpyridin-3-ol90

Notebook Entry: PSB220, PSC265
A 1 L flat bottom flask equipped with stir bar was charged with 3.21 (54.5 g, 0.50 mol) DI
H2O, NEt3 (69.7 mL, 0.50 mol) and formaldehyde (37%, 37.5 mL, 0.50 mol). The solution
was refluxed for 6 h. The solution was concentrated give a crude solid which was
subsequently recrystallized from 95% ethanol to provide 2.11 (35 g, 50%).
1H

NMR (DMSO-d6, 500 MHz): δ 7.80 (d, J = 7.8, 1 H, Ar-H), 6.98 (d, J = 8.3, 1 H, Ar-H),

5.0 (s, 2 H, Ar-CH2), 2.42 (s, 3 H, Ar-CH3).
13C

NMR (DMSO-d6, 125 MHz): δ 149.3, 147.0, 146.4, 123.2, 122.8, 60.4, 23.3.

FT-IR (Diamond ATR): 3074 (m, br), 2625 (m, br), 1586 (m), 1296 (m), 1160 (m), 1010 (s),
798 (s).

____________________________________________________
90

Abblard, J.; Viricel, R.; Ger. Offen., 1973.
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Preparation of 6-methyl-2-((phenylthio)methyl)pyridin-3-ol

Notebook Entry: PSB217
A 50 mL round bottom flask was equipped with a stir bar and charged with 2.11 (1.44 g, 10.4
mmol), HBr (48%, 13.3 mL) and the mixture stirred for 10 min. PhSH (1.26 g, 11.4 mmol)
was added to flask and the solution was heated at reflux 18 h before cooling to room
temperature. The solution was transferred to a 125 mL Erlenmeyer flask containing sat.
Na2CO3 (25 mL) and made basic with sat. Na2CO3 (pH = 11). The solution was extracted
with diethyl ether (2 × 20 mL) and the combined organic layers were dried over anhydrous
Na2SO4, filtered and concentrated to give 3.22 (0.108 g, >1%).*
* the crude aqueous solution was again extracted at ~pH’s 7-10), but no additional product was isolated.
1H

NMR (CDCl3, 500 MHz): δ 7.39 (m, 1.5, 2 H, Ar-H), 7.24 (m, 3 H, Ar-H), 7.06 (d, J =

8.3, 1 H, Ar-H), 6.94 (d, J = 8.3, 1 H, Ar-H), 4.36 (s, 2 H, Ar-CH2-S) 2.41 (s, 3 H. Ar-CH3).
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Preparation of 3-(methoxymethoxy)-6-methyl-2((phenylthio)methyl)pyridine

Notebook Entry: PSB223
In accordance with General Procedure O, 3.22 (0.099 g, 0.46 mmol), NaH (60% in mineral
oil, 0.022 g, 0.922 mmol), MOMCl (0.941 mg, 0.507 mmol) and THF (8 mL) were charged
to a 25 mL round bottom flask. After work-up, purification via flash chromatography (½”
diameter column, 100 mL reservoir, 1:1 hexanes:EtOAc) provided 3.19 (0.067 g, 55%).
1H

NMR (CDCl3, 500 MHz): δ 7.43 (dd, J = 6.8, 1.5, 2 H, Ar-H), 7.30 (d, J = 8.3, 1 H, Ar-

H), 7.26 (m, 2 H, Ar-H), 7.17 (tt, J = 7.3, 1.0, 1 H, Ar-H), 6.98 (d, J = 8.3, 1 H, Ar-H), 5.12
(s, 2 H, O-CH2-O), 4.22 (s, 2 H, Ar-CH2-S) 3.42 (s, 3 H, O-CH3), 2.42 (s, 3 H, Ar-CH3).
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Preparation of but-4-enyltriphenylphosphonium bromide91

Notebook Entry: PSB233, PSB244, PSC034
PPh3 (1.06 g, 4.03 mmol) was dissolved in toluene (6.5 mL) in a 25 mL round bottom flask.
3.23 (0.500 g, 3.36 mmol) was added all at once and the solution was refluxed for 18 h. The
solution was cooled to room temperature at which point a solid precipitated. The solid was
filtered under vacuum, rinsed with hot toluene, and dried in a desiccator to provide 3.24
(0.560 g, 41%).
1H

NMR (acetone-d6, 500 MHz): δ 7.90 (m, 15 H, PPh3), 5.83 (ddt, J = 13.7, 10.3, 6.8, 1 H,

CH2=CH), 5.07, (dd, J = 17.1, 2.0, 1 H, CH2=CH), 5.00 (dd, J = 10.3, 2.0, 1 H, CH2=CH),
3.75 (m, 2 H, CH2-P), 2.38 (app. q, J = 7.3, 2 H, CH-CH2), 1.6 (m, 2 H, CH-CH2-CH2).

____________________________________________________
91

Hauser, C.F.; Brooks, T.W.; Miles, M.L.; Raymond, M.A.; Butler, G.B.; J. Org. Chem., 1963, 24, 372-379.
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Preparation of 2-(bromomethyl)-3-hydroxy-6-methylpyridin-1-ium
bromide

Notebook Entry: PSB265
Diol 2.11 (0.309 g, 2.10 mmol) was dissolved in 48% HBr (25 mL) and stirred at reflux for
20 min. The solution was concentrated under vacuum to approximately 5 mL and then
cooled. The white crystals formed were filtered and washed with acetone and hexanes to
provide the pyridinium salt 3.31 (0.409 g, 65%).
mp = 217-222 °C
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Preparation of 6-methyl-2-((((trifluoromethyl)sulfonyl)oxy)methyl)pyridin3-yl trifluoromethanesulfonate

Notebook Entry: PSB279, PSB283, PSB286
A 50 mL two-neck round bottom flask was charged with diol 2.11 (0.500 g, 3.59 mmol) and
equipped with stir bar and addition funnel. The flask was brought under Ar atmosphere and
charged with CH2Cl2 (16 mL) and NEt3 (1.25 mL, 8.98 mmol). The solution was cooled in a
dry ice/isopropanol bath at which time Tf2O (1.26 mL, 7.54 mmol) was added drop-wise in a
solution of CH2Cl2 (2 mL). The solution was warmed to room temperature overnight. The
reaction was quenched with sat. NaHCO3 and the aqueous layer was extracted with CH2Cl2
(2 × 20 mL). The combined organic layers were washed with sat. NaCl and dried over
anhydrous MgSO4. The solution was filtered, concentrated, and purified via flash
chromatography (1½” diameter column, 10% acetone in EtOAc) to provide impure bistriflate 3.32.
1H

NMR (CDCl3, 125 MHz): δ 7.68 (d, J = 8.8, 1 H, Ar-H), 7.44 (d, J = 8.8, 1 H, Ar-H),

4.43 (s, 2 H, Ar-CH2-OTf), 2.62 (s, 3 H, Ar-CH3).
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Preparation of methyl hex-5-enoate91

Notebook Entry: PSB257
A 25 mL recovery flask was charged with hexenoic acid (1.00 g, 8.76 mL), MeOH (1.06 mL,
26.3 mmol) and sulfuric acid (2 drops). The solution was stirred at reflux for 1 h before
dilution with diethyl ether and sat. NaCl (10 mL each). The solution was then extracted with
diethyl ether (2 × 10 mL) and the combined organic layers were dried over anhydrous
Na2SO4. The solution was then filtered and concentrated under vacuum to provide methyl
hex-5-enoate 3.29 (0.690 g, 61%).
1H

NMR (CDCl3, 500 MHz): δ 5.78 (ddt, J = 13.2, 9.8, 6.4, 1 H, CH=CH2), 5.15 (dd, J =

17.1, 1.5, 1 H, CH=CH2), 4.95 (dd, J = 10.3, 1.0, 1 H, CH=CH2), 3.67 (s, 3 H, O-CH3), 2.33
(t, J = 7.3, 2 H, C-CH2), 2.10 (dt, J = 15.6, 8.3, 2H, CH2-CH), 1.74 (quin., J = 7.8, 2 H, CH2CH2-CH2).

____________________________________________________
92

Baudart, P.; Bulletin de la Societe Chimique de France, 1946, 85-87.
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Preparation of methyl 2-((6-methyl-3(((trifluoromethyl)sulfonyl)oxy)139yridine-2-yl)methyl)hex-5-enoate

Notebook Entry: PSB281
A 25 mL recovery flask was brought under Ar atmosphere. LHMDS (1.06 M, 3.20 mL, 2.39
mmol) and THF (5 mL) were charged to the flask and cooled in a dry ice/isopropanol bath.
Methyl hex-5-enoate (0.334 g, 2.61 mmol) was added to solution drop-wise and stirred for 15
min before quick addition of bis-triflate 3.32 (1.16 g, 2.82 mmol) in THF (5 mL). The
reaction warmed to rt overnight and quenched with sat. NaHCO3 followed by extraction with
diethyl ether (2 × 10 mL). The combined organic layers were dried over anhydrous MgSO4,
filtered, concentrated and purified by flash chromatography (1½” diameter column, 500 mL
reservoir, 6:1 hexanes:EtOAc) to provid impure product 3.30 (0.071 g, 7%).
1H

NMR (CDCl3, 500 MHz): δ 7.45 (d, J = 8.8, 1 H, Ar-H), 7.40 (d, J = 8.8, 1 H, Ar-H),

5.79 (ddt, J = 13.2, 9.8 ,6.4, 1 H, CH=CH2), 5.03 (dd, J = 17.1, 2.0, 1 H, CH=CH2), 4.98 (m,
1 H, CH=CH2), 2.68 (m, 2 H, Ar-CH2), 2.44 (s, 3 H, Ar-CH3), 2.08 (app. q, J = 6.8, 2 H,
CH2-CH=CH2), 1.94 (m, 2 H, CH2-CH2), 1.92 (s, 3 H, O-CH3), 1.74 (app. quin., J = 7.3, 2
H, Ar-CH2-CH).
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Preparation of 2-(hydroxymethyl)-6-methylpyridin-3-yl methanesulfonate

Notebook Entry: PSC045
A 100 mL round bottom flask was charged with diol 3.43 (0.500 g, 3.59 mmol). The flask
was brought under Ar atmosphere and charged with CH2Cl2 (35 mL) and NEt3 (2.00 mL,
14.4 mmol) and cooled in a dry ice/isopropanol bath. MsCl (1.11 mL, 14.4 mmol) was
added drop wise via syringe and the solution warmed to room temperature before it was
concentrated via rotary evaporation. The crude product was purified by flash
chromatography (1” diameter column, 250 mL reservoir, 1:1 hexanes:EtOAc) to provide
compound 3.34 (0.587 g, 62%) as a light yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 7.67 (d, J = 8.3, 1 H, Ar-H), 7.20 (d, J = 8.3, 1 H, Ar-H),

4.75 (s, 2 H, Ar-CH2-Cl), 3.30 (s, 3 H, SO2-CH3), 2.60 (s, 3H, Ar-CH3).
13C

NMR (CDCl3, 500 MHz): δ 157.4, 148.3, 142.1, 130.7, 124.6, 41.8, 38.6, 31.5, 23.9.
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Preparation of 3-(allyloxy)-6-methylpyridin-2-yl)methanol

Notebook Entry: PSC046, PSC082, PSC099, PSC138, PSC193, PSC271
A 500 mL round bottom flask was charged with diol 2.11 (5.00 g, 735.9mmol) and acetone
(240 mL) and equipped with stir bar. K2CO3 (9.93 g, 71.9 mmol) was with stirring followed
by quick, drop-wise addition of allyl bromide (3.89 mL, 44.9 mmol). The mixture was
refluxed for 3 h and monitored by TLC. The reaction mixture was then filtered under
vacuum and concentrated via rotary evaporation to provide a crude yellow solid. The solid
was dissolved in EtOAc, washed with sat. NaHCO3 (2 × 20 mL), water (1 × 20 mL) and the
organic layer was dried over anhydrous Na2SO4. The solution was filtered and concentrated
to provide compound 3.36 (6.44 g, 99%) as a yellow solid.
mp = 53-55 °C
1H

NMR (CDCl3, 500 MHz): δ 7.04 (d, J = 8.3, 2 H, Ar-H), 7.00 (d, J = 8.3, 2 H, Ar-H),

6.02 (ddt, J = 15.6, 10.3, 5.4, 1 H, CH=CH2), 5.39 (dd, J = 17.6, 1.5, 1 H, CH=CH2), 5.30
(dd, J = 10.7, 1.5, 1 H, CH=CH2), 4.74 (d, J = 4.4, 2 H, Ar-CH2-OH), 4.55 (app. dt, J = 4.9,
2.0, 2 H, O-CH2-CH), 2.50 (s, 3 H, Ar-CH3).
13C

NMR (CDCl3, 125 MHz): δ 149.1, 148.2, 147.3, 132.6, 121.6, 118.7, 117.9, 68.8, 59.8,

23.1.
FT-IR (Diamond ATR): 3093 (m), 2823 (m), 1652(w), 1581 (w), 1478 (m), 1458 (m), 1271
(s), 1012 (s), 993 (s), 927 (s).
HRMS (ESI, M+Na) Calculated for C10H13NNaO2: 202.0844. Found: 202.0844.
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Preparation of 3-(allyloxy)-2-(bromomethyl)-6-methylpyridine

Notebook Entry: PSC050, PSC085, PSC105, PSC145, PSC164, PSC168, PSC192
A two-neck, 100 mL round bottom flask was charged with alcohol 3.36 (1.09 g, 6.07 mmol)
and PPh3 (1.67 g, 6.37 mmol) and equipped with a solid addition funnel. NBS (1.11 g, 6.25
mmol) was added to addition funnel and the apparatus was brought under Ar atmosphere.
CH2Cl2 (40 mL) was charged to the flask and the solution was cooled in a dry ice/MeCN
bath. NBS was added to solution in portions over ~15 min. The solution warmed to room
temperature overnight. The reaction was diluted with diethyl ether (40 mL) and washed with
sat. NaHSO3 and sat. NaHCO3 (2 × 20 mL each) and dried over anhydrous CaCl2. The
solution was filtered, concentrated and purified by flash chromatography (2¾” diameter
column, 1 L reservoir, 3:1 hexanes:EtOAc) to give pyridyl bromide 3.37 (1.07 g, 73%) as a
bright pink solid.
mp = 43-44 °C
1H

NMR (CDCl3, 500 MHz): δ 7.09 (d, J = 8.3, 1 H, Ar-H), 7.04 (d, J = 8.3, 1 H, Ar-H),

6.05 (ddt, J = 15.5, 10.3, 4.9, 1 H,CH=CH2), 5.43 (dd, J = 17.1, 1.5, CH=CH2), 5.31 (dd, J =
10.7, 1.5, 1 H, CH=CH2), 4.64 (s, 2 H, Ar-CH2-Br), 4.61 (app. q, J = 4.9, 2 H, O-CH2-CH),
2.50 (s, 3 H, Ar-CH3).
13C

NMR (CDCl3, 125 MHz): δ 150.7, 149.8, 145.4, 132.5, 123.9, 120.4, 117.9, 69.1, 39.7,

23.4.
FT-IR (Diamond ATR): 3097 (w), 2887 (w), 1650 (w), 1573 (m), 1470 (s), 1442 (s), 1279
(s), 1153 (s), 987 (s), 820 (s), 589 (m).
HRMS (CI+) Calculated for C10H13BrNO: 242.0181. Found: 242.0185.
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Preparation of tert-butyl hex-5-enoate

Notebook Entry: PSC068, PSC070, PSC079, PSC109
A 10 mL round bottom flask was charged with 5-hexenoic acid (0.981 g, 8.59 mmol), DMAP
(0.210 g, 1.72 mmol), t-BuOH (4.93 mL, 51.5 mmol), and DIC (2.02 mL, 12.9 mmol). The
solution was stirred at room temperature overnight. The solution was poured over DI H2O (5
mL) and extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers were dried over
anhydrous MgSO4. The solution was filtered, concentrated and purified via flash
chromatography (1½” diameter column, 500 mL, 30:1 hexanes:EtOAc) to provide ester 3.38
(0.890 g, 61%) as a clear, colorless oil.
1H

NMR (CDCl3, 500 MHz): δ 5.79 (ddt, J = 17.1, 10.3, 3.4, 1 H, CH=CH2), 5.03 (dd, J =

17.1, 2.0, 1 H, CH=CH2), 4.98 (dd, J =10.3, 1.0, 1 H, CH=CH2), 2.23 (t, J = 7.8, 2 H, CCH2), 2.09 (dt, J = 14.2, 6.3, 2 H, C-CH2-CH2-CH2), (quin., J = 7.8, 2 H, C-CH2-CH2), 1.43
(s, 9 H, C-(CH3)3).
13C

NMR (CDCl3, 125 MHz): δ 173.0, 137.9, 115.2, 80.0, 34.8, 33.0, 28.1, 24.3.

IR (Diamond ATR): 3079 (w), 2978 (m), 2116 (m), 1729 (s), 1366 (m), 1149 (s), 912 (m).
HRMS (CI, M+NH4) Calculated for C10H22NO2: 188.1651. Found: 188.1656.
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Preparation of tert-butyl 2-((3-(allyloxy)-6-methylpyridin-2-yl)methyl)
hex-5-enoate

Notebook Entry: PSC071, PSC086, PSC110, PSC155
A 25 mL recovery flask was equipped with a stir bar and septum and brought under Ar
atmosphere. THF (1 mL) and LHMDS (1.06 M, 1.25 mL, 1.32 mmol) were charged to flask
and cooled in a dry ice/isopropanol bath. Ester 3.38 (0.150 g, 0.881 mmol) was added dropwise to the flask in a solution of THF (1 mL). The solution was stirred for ~15 min at
reduced temperature followed by quick addition of pyridyl bromide 3.37 (0.235 g, 0.969
mmol) in a solution of THF (1 mL). The solution gradually warmed to rt. The reaction was
quenched with sat. NaHCO3 and the aqueous layer was extracted with diethyl ether (3 × 10
mL). The combined organic layers were dried over anhydrous MgSO4, filtered, concentrated
Purification via flash chromatography (1” diameter column, 250 mL reservoir, 6:1
hexanes:EtOAc) provided compound 3.39 (0.158 g, 54%) as a yellow oil.
1H

NMR (CDCl3, 500 MHz): δ 6.98 (d, J = 8.3, 1 H, Ar-H), 6.91 (d, J = 8.3, 1 H, Ar-H),

6.04 (ddt, J = 17.1, 9.9, 4.9, 1 H, O-CH2-CH), 5.79 (ddt, J = 13.2, 10.3, 6.8, 1 H, CH2-CH2CH), 5.43 (dd, J = 17.1, 1.5, 1 H, O-CH2-CH=CH2), 5.29 (dd, J = 10.8, 1.5, 1 H, O-CH2CH=CH2), 5.00 (dd, J = 17.1, 2.0, 1 H, CH2-CH2-CH=CH2), 4.94 (dd, 10.3, 2.0, 1 H, CH2CH2-CH=CH2), 4.51 (d, 2 H, O-CH2), 3.03 (dd, J = 14.2, 8.3, 1 H, Ar-CH2), 2.99 (dd, J =
14.2, 6.7, 1 H, Ar-CH2), 2.92 (dddd, J = 13.7, 8.8, 5.8, 4.4, 1 H, Ar-CH2-CH), 2.43 (s, 3 H,
Ar-H), 2.10 (m, 2 H, CH2-CH2), 1.76 (m, 1 H, CH2-CH2), 1.56 (m, 1 H, CH2-CH2), 1.38 (s, 9
H, C-(CH3)3).
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13C

NMR (CDCl3, 125 MHz): δ 174.9, 150.7, 148.8, 138.5, 133.0, 120.8, 118.5, 117.8,

114.9, 79.8, 69.0, 44.3, 34.6, 31.7, 28.1, 23.5.
FT-IR (Diamond ATR): 2983 (m), 1705 (s), 1605 (m), 1229 (m), 1029 (m), 854 (s), 825 (s).
HRMS (CI, M+Na) Calculated for C20H29NNaO3: 354.2045. Found: 354.2039.
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Preparation of tert-butyl 2-((3-hydroxy-6-methylpyridin-2-yl)methyl)
hex-5-enoate

Notebook Entry: PSC073, PSC087, PSC114, PSC156
A 25 mL round bottom flask was charged with pyridyl ester 3.39 (0.743 mg, 0.224 mmol)
and Pd(PPh3)4 0 (0.129 g, 0.112 mmol). The flask was brought under Ar atmosphere before
addition of absolute EtOH (22 mL). The solution was stirred for 5 min before quick addition
of K2CO3 (0.929 mg, 6.72 mmol). The solution stirred for 3 h before it was poured over DI
H2O (20 mL). The aqueous layer was extracted with CH2Cl2 (3 × 20 mL). The combined
organic layers were dried over anhydrous Na2SO4, filtered, concentrated and purified by flash
chromatography (1” diameter column, 250 mL reservoir, 2:1 hexanes:EtOAc) to provide
compound 3.40 (0.602 g, 92%).
1H

NMR (CDCl3, 300 MHz): δ 7.55 (s, br, 1 H, Ar-OH), 7.06 (d, J = 8.2, 1 H, Ar-H), 6.87

(d, J = 8.2, 1 H, Ar-H), 5.8 (ddt, J = 12.9, 10.0, 6.5, 1 H, CH=CH2), 5.04 (dd, J = 17.0, 1.8, 1
H, CH=CH2), 4.8 (app. d, J = 11.7, 1 H, CH=CH2), 3.20 (dd, J = 13.5, 11.1, 1 H, Ar-CH2),
2.88 (m, 1 H, Ar-CH2-CH), 2.68 (dd, J = 14.1, 3.5, 1 H, Ar-CH2), 2.42 (s, 3 H, Ar-CH3),
2.16 (m, 2 H, CH2-CH2), 1.78 (m, 2 H, CH2-CH2), 1.40 (s, 9 H, C-(CH3)3).
13C

NMR (CDCl3, 125 MHz): δ 177.7, 149.3, 148.8, 146.5, 137.9, 125.0, 122.3, 115.2, 81.7,

45.8, 34.1, 32.7, 31.0, 28.0, 23.3.
HRMS (CI+) Calculated for C17H26NO3: 292.1913. Found: 292.1918.
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Preparation of tert-butyl 2-((6-methyl-3(((trifluoromethyl)sulfonyl)oxy)147yridine-2-yl)methyl)hex-5-enoate

Notebook Entry: PSC074, PSC094, PSC115
A 10 mL round bottom flask was brought under Ar atmosphere. CH2Cl2 (13.5 mL), pyridyl
ester 3.40 (0.784 mg, 2.69 mmol) and NEt3 (0.49 mL, 3.50 mmol) were charged to the flask
and cooled in a dry ice/isopropanol bath. Tf2O (0.50 mL, 2.960 mmol) was added drop-wise
to the solution which then warmed gradually to rt. The reaction was quenched with sat.
NaHCO3 and the aqueous layer was extracted with diethyl ether (2 × 10 mL). The combined
organic layers were washed with sat. NaCl and dried over anhydrous MgSO4. The solution
was filtered, concentrated, and purified by flash chromatography (1” diameter column, 250
mL reservoir, 3:1 hexanes:EtOAc) to provide pyridyl triflate 3.41 (0.972 g, 88%).
1H

NMR (CDCl3, 500 MHz): δ 7.44 (d, J = 8.3, 1 H, Ar-H), 7.06 (d, J = 8.3, 1 H, Ar-H),

5.82 (ddt, J = 13.2, 9.8, 6.3, 1 H, CH=CH2), 5.04 (dd, J = 17.1, 2.0, 1 H, CH=CH2), 4.97 (dd,
J = 10.3, 2.0, 1 H, CH=CH2), 3.18 (dd, J = 14.2, 7.8, 1 H, Ar-CH2), 2.96 (m, 2 H, Ar-CH2CH), 2.55 (s, 3 H, Ar-CH3), 2.13 (m, 2 H, CH2-CH2), 1.80 (m, 1 H, CH2-CH2), 1.61 (m, 1 H,
CH2-CH2), 1.40 (s, 9 H, C-(CH3)3).
HRMS (ESI, M+Na) Calculated for C18H24F3NNaO5S: 446.1225. Found: 446.1206.
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Preparation of tert-butyl 2-methyl-5-methylene-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-carboxylate

Notebook Entry: PSC080, PSC095, PSC119
A 10 mL screw-top culture tube was charged with PPh3 (0.057 g, 0.0.218 mmol), K2CO3
(0.437 g, 3.16 mmol), MeCN (17 mL), and pyridyl triflate 3.41 (0.178 g, 0.436 mmol) and
degassed in a sonicator for 15 min. The reaction vessel was fitted with a septum and flushed
with Ar. Pd(PPh3)4 (0.126 g, 0.109 mmol) was then quickly added and the septum was
replaced with a screw-cap. The solution was heated at 90 °C for ~20 h. The culture tube was
allowed to cool to room temperature and solution was then filtered over Celite® and
concentrated. The residue was filtered over an alumina plug with EtOAc to remove
remaining impurities. Concentration of the sample provided compound 3.42 (0.100 g, 84%)
as a clear, colorless oil.
1H

NMR (CDCl3, 500 MHz): δ 7.40 (d, J = 7.8, 1 H, Ar-H), 6.97 (d, J = 7.8, 1 H, Ar-H),

5.17 (s, 1 H, C=CH2), 5.05 (s, 1 H, C=CH2), 3.21 (dd, J = 14.7, 2.4, 1 H, Ar-CH2), 3.14 (dd,
J = 14.7, 10.7, 1 H, Ar-CH2), 2.65 (m, 2 H, CH2-CH2), 2.52 (s, 3 H, Ar-CH3), 2.33 (ddd, J =
13.8, 9.8, 3.9, 1 H, Ar-CH2-CH), 2.11 (m, 1 H, CH2-CH2), 1.97 (m, 1 H, CH2-CH2), 1.41 (s,
9 H, C-(CH3)3).
13C

NMR (CDCl3, 125 MHz): δ 174.6, 156.4, 148.7, 136.0, 135.3, 121.2, 115.3, 80.3, 42.8,

40.7, 33.9, 33.2, 28.0, 24.1.
FT-IR (Diamond ATR): 2976 (w), 1723 (s), 1366 (m), 1146 (m).
HRMS (CI+) Calculated for C17H22NO2: 274.1807. Found: 274.1803.
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Preparation of tert-butyl (5R)-2,5-dimethyl-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-carboxylate & tert-butyl (5S)-2,5-dimethyl-6,7,8,9tetrahydro-5H-cyclohepta[b]pyridine-8-carboxylate

Notebook Entry: PSC107
In accordance with General Procedure G, pyridyl ester 3.42 (0.028 g, 0.103 mmol),
Wilkinson’s catalyst (0.005 g, 0.005 mmol), NEt3 (19 µL, 0.105 mmol), THF (1.8 mL) and
EtOH (0.2 mL) were combined in a Fischer-Porter tube in a glovebox. The reaction vessel
was assembled and brought outside the glovebox and charged with 50 psi H2 gas and the
solution was stirred overnight. The solution was filtered through an alumina plug with
EtOAc, yielding a crude mixture of 3.43 and 3.43a (0.29 g, 100%, ~1:1 mixture) upon
concentration.
1H

NMR 3.43 (CDCl3, 500 MHz): δ 7.38 (d, J = 7.8, 1 H, Ar-H), 6.99 (7.8, 1 H, Ar-H), 3.34

(dd, J = 14.5, 10.0, 1 H, Ar-CH2), 3.26 (dd, J = 14.5, 3.0, 1 H, Ar-CH2), 3.00 (m, 1 H, ArCH), 2.50 (s, 3 H, Ar-CH3), 2.36 (dt, J = 10.9, 2.9, 1 H, Ar-CH2-CH), 2.14 (m, 1 H, Ar-CH2CH-CH2), 1.96 (m, 1 H, Ar-CH2-CH-CH2), 1.87 (m, 1 H, Ar-CH-CH2), 1.77 (m, 1 H, ArCH-CH2), 1.47 (s, 9 H, O-C-(CH3)3), 1.35 (d, J = 6.8, 3 H, Ar-CH-CH3).
1H

NMR 3.43a (CDCl3, 500 MHz): δ 7.32 (d, J = 7.8, 1 H, Ar-H), 6.94 (d, J = 7.8, 1 H, Ar-

H), 3.28 (dd, 13.6, 10.0, 1 H, Ar-CH2), 3.26 (dt, J = 13.6, 2.0, 1 H, Ar-CH2), 3.00 (m, 1 H,
Ar-CH), 2.50 (s, 3 H, Ar-CH3), 2.56 (m, J = 10.7, 2.4, 1 H, Ar-CH2-CH), 2.14 (m, 1 H, ArCH2-CH-CH2), 1.96 (m, 1 H, Ar-CH2-CH-CH2), 1.87 (m, 1 H, Ar-CH-CH2), 1.77 (m, 1 H,
Ar-CH-CH2), 1.42 (s, 9 H, O-C-(CH3)3), 1.33 (d, J = 7.3, 3 H, Ar-CH-CH3).
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Preparation of tert-butyl 2-methyl-5-methylene-6,7,8,9-tetrahydro-5Hcyclohepta[b]pyridine-8-carboxylate & tert-butyl 2,5-dimethyl-8,9-dihydro7H-cyclohepta[b]pyridine-8-carboxylate

Notebook Entry: PSC123
A 10 mL round bottom flask equipped with a stir bar was charged with 3.41 (0.065 g, 0.159
mmol) and DMF (2.5 mL) followed by addition of Bu4NBr (0.154 g, 0.478 mmol), HCO2Na
(0.014 g, 0.191 mmol, 1.2 eq.) and Pd(OAc)2 (0.005 g, 0.159 mmol). The flask was brought
under Ar atmosphere and stirred at rt. After 24 h, TLC analysis indicated consumption of the
starting material. The solution was washed with sat. LiCl (1 × 10 mL) and extracted with
ether (2 × 10 mL). The combined organic layers were dried over anhydrous MgSO4, filtered
and concentrated. The crude product was purified via flash chromatography (½” diameter
column, 100 mL reservoir, 2:1 hexanes:EtOAc) to provide a mixture of products 3.42 and
3.46 (0.020 g, 45%, ~1:3 mixture).
1

H NMR analysis indicated a ~3:1 mixture of internal and terminal olefin isomers, 3.42 and

3.46.
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